EP1367998A2 - Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies - Google Patents

Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies

Info

Publication number
EP1367998A2
EP1367998A2 EP01981317A EP01981317A EP1367998A2 EP 1367998 A2 EP1367998 A2 EP 1367998A2 EP 01981317 A EP01981317 A EP 01981317A EP 01981317 A EP01981317 A EP 01981317A EP 1367998 A2 EP1367998 A2 EP 1367998A2
Authority
EP
European Patent Office
Prior art keywords
antibody
hydrogen peroxide
superoxide
molecule
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01981317A
Other languages
German (de)
French (fr)
Other versions
EP1367998A4 (en
Inventor
Paul Wentworth
Anita D. Wentworth
Lyn H. Jones
Kim D. Janda
Richard A. Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP1367998A2 publication Critical patent/EP1367998A2/en
Publication of EP1367998A4 publication Critical patent/EP1367998A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the invention relates to methods for the antibody-mediated generation of superoxide free radical from singlet oxygen.
  • the invention also relates to the generation of hydrogen peroxide from singlet oxygen.
  • Therapeutic methods are based upon both enhancing and inhibiting these processes. Screening methods relate to identifying modulators of antibody-mediated generation of hydrogen peroxide and superoxide free radical through the respective increase or decrease in detectable hydrogen peroxide or superoxide.
  • the invention further relates to a simplified immunoassay based on detecting hydrogen peroxide.
  • the invention also relates to therapeutic compositions that are engineered to increase the production of hydrogen peroxide and superoxide free radical as well as compositions that are engineered to prevent this production.
  • reactive oxygen species resulting from incomplete reduction of oxygen include among others the free radicals, superoxide radical (O 2 " ) and hydroxyl radical (OH * ), that have one or more unpaired electrons.
  • Superoxide spontaneously reacts with itself in a dismutation reaction to form hydrogen peroxide (H 2 O 2 ).
  • the formed hydrogen peroxide while not being a free radical, under certain situations, e.g., in the absence of catalase, becomes a cytotoxic oxidant through the formation of hydroxyl radical and hypochlorous acid (HOCl) (McCord, Amer. J. Med.. 108:652-659 (2000)).
  • Singlet oxygen results from irradiation by light of metal- free porphyrin precursors that are present in the skin of porphyria sufferers. Singlet oxygen is also generated by neutrophils and is thought to be responsible for damage created by phagocytes on their targets (Babior et al., Amer. J. Med.. 109:33-34 (2000)). Based on its high reactivity with biomolecules, singlet oxygen has generally been considered to be an endpoint in the cascade of oxygen-scavenging agents.
  • the invention provides methods for utilizing the newly discovered abilities of an antibody to reduce singlet oxygen to superoxide. This catalytic reaction ultimately results in the formation of hydrogen peroxide.
  • the invention also provides methods to utilize antibodies to produce hydrogen peroxide from singlet oxygen by the oxidation of water. Hydrogen peroxide, under certain biological conditions, itself generates reactive molecules. Thus, the invention generally provides methods to inhibit and facilitate these processes depending on the desired outcome.
  • the invention further relates to screening methods to identify agents that modulate the newly discovered antibody-mediated processes.
  • the invention further contemplates an improved immunoassay format based on the direct detection of hydrogen peroxide that is produced by antibody catalyzed oxidation of water.
  • the invention also provides an improved immunoassay based on hydrogen peroxide produced from antibody-generated superoxide in the presence of singlet oxygen.
  • the invention also contemplates therapeutic compositions, preferably antibody compositions, that are engineered to exhibit increased or decreased oxidative function.
  • Figure 1 illustrates the oxygen-dependent microbicidal action of phagocytes.
  • the interconversion of O 2 and O 2 *" is indicated and is an intrinsic ability to antibodies.
  • Figure 2 illustrates the amplex red assay.
  • Figure 3 shows the initial time course of H 2 O 2 production in PBS (pH 7.4) in the presence ( ⁇ ) or absence ( ⁇ ) of murine monoclonal IgG EP2-19G2 (20 ⁇ M). Error bars show the range of the data from the mean.
  • Figure 4 shows the fluorescent micrograph of a single crystal of murine antibody 1D4 Fab fragment after UN irradiation and H 2 O 2 detection with the amplex red reagent.
  • Figure 5 illustrates the (A) HP sensitization assay. Time course of H 2 O 2 formation in PBS (pH 7.4) with HP (40 ⁇ M) and visible light, in the presence (O) or absence ( ⁇ ) of 31127 (horse IgG, 20 ⁇ M).
  • B Initial time course of H 2 O 2 production with HP (40 ⁇ M) and visible light, in the presence of 31127 (horse IgG, 6.7 ⁇ M) with no additive in PBS (pH 7.4) (D) or ⁇ a ⁇ 3 in PBS (pH 7.4) (O, 100 ⁇ M) or in a D 2 O solution of PBS (pH 7.4) (0).
  • Figure 6 is a bar graph showing the measured initial rate of H 2 O 2 formation for a panel of proteins and comparison with antibodies (data from Table I). All points are mean values of at least duplicate experimental determinations. Error bars are the range of experimentally measured values form the mean. ONA, chick-egg ovalbumin; SOD, superoxide dismutase.
  • Figure 8 shows H 2 O 2 production.
  • A Production of H 2 O 2 by immunoglobulins and non-immunoglobulin proteins. Assays were performed by near-UV irradiation (312 nm, 800 ⁇ W cm “2 ) of individual protein samples (100 ⁇ L, 6.7 ⁇ M) in phosphate-buffered saline (PBS) [10 mM sodium phosphate, 150 mM ⁇ aCl (pH 7.4)] in a sealed glass vial on a transilluminator (Fischer Biotech) under ambient aerobic conditions at 20°C. Aliquots (10 ⁇ L) were removed throughout the assay. H 2 O 2 concentration was determined by the amplex red method.
  • PBS phosphate-buffered saline
  • D Determination of IC 50 of H 2 O 2 on the photo-production of H 2 O 2 by horse polylgG. A solution of horse IgG (6.7 ⁇ M) was incubated with varying concentrations of H 2 O 2 (0-450 ⁇ M) and the initial rate of H 2 O 2 formation measured as described in (A). The graph is a plot of rate of H 2 O 2 formation versus H 2 O 2 concentration and reveals an IC 50 of 225 ⁇ M.
  • Figure 9 illustrates the superposition of native 4C6 Fab (light blue and pink in a color photograph) and 4C6 Fab in the presence of H 2 O 2 (dark blue and red in a color photograph) (A).
  • the native 4C6 crystals were soaked for 3 minutes in 4 mM H 2 O 2 , and immediately flash frozen for data collection at SSRL BL 9-1.
  • the RMSD was calculated in C ⁇ S.
  • B High resolution x-ray structures show that Fab 4C6 is cross-reactive with benzoic acid.
  • Figure 10 shows the absorbance spectra of horse polyclonal IgG measured on a diode array HP8452A spectrophotometer, Abs max 280 nm (A).
  • the assay was performed in duplicate and involved addition of an antibody solution [6.7 ⁇ M in PBS (pH 7.4)] to a quartz tube that was then placed in a light beam produced by a xenon arc lamp and monochromator of an SLM specfrofluorimeter for 1 hour. H 2 O 2 concentration was measured by the amplex red assay.
  • Figure 11 shows the production of H 2 O 2 .
  • A Production of H 2 O 2 by tryptophan (20 ⁇ M). The conditions and assay procedures were as described in Figure 8 A.
  • B Effect of chloride ion on antibody-mediated photo-production of H 2 O 2 A solution of sheep polylgG ⁇ (6.7 ⁇ M, 200 ⁇ L) or horse polylgG * (6.7 ⁇ M, 200 ⁇ L) was lyophilized to dryness and then dissolved in either deionized water or NaCl (aq.) such that the final concentration of chloride ion were (0-160 mM).
  • Figure 12 shows ESI (negative polarity) mass spectra of TCEP [(M-H) " 249] and its oxide [(M-H) " 265 ( 16 O) and (M-H) “ 267 ( 18 O)] produced by oxidation with H 2 O 2 .
  • A MS of TCEP and its oxides after irradiation of sheep polylgG (6.7/ ⁇ M) under 16 O 2 aerobic conditions in H 2 18 O (98 % 18 O) PB.
  • B MS of TCEP and its oxides after irradiation of sheep polylgG (6.7 ⁇ M) under enriched 18 O 2 (90 % 18 O) aerobic conditions in H 2 16 O PB.
  • Figure 13 shows the Xe binding sites in antibody 4C6 as described in materials and methods (Example II).
  • A Standard side view of the Ca trace of Fab 4C6 with the light chain in pink and the heavy chain in blue in a color photograph. Three bound xenon atoms (green in a color photograph) are shown with the initial F 0 -F c electron density map contoured at 5 ⁇ .
  • B Overlay of Fab 4C6 and the 2C ⁇ TCR (PDB/TCR) around the conserved xenon site 1.
  • the present invention concerns the discovery that antibodies, as a class of molecules, have an inherent capability to intercept singlet oxygen and convert it to either superoxide or hydrogen peroxide. This process acts to rescue and recycle oxygen, particularly during phagocyte-mediated processes, thereby contributing to microbicidal action of the immune system. These properties are common to all antibodies and were not known prior to the present invention. The common ability to convert singlet oxygen to superoxide or hydrogen peroxide, regardless of source or antigenic specificity, is thought to link the previously appreciated recognition properties of antibodies with killing events.
  • the present invention provides methods that relate to the ability of an antibody to reduce singlet oxygen ( ! O 2 ) to superoxide radical (O 2 " ) and hydrogen peroxide. In view of the critical nature and role of oxygen metabolism in an aerobic organism, the identification of this biological process provides multiple and varied methods as described herein. The detailed determination and characterization of the antibody-mediated reduction of singlet oxygen is described in examples I and II.
  • the ability to produce superoxide from singlet oxygen is present in both intact immunoglobulins and well as Fab and F(ab') 2 fragments (see examples).
  • the activity does not reside in molecules, including R ⁇ aseA, superoxide dismutase, and Bowman-Birk inhibitor protein, that can be oxidized (example I and Table 1). Also, the activity is not associated with the presence of disulfides in a molecule, even though they are sufficiently electron rich that they can be oxidized (Bent et al. J. Am. Chem. Soc. 87:2612-2619 (1975T).
  • the activity resides in an aromatic amino acid such as tryptophan that can be oxidized by singlet molecular oxygen via electron transfer (Grossweiner, Curr. Top. Radiat. Res. P..11:141-199 (1976)).
  • the activity is further attributed to the indole component of the tryptophan residue.
  • the indole acts as a reductive center in connection with the redox reaction.
  • the indole portion becomes oxidized to form a radical cation in the course of reducing singlet molecule oxygen to superoxide free radical.
  • the antibody is called a reductant because it is oxidized in providing an electron to singlet molecular oxygen.
  • TRP-36 and TRP-47 two aromatic tryptophan resides are conserved, referred to as TRP-36 and TRP-47, and are both deeply buried (Kabat, et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD (1991)).
  • the ability of antibodies as a class of proteins to reduce singlet molecular oxygen to superoxide anion is thus based on the presence of the conserved buried aromatic tryptophan residues.
  • the ability to produce hydrogen peroxide in an efficient and long term manner from singlet oxygen is present in immunoglobulins and in the T-cell receptor (example II, Figure IF).
  • the T-cell receptor shares a similar arrangement of its immunoglobulin fold domains with antibodies (Garcia et al., Science, 274:209 (1996)). However, possession of this structural motif does not appear necessary to confer a hydrogen peroxide-generating ability on proteins.
  • ⁇ 2 -macroglobulin a member of the immunoglobulin superfamily having this structural motif, does not generate hydrogen peroxide (Welinder et al., Mol. Immunol.. 28:177 (1991)).
  • Information relating the structure to the function of immunoglobulins and the T-cell receptor allows molecules to be designed that will catalyze the oxidation of water. This information also provides many new methods and treatment schemes that may be utilized based on existing molecules.
  • agent herein is used to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials such as bacteria, plants, fungi, or animal
  • Agents are evaluated for potential activity as antibody modulatory agents by inclusion in screening assays as described herein.
  • antibody as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab') 2 , and Fv which are capable of binding an epitope. These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows:
  • Fab the fragment which contains a monovalent antigen-binding fragment of an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
  • Fab' the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab') 2 , the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab') 2 is a dimer of two Fab' fragments held together by two disulfide bonds;
  • Fv defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains
  • Single chain antibody defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
  • the preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green, et al., Production of Polyclonal Antisera, in: Immunochemical Protocols (Manson, ed.), pages 1-5 (Humana Press); Coligan, et al., Production of Polyclonal Antisera in Rabbits, Rats Mice and Hamsters, in: Current Protocols in Immunology, section 2.4.1 (1992), which are hereby incorporated by reference.
  • Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography.
  • Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli of DNA encoding the fragment.
  • Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies conventional methods.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') 2 .
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • a thiol reducing agent optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages
  • an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly.
  • Fv fragments comprise an association of N H and N L chains. This association may be noncovalent or the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.
  • the Fv fragments comprise N H and N L chains connected by a peptide linker.
  • These single-chain antigen binding proteins are prepared by constructing a structural gene comprising D ⁇ A sequences encoding the N H and N L domains connected by an oligonucleotide.
  • the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
  • the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two N domains.
  • Methods for producing sFvs are described, for example, by Whitlow, et al., Methods: a Companion to Methods in ⁇ nzymology. Vol. 2, page 97 (1991); Bird, et al, Science.
  • CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick, et al., Methods: a Companion to Methods in ⁇ nzymology. Nol. 2, page 106 (1991).
  • an effective amount is an amount that results in reducing, reversing, ameliorating, inhibiting, and the like improving directions, the effects of an oxidant generated by an antibody.
  • an “engineered molecule” is a polypeptide that has been produced through recombinant techniques. Such molecules can include a reactive center that can catalyze the production of superoxide or hydrogen peroxide from singlet oxygen. Such engineered molecules may have a reactive indole contained within a polypeptide structure. The indole of such a molecule may be present as a tryptophan residue. Engineered molecules may also contain non- natural amino acids and linkages as well as peptidomimetics. Engineered molecules also include antibodies that are modified to eliminate the reaction center such that they are no longer able to generate superoxide or hydrogen peroxide.
  • epitopic determinants means any antigenic determinant on an antigen to which the paratope of an antibody binds.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • Antigens can include polypeptides, fatty acids, lipoproteins, lipids, chemicals, hormones and the like.
  • antigens include, but are not limited to, proteins from viruses such as human immunodeficiency virus, influenza virus, herpesvirus, papillomavirus, human T-cell leukemia virus and the like.
  • antigens include, but are not limited to, proteins expressed on cancer cells such as lung cancer, prostate cancer, colon cancer, cervical cancer, endometrial cancer, bladder cancer, bone cancer, leukemia, lymphoma, brain cancer and the like.
  • Antigens of the invention also include chemicals such as ethanol, tetrahydrocanabinol, LSD, heroin, cocaine and the like.
  • modulate refers to the capacity to either enhance or inhibit a functional property of an antibody or engineered molecule of the invention, such as production of superoxide or hydrogen peroxide.
  • a "non-natural” amino acid includes D-amino acids as well as amino acids that do not occur in nature, as exemplified by 4-hydroxyproline, ⁇ - carboxyglutamate, O-phosphoserine, N-acetylserine, N-formylmethionine, 3- methylhistidine, 5-hydroxylysine and other such amino acids and imino acids.
  • the term "peptidomimetic” or “peptide mimetic” describes a peptide analog, such as those commonly used in the pharmaceutical industry as non- peptide drugs, with properties analogous to those of the template peptide. (Fauchere, J., Adv. Drug Res.. 15: 29 (1986) and Evans et al., J. Med. Chem..
  • Advantages of peptide mimetics over natural polypeptide embodiments may include more economical production, greater chemical stability, altered specificity, reduced antigenicity, and enhanced pharmacological properties such as half-life, absorption, potency and efficacy.
  • the terms “phamiaceutically acceptable”, “physiologically tolerable” and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
  • protein and “polypeptide” are used to describe a native protein, fragments, or analogs of a polypeptide sequence. These terms may be used interchangeably.
  • Antibodies are used to describe a native protein, fragments, or analogs of a polypeptide sequence. These terms may be used interchangeably.
  • the invention provides therapeutic antibodies. All antibody molecules belong to a family of plasma proteins called immunoglobulins. Their basic building block, the immunoglobulin fold or domain, is used in various forms in many molecules of the immune system and other biological recognition systems.
  • a typical immunoglobulin has four polypeptide chains, contains an antigen binding region known as a variable region, and contains a non- varying region known as the constant region.
  • An antibody contemplated for use in the present invention can be in any of a variety of forms, including a whole immunoglobulin, Fv, Fab, other fragments, and a single chain antibody that includes the variable domain complementarity determining regions (CDR), or other forms. All of these terms fall under the broad term "antibody” as used herein.
  • the present invention contemplates the use of any specificity of an antibody, polyclonal or monoclonal, and is not limited to antibodies that recognize and immunoreact with a specific antigen.
  • an antibody or fragment thereof is used that is immunospecific for an antigen.
  • the preparation of a therapeutic antibody of this invention can be accomplished by recombinant expression techniques as well as protein synthesis, methods of which are well known to one of ordinary skill in the art.
  • mutation of a nucleic acid that encodes an antibody or fragment thereof can be conducted by a variety of means, but is most conveniently conducted using mutagenized oligonucleotides that are designed to introduce mutations at predetermined sites that then encode an altered amino acid sequence in the expressed molecule.
  • Such alterations include substitutions, additions, and/or deletions of particular nucleotide sequences that similarly encode substitutions, additions, and/or deletions of the encoded amino acid residue sequence.
  • Site-directed mutagenesis also referred to as oligonucleotide-directed mutagenesis and variations thereof, and the subsequent cloning of the altered genes are well known techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed., Chapter 15, Cold Spring Harbor Laboratory Press, (1989)).
  • Another recombinant approach includes synthesizing the gene encoding a therapeutic molecule of this invention by combining long oligonucleotide strands that are subsequently annealed and converted to double-stranded DNA suitable for cloning and expression (Ausebel et al., Current Protocols in Molecular Biology. Units 10 and 15, Wiley and Sons, Inc. (2000)).
  • Such techniques can be used to create engineered molecules that contain a reduction center and are able to generate hydrogen peroxide or superoxide from singlet oxygen. It is contemplated that such engineered molecules can be designed based on antibody structure and on the T-cell receptor, in the case of hydrogen peroxide.
  • the present invention contemplates an antibody that has been engineered to generate more superoxide free radical or hydrogen peroxide in a desired location.
  • the antibody is engineered to contain additional reductive centers, as described in examples I and II herein, that increase the reduction of singlet molecular oxygen to superoxide free radical or hydrogen peroxide.
  • the invention also contemplates an antibody that has been engineered to have at least a diminished capacity to generate superoxide free radical or hydrogen peroxide from singlet oxygen. In that context, the antibody lacks at least one of its reductive centers and preferably is substantially free of a reductive center.
  • Such antibody compositions are readily prepared with methods well known to one of ordinary skill in the art.
  • polyclonal or monoclonal antibodies prepared for use as therapeutic compositions or in the methods of invention can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
  • a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
  • Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (Coligan, et al., Unit 9, Current Protocols in Immunology. Wiley Interscience, (1991)).
  • the free radicals that result from oxygen activation are by definition chemical species that possess one or several mismatched electrons. Free radicals are generated when a single electron is removed from the molecule. This results in a molecule that has at least one of its electrons unpaired to another electron. The resultant free radical is reactive since it seeks out available electrons from other molecules, the process of which can create a second reactive molecule thereby setting off a chain reaction. Free radicals, also referred to as oxidants herein include superoxide, hydroxyl radical, halogenated oxygens and nitrogen containing molecules. Superoxide radical generated from the antibody-mediated reduction of singlet oxygen is itself an oxidant and also provides for the production of hydrogen peroxide.
  • the latter which while not itself an oxidant or reactive molecule, can generate reactive oxygen species that include hydroxyl radical, its secondary products such as carbon, oxygen, nitrogen or sulfur, which can react with other compounds to produce yet other free radicals creating a free radical chain reaction.
  • reactive oxygen species that include hydroxyl radical, its secondary products such as carbon, oxygen, nitrogen or sulfur, which can react with other compounds to produce yet other free radicals creating a free radical chain reaction.
  • Other reactive species that are a consequence of the oxygen cascade include oxidized halogens, such as hypochlorous acid (HOCl), the HOCl-generated reactive species chloramine (NH 2 C1) and aldehydes, and reactive nitrogen species.
  • a potential consequence of uncontrolled reactivity of free radicals is damage to DNA, RNA, membrane lipids, lipoproteins or enzymes, ultimately affecting the body.
  • An end result is poor cell function leading to disease and even tissue death.
  • free radicals aid the process of riding the body of unwanted bacteria or viruses.
  • acute and chronic cellular and tissue injury can occur.
  • Neutralizing processes include 1) enyzmes such as superoxide dismutase and catalase that together produce peroxidases and 2) molecules such as tocopherols, carotenoids, ubiquinones, flavonoids, ascorbic acid, uric acid and similar molecules that serve as a source of electrons that are provided to free radicals without damaging cellular components. Such processes are considered beneficial to the well being of an organism.
  • any molecule that inhibits the antibody mediated generation of hydrogen peroxide or superoxide that ultimately leads to hydrogen peroxide formation is referred to as an antioxidant.
  • an antioxidant any molecule that inhibits the antibody mediated generation of hydrogen peroxide or superoxide that ultimately leads to hydrogen peroxide formation.
  • oxidative stress When the balance of oxidants to antioxidants tips in favor of the former, the oxidative state is generally referred to as "oxidative stress". This situation occurs in the presence of an excess production of oxidants or free radicals and a diminishing of the control antioxidant mechanisms.
  • Advantages of the present invention are that the discovery of the role an antibody plays in the generation of oxidants in the oxygen cascade provides the basis for therapeutic methods that are useful in maintaining oxygen balance and control of oxygen metabolism, depending on the desired outcome.
  • the methods of this invention provide 1) for the production of oxidants when their production is warranted, such as in promoting wound healing, lysing bacteria, eliminating viruses, targeting cancer cells for oxidant-induced lysis and the like processes, and 2) for the inhibition of antibody generated oxidants by exposure of antioxidants when the inhibition of antibody generated oxidants is warranted, such as in inflammation, heart conditions, diabetes and unwanted cellular proliferation.
  • oxidants when their production is warranted, such as in promoting wound healing, lysing bacteria, eliminating viruses, targeting cancer cells for oxidant-induced lysis and the like processes
  • the inhibition of antibody generated oxidants by exposure of antioxidants when the inhibition of antibody generated oxidants is warranted, such as in inflammation, heart conditions, diabetes and unwanted cellular proliferation.
  • one may want to use antibody mediated generation of superoxide or hydrogen peroxide to supplement the local concentration of superoxide concentration generated by phagocytic neutrophils to combat a bacterial infection in a wound.
  • the superoxide in effect acts as bactericidal agent destroying the bacteria and ultimately the neutrophil in the process.
  • the method of this invention to provide an antibody composition to the area to cause an increase in the local concentration of superoxide.
  • neutrophil-generated superoxide is deleterious in inflamed joints such as in patients with rheumatoid arthritis who are concomitantly undergoing intensive humoral antibody-mediated immune responses.
  • the decision to use the methods of this invention to inhibit or promote the antibody- mediated generation of superoxide and hydrogen peroxide and their derivatives (i.e., molecules derived therefrom) products and/or their effects is thus dependent on the desired outcome.
  • antibody mediated production of hydrogen peroxide encompasses the reactive species that are both precursor and derivative to the generation of hydrogen peroxide.
  • antioxidants include 1) inhibitors of an antibody thereby inhibiting superoxide generation, 2) inhibitors of hydrogen peroxide generation, 3) inhibitors of the reactions converting hydrogen peroxide into derivative reactive oxidants; and 4) inhibitors of the reactive oxidants themselves.
  • Preferred antioxidants include those that inhibit the activation of oxygen producing reactive oxidants as well as those neutralizing those already formed. The antioxidant effect can occur by any mechanism, including catalysis.
  • Antioxidants as a category include oxygen scavengers or free radical scavengers. Antioxidants may be of different types so they are available if and when they are needed. In view of the presence of oxygen throughout an aerobic organism, antioxidants may be available in different cellular, tissue, organ and extracellular compartments. The latter include extracellular fluid spaces, intraocular fluids, synovial fluid, cerebrospinal fluid, gastrointestinal secretions, interstitial fluid, blood and lymphatic fluid. Antioxidants are present within an organism but are also provided by supplementing the diet and in the methods of this invention.
  • antioxidants include but are not limited to ascorbic acid, ⁇ -tocopherol, ⁇ -glutamylcysteinylglycine, ⁇ -glutamyl transpeptidase, ⁇ -lipoic acid, dihydrolipoate, -acetyl-5-methoxytryptamine, flavones, flavonenes, flavanols, catalase, peroxidase, superoxide dismutase, metallothionein, and butylated hydroxytoluene.
  • a further preferred molecule that has the capacity to function as an antioxidant in the context of the methods of this invention is an engineered antibody in which the ability to generate superoxide free radical from reducing singlet oxygen is diminished or preferably absent altogether. Such antibody molecules are described herein.
  • antioxidants are directed to situations in which an antioxidant is required to prevent, control, minimize, reduce, or inhibit the damage of an oxidant.
  • the invention contemplates the use of an antioxidant for reducing the antibody mediated production of hydrogen peroxide in a cell.
  • the cellular damage may be so extensive that tissue injury results, for example, in inflammatory conditions, in trauma conditions, in organ transplantation and the like.
  • the antibody having diminished or substantially no ability to generate superoxide or hydrogen peroxide since it lacks the reductive centers that reduce singlet oxygen, provides a therapeutic benefit in promoting a desired immune response without inducing additional tissue damage resulting from excess superoxide production.
  • Preferred engineered therapeutic antibody compositions retain their antigen binding site so that targeting to a particular antigen is achieved in concert with the desired therapeutic benefits.
  • the present invention further contemplates a method of ameliorating oxidative stress in a subject as well as alleviating a symptom in a subject where the symptom is associated with production of oxidant.
  • Exemplary of conditions in which the therapeutic methods of inhibiting the antibody mediated production of hydrogen peroxide with an antioxidant of the present invention include but are not limited to inhibiting aberrant smooth muscle disorder, inhibiting liver disease, proliferation of cancer cells, inhibiting inflammation in cancer patients receiving radiotherapy, inflammatory diseases (arthritis, vasculitis, glomerulonephritis, systemic lupus erythematosus, and adult respiratory distress syndrome), ischemic diseases (heart disease, stroke, intestinal ischemia, and reperfusion injury), hemochromatosis, acquired immunodeficiency syndrome, emphysema, organ transplantation, gastric ulcers, hypertension, preeclampsia, neurological diseases (multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and muscular dystrophy) alcoholism and smoking-related diseases.
  • inflammatory diseases arthritis, vasculitis, glomerulonephritis, systemic lupus erythematosus, and
  • Cells in which oxidative stress is deleterious include but are not limited to endothelial, interstitial, epithelial, muscle (smooth, skeletal or cardiac), phagocytic (including neutrophils and macrophages), white blood cells, dendritic, connective tissue and nervous system cells.
  • Effected tissues include but are not limited to muscle, nervous, skin, glandular, mesenchymal, splenic, sclerous, epithelial and endothelial tissues.
  • the oxidants and oxygen scavengers of the invention may be formulated into a variety of acceptable compositions. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate.
  • pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, - ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • salts are obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording a physiologically acceptable anion.
  • Alkali metal for example, sodium, potassium or lithium
  • alkaline earth metal for example calcium
  • the oxidants and oxygen scavengers may be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
  • the present compounds may be systemically administered, e.g., . orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
  • a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
  • the oxidants and oxygen scavengers may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
  • amount of oxidants and oxygen scavengers in such therapeutically useful compositions is such that an effective dosage level will be obtained.
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts may be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient that are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the oxidants and oxygen scavengers in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the oxidants and oxygen scavengers plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the oxidants and oxygen scavengers may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • a dermatologically acceptable carrier which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Examples of useful dermatological compositions that can be used to deliver the oxidants and oxygen scavengers of the present invention to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
  • Useful dosages of the oxidants and oxygen scavengers of the present invention can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • the concentration of the oxidants and oxygen scavengers of the present invention in a liquid composition will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%.
  • concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%), preferably about 0.5-2.5 wt-%.
  • the amount of the oxidants and oxygen scavengers, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
  • the oxidants and oxygen scavengers are conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
  • the oxidants and oxygen scavengers should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the oxidants and oxygen scavengers, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the oxidants and oxygen scavengers.
  • Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the oxidants and oxygen scavengers.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • an antioxidant enters the cell and reacts with the hydrogen peroxide or its precursor oxygen molecules thereby reducing the hydrogen peroxide concentration in the cell.
  • an antioxidant enters the cell or is present in the surrounding extracellular milieu and reacts with the oxidants generated from hydrogen peroxide.
  • compositions of this invention are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount .
  • the quantity to be administered and timing depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for various types of applications depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at intervals to result in the desired outcome of the therapeutic treatment.
  • Antioxidants contemplated for use in the present invention are delivered to the site of interest to mediate the desired outcome in a composition such as a liposome, the preparation of which is well known to one of ordinary skill in the art of liposome-mediated delivery.
  • Alternative delivery means include but are not limited to administration intravenously, topically, orally, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, and subcutaneously.
  • Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with an antioxidant as described herein or an antibody as described herein for providing antibody activity, dissolved or dispersed therein as an active ingredient.
  • the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.
  • compositions that contains active ingredients dissolved or dispersed therein are well understood in the art and need not be limited based on formulation.
  • compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • compositions of the present invention can include pharmaceutically acceptable salts of the components therein.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • Physiologically tolerable carriers are well known in the art.
  • Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
  • aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.
  • the present invention also generally contemplates the use of any antibody to generate superoxide radical or hydrogen peroxide in a situation where the production of superoxide or hydrogen peroxide is warranted.
  • the present invention also contemplates the use of engineered molecules including engineered antibodies that have been altered to contain a reductive center, the presence of which provides for the capability to generate superoxide or hydrogen peroxide from singlet oxygen when such production is desired.
  • engineered molecules having more than two reductive centers compared to a non-engineered antibody having the two conserved tryptophan residues is wa ⁇ anted when enhanced production of superoxide is needed.
  • the present invention contemplates the use of antibodies as defined above that contain the naturally occurring buried tryptophan residues as well as the engineered antibodies and other molecules described herein.
  • superoxide free radical also called superoxide
  • the use of engineered molecules having additional reductive centers is warranted when enhanced production of hydrogen peroxide is needed.
  • the present invention contemplates the use of antibodies as defined above that contain naturally occurring tryptophan residue as well as the engineered antibodies and other molecules described herein.
  • the present invention contemplates the therapeutic use of an antibody to create an superoxide or hydrogen peroxide environment where one does not exist or enhance an already existing one.
  • Such conditions are well known to practitioners in the art of oxygen cascade chemistry and the generation of oxidants to provide a desired beneficial outcome such as those described herein.
  • the invention contemplates a method for exposing an antigen to superoxide and hydrogen peroxide where the antigen is contacted with a composition including an antibody able to generate hydrogen peroxide or superoxide from singlet oxygen.
  • a composition including an antibody able to generate hydrogen peroxide or superoxide from singlet oxygen As previously discussed, the method is successful with either nonspecific or immunospecific (antigen directed ) intact antibody, fragments derived therefrom and further including single chain antibodies as well as the engineered molecules and antibodies described herein.
  • Exemplary concentrations of antibody at the cell surface range from 1 to 5 micromolar. However, the concentration may vary depending on the desired outcome where the amount of antibody provided is that amount of antibody that is sufficient to obtain the desired physiological effect, i.e, the generation of hydrogen peroxide or superoxide radical and its derivative oxidants to generate oxidative stress.
  • the antigen is preferably presented on a cell but need not be so limited.
  • the antigen can be any antigen that is present in a cell, tissue or organ including extracellular fluids where the presence of superoxide and the antibody mediated process of producing it is warranted.
  • the antigen is a fatty acid, a low density lipoprotein, an antigen associated with inflammation, a cancer cell antigen, a bacterial antigen or a similar molecule.
  • Cells on which antigens are associated include but are not limited to endothelial, interstitial, epithelial, muscle, phagocytic, blood, dendritic, connective tissue and nervous system cells. Particularly preferred target cells for the present therapeutic approach are neutrophils or macrophages.
  • the invention further contemplates exposing a target cell to irradiation with either ultraviolet, infrared or visible light in the method of generating antibody superoxide or hydrogen peroxide.
  • a superoxide or hydrogen peroxide generating amount of a photosensitizer is utilized in the therapeutic methods described herein.
  • a sensitizer is any molecule that induces or increases the concentration of singlet oxygen.
  • Sensitizers are generally used in the presence of irradiation, the process of which includes exposure to ultraviolet, infrared or visible light for a period sufficient to activate the sensitizer. Exemplary exposures are described in examples I and II.
  • a superoxide or hydrogen peroxide generating amount of sensitizer is the amount of sensitizer that is sufficient to obtain the desired physiological effect, e.g., generation of superoxide or hydrogen peroxide from singlet oxygen mediated by an antibody in any situation where superoxide or hydrogen peroxide presence and the derivatives thereof is warranted.
  • a sensitizer is conjugated to the antibody.
  • a sensitizer conjugated antibody is capable of binding to a antigen, i.e., retains an active antigen binding site, allowing for antigen recognition and complexing to occur.
  • sensitizers include but are not limited to pterins, flavins, hematoporphyrin, tetrakis(4-sulfonatophenyl)porphyrin, bipyridyl ruthemium(II) complexes, rose bengal dye, quinones, rhodamine dyes, phtalocyanine, and hypocrellins.
  • the generation of superoxide or hydrogen peroxide is enhanced by administering a means to enhance the production of singlet oxygen. Reduced singlet oxygen is the source of superoxide or hydrogen peroxide as previously discussed. Such reduction can occur through the action of an antibody or molecule containing greater than two reductive centers.
  • prodrug that is any molecule, compound, reagent and the like that is useful in generating singlet oxygen.
  • a preferred prodrug is endoperoxide, that is administered at a time subsequent to the administering or contacting of an antibody with a desired target cell, tissue or organ as described below.
  • endoperoxide is preferably delivered after a superoxide or hydrogen peroxide producing antibody or molecule has immunoreacted with its target antigen forming an antibody- antigen complex.
  • a preferred concentration of endoperoxide to achieve at the antibody-antigen complex site is about 10 micromolar.
  • Preferred therapeutic methods based on the use of an antibody including an engineered antibody or molecule having reductive centers to generate superoxide or hydrogen peroxide from singlet oxygen includes a method for killing a cancer cell where the cancer cell is contacted with a composition including an antibody capable of generating superoxide or hydrogen peroxide from singlet oxygen.
  • the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell.
  • Such methods are therapeutically useful for a subject with lung cancer, prostate cancer, colon cancer, cervical cancer, endometrial cancer, bladder cancer, bone cancer, leukemia, lymphoma, or brain cancer.
  • the cancer cell is removed from a subject with cancer and cultured ex vivo for exposing to an antibody, and can further be exposed to ultraviolet light, infrared light or visible light for the cell to then be returned to the subject.
  • the antibody composition is delivered in vivo to a subject with cancer. Preferred in vivo delivery methods include administration intravenously, topically, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, subcutaneously or by liposome containing the antibody.
  • the antibody is a recombinant antibody, that is provided as above or alternatively is expressed from an expression vector delivered to the cell.
  • the expression vector in this context can also express a sensitizer molecule.
  • Therapeutic compositions in pharmaceutically acceptable excipients and pharmaceutically effective amounts as described for antioxidant containing compositions are applicable to the use of antibody containing compositions.
  • Additional therapeutic methods based on using an antibody that is able to generate superoxide or hydrogen peroxide from singlet oxygen are 1) for inhibiting proliferation of a cancer cell, 2) for targeting and killing a cancer cell in a patient where the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell, 3) for inhibiting tissue injury associated with neutrophil mediated inflammation in a subject, for example where the inflammation results from a bacterial infection or when the subject has an autoimmune disease, 4) for enhancing the bactericidal effectiveness of a phagocyte in a subject, 5) for promoting wound healing in a subject having a open wound where the superoxide or hydrogen peroxide stimulates fibroblast proliferation and/or the immune response that further includes lymphocyte proliferation, 6) for stimulating cell proliferation, such as stimulating fibroblast proliferation in a wound in a subject, and the like situations.
  • topical application to a wound on a subject is a preferable delivery approach such as with a bandage containing an antibody.
  • Other therapeutic conditions that would benefit from the creation or enhancement of superoxide or hydrogen peroxide in a cell, tissue, organ or extracellular compartment are well known to those of ordinary skill in the art and have been reviewed by
  • the invention further contemplates screening methods that are based on the newly discovered antibody reduction of singlet oxygen to hydrogen peroxide or superoxide radical.
  • the invention contemplates a method for identifying an agent that modulates antibody mediated production of hydrogen peroxide or superoxide.
  • a modulator is a molecule that either inhibits or promotes the production of superoxide or hydrogen peroxide. Either type of modulator is identifiable with the same method.
  • the method includes the steps of: a) contacting a composition comprising an antibody capable of generating superoxide or hydrogen peroxide with an agent to form an admixture in an assay solution in the presence of molecular oxygen; b) irradiating the admixture to generate singlet oxygen from molecular oxygen, wherein the singlet oxygen is reduced to hydrogen peroxide or superoxide by the antibody, wherein the superoxide dismutates to form hydrogen peroxide; c) detecting the formed hydrogen peroxide; and d) comparing the detected hydrogen peroxide with a suitable control, thereby determining how the agent modulates the production of hydrogen peroxide or superoxide.
  • the irradiating step is performed with either ultraviolet light or visible light.
  • a sensitizer as previously described can be added with the antibody composition.
  • the formed hydrogen peroxide is detected through reaction directly with a hydrogen peroxide where the reacted substrate is detected with a fluorescent means, such as with fluorescent microscopy or fluorescent spectrometry.
  • a fluorescent means such as with fluorescent microscopy or fluorescent spectrometry.
  • detection is ELISA based or with done with a standard cuvette. Exemplary assay methods are performed as described in examples I and II.
  • a method for performing an immunoassay to detect antibody immunoreactivity with an antigen is also contemplated based on the discovery of antibody generated superoxide or hydrogen peroxide.
  • the method comprises the steps of: a) contacting in a singlet oxygen-generating medium a substrate having immobilized thereon a composition comprising a first reagent comprising an antigen or an antibody, with a second composition comprising an antigen or an antibody that is reactive with the first reagent to form an immobilized antigen-antibody complex, wherein the antibody generates superoxide or hydrogen peroxide from singlet oxygen in the presence of oxygen; and b) detecting the antibody-generated superoxide or hydrogen peroxide, thereby detecting the antibody immunoreactivity with the antigen.
  • the reaction and detection means are those as described herein.
  • the first composition is an antigen and the second composition is an antibody.
  • the first composition is an antibody and the second composition is an antigen.
  • the invention further contemplates a similar method for performing an immunoassay to detect antibody immunoreactivity with an antigen where an antigen is immobilized and contacted with an antibody composition.
  • Such immunoassay methods are an improvement over those that are well known as methods to assess antigen-antibody immunoreactivity and to identify antigens and/or antibodies.
  • the advantage of the present method over previous other immunoassay methods lies in the present elimination of at least one method step and/or the incorporation of a secondary labeled immunoreactive molecule, the labeling either being a radioactive or enzymatic compound.
  • the minimum requirements are oxygen, an antibody reagent, an antigen reagent, and a detectable reactant that reacts with hydrogen peroxide generated from the antibody.
  • a preferred reactant is a fluorogenic substrate.
  • One such reactant used as described in examples I and II is called
  • AMPLEXTM Red It is a commercially available reagent sold by Molecular Probes (Eugene, Oregon) for reacting antibody generated hydrogen peroxide in the immunoassay. It is sold in a kit that provides a one-step fluorometric method for measuring hydrogen peroxide using a fluorescent microplate or fluorimeter for detection. The assay is based on the detection of hydrogen peroxide using 10-acetyl- 3,7-dihyroxyphenoxazine, a highly sensitive and stable probe for hydrogen peroxide.
  • the AMPLEXTM Red reagent reacts with hydrogen peroxide in a 1 :1 stoichiometry to produce highly fluorescent resorufin, that provides a detection mechanism to detect as little as 10 picomoles of hydrogen peroxide in a 200 microliter volume.
  • prior immunoassay techniques including radioimmunoassays
  • RIA radioactively labeled immunoreactive molecule
  • EIA enzyme-immunoassays
  • ELISA enzyme-linked immunosorbent assay
  • the antibody mediated generation of hydrogen peroxide is detected with high detection capacity without radioactive agents, without requiring an additional reagent and or admixing step such as those practiced in US Patents 3,905,767; 4,016,043; USRE032696; and 4,376,110, the disclosures of which are hereby incorporated by reference. 3.
  • Therapeutic Compositions are described in detail below.
  • the present invention contemplates therapeutic compositions useful in practicing the therapeutic methods as described above.
  • Antibodies as a class of proteins, are now known to act as reductants in reducing singlet molecular oxygen (also referred to herein as singlet oxygen) to generate superoxide free radical (also referred to herein as superoxide).
  • singlet oxygen also referred to herein as singlet oxygen
  • superoxide free radical also referred to herein as superoxide
  • the indole in view of the redox reaction where the indole portion becomes oxidized forming a radical cation in the reaction of reducing singlet molecule oxygen to superoxide free radical, the indole is referred to as a reductive center.
  • a reductive center is more efficient if it is not solvent-exposed, i.e., is buried within the therapeutic composition defined herein.
  • compositions may also be produced and used according to the therapeutic methods described above with antibodies and engineered molecules that produce hydrogen peroxide through oxidation of water.
  • Antibodies as a class of proteins, are now known to catalyze the oxidation of water to produce hydrogen peroxide. The activity is ascribed to a conserved tryptophan residue.
  • compositions that are useful in either acting to reduce the local concentration of hydrogen peroxide or superoxide production or in the alternative useful in acting to enhance it.
  • Such compositions contain reagents referred to generally as being "engineered”, defined herein to connote a reagent, such as an antibody or fragment thereof as defined herein, or other molecule, that has been altered in some form to either increase or decrease the number of reductive centers as defined herein.
  • the invention thus contemplates an antibody that has been engineered to have at least a diminished capacity to generate hydrogen peroxide or superoxide free radical from singlet oxygen.
  • the antibody lacks at least one of its reductive centers and preferably is substantially free of a reductive center.
  • Such antibody compositions are readily prepared with recombinant expression methods well known to one of ordinary skill in the art.
  • the antibody retains the same amino acid residue number but the reductive center has been replaced or substituted with a component that lacks the ability to reduce singlet oxygen.
  • the reductive center comprises a buried indole and preferably, in the case of superoxide, two buried indoles.
  • the reductive center comprises an indole on a tryptophan residue that is substituted by another amino acid that does not have reductive capacity.
  • Such preferred substitutions includes the amino acids phenylalanine and alanine.
  • the present invention also contemplates deletion of the tryptophan without replacement or substitution thereof as long as the desired antibody activity, particularly antigen binding activity, is not adversely affected.
  • an engineered antibody having reduced or absent reductive centers while retaining antigen targeting ability provides the therapeutic advantage of providing an antibody to stimulate a desired immune response in particular situations while reducing or eliminating altogether the undesirable production of hydrogen peroxide or superoxide and its byproducts that can further damage cells and tissues.
  • Methods for making an engineered antibody that functions as an antioxidant in the context of the therapeutic methods described herein are well known in the art, such as site- directed mutagenesis of a nucleotide sequence encoding the antibody of interest as previously discussed.
  • Engineered antibodies that function as an antioxidant according to the methods of the invention are contemplated for any of the methods as described herein.
  • the present invention also contemplates engineered therapeutic molecules including engineered antibodies that have been altered to contain a reductive center where they were in an insufficient amount to effect adequate production of superoxide or hydrogen peroxide, or where they are needed to increase the number of reductive centers to a number in excess of those that were naturally occurring in the molecule or antibody.
  • Introduction of a reductive center in a engineered molecule or antibody is accomplished by methods well known to one of ordinary skill in the art. Preferred means including recombinant expression methods and well as direct protein synthesis methods have been previously described. The choice of method is necessarily dependent on the length of the molecule being engineered.
  • the positioning, i.e., the location, of the engineered reductive center is based upon the ability of the engineered molecule to exhibit reducing activity on singlet oxygen.
  • the incorporation of reductive centers are positioned such that they are deeply buried in the folded molecule allowing a retention of structural ability without comprising superoxide or hydrogen peroxide production.
  • the location of an engineered reductive center is adjacent to a variable binding domain.
  • one reductive center is contemplated.
  • two reductive centers are contemplated.
  • more than three reductive centers are contemplated.
  • the reductive centers comprise indole.
  • reductive centers comprising indole present in tryptophan residue. Any technique to engineer such reductive centers in a molecule or antibody is contemplated for use in the present invention.
  • the reductive centers are introduced by site-directed mutagenesis of nucleotide sequences encoding the engineered antibody such that the substituted nucleotides encode tryptophan residues at predeteraiined locations in the encoded molecule.
  • an engineered molecule such as an antibody to include desired reductive centers
  • such molecule that is produced by recombinant technology is also contemplated to be in the form of a fusion conjugate, where the conjugate provides a sensitizer molecule as previously described for use in therapeutic methods as described herein.
  • Antibodies have the intrinsic capacity to destroy antigens Materials and Methods Antibodies: The following whole antibodies were obtained from PharMingen: 49.2 (mouse IgG 2b K), G155-178 (mouse IgG 2a K), 107.3 (mouse IgG, K), A95-1 (rat IgG 2b ), G235-2356 (hamster IgG), R3-34 (rat IgG K), R35-95 (rat IgG 2a K), 27-74 (mouse IgE), Al 10-1 (rat IgG, X), 145-2C11 (hamster IgG groupl K), Ml 8-254 (mouse IgA K), and MOPC-315 (mouse IgA ⁇ ). The following were obtained from Pierce: 31243 (sheep IgG), 31154 (human IgG), 31127 (horse IgG), and 31146 (human IgM).
  • F(ab') 2 fragments were obtained from Pierce: 31129 (rabbit IgG), 31189 (rabbit IgG), 31214 (goat IgG), 31165 (goat IgG), and 31203 (mouse IgG).
  • Protein A protein G, trypsin-chymotrypsin inhibitor (Bowman-Birk inhibitor), ⁇ -lactoglobulin A, ⁇ -lactalbumin, myoglobin, ⁇ -galactosidase, chicken egg albumin, aprotinin, trypsinogen, lectin (peanut), lectin (Jacalin), BSA, superoxide dismutase, and catalase were obtained from Sigma.
  • Ribonuclease I A was obtained from Amersham Pharmacia. The following immunoglobulins were obtained in-house using hybridoma technology: OB2-34C12 (mouse IgG, ⁇ ) 5 SHO1-41G9 (mouse IgG, K), OB3-14F1 (mouse IgG 2a K), DMP-15G12 (mouse IgG 2a K), AD1-19G1 (mouse IgG 2b K), NTJ-92C12 (mouse IgG, K), NBA-5G9 (mouse IgG, K), SPF-12H8 (mouse IgG 2a K), TIN-6C11 (mouse IgG 2a K), PRX-1B7 (mouse IgG 2a K), HA5-19A11 (mouse IgG 2a K), EP2-19G2 (mouse IgG, K), GNC- 92H2 (mouse IgG, K), WD1-6G6 (
  • DRB polyclonal (human IgG) and DRB-M2 (human IgG) were supplied by Dennis R. Burton (The Scripps Research Institute).
  • 1D4 Fab (crystallized) was supplied by Ian A. Wilson (The Scripps Research Institute).
  • IgG 19G12 (100 ⁇ l, 6.7 ⁇ M) was heated to 100°C in an Eppendorf tube for 2 min. The resultant solution was transferred to a glass, screw- cap vial and irradiated with UV light for 30 min. The concentration of H 2 O 2 was determined after 30 min.
  • the antibody is a remarkable adaptor molecule, having evolved both targeting and effector functions that place it at the frontline of vertebrate defense against foreign invaders (Burton, D. R., Trends Biochem. Sci.. 15. 64-69 (1990)).
  • the central idea is that antibodies themselves do not possess destructive ability but mark foreign substances for removal by the complement cascade and/or phagocytosis (Arlaud et al., Immunol. Today. 8, 106- 111 (1987): Sim & Reid. Immunol. Today. 12. 307-311 (1991)).
  • the advent of antibody catalysis has demonstrated that antibodies are capable of much more complex chemistry than simple binding (Wentworth & Janda, Curr. Opin. Chem. Biol..
  • the preliminary step in the phagocytic oxidative burst is the single electron reduction of ground-state molecular oxygen ( 3 O 2 ) by the NADPH-dependent transmembrane phagocyte oxidase enzyme system that generates superoxide anion (O 2 * ⁇ ) (Figure 1) (Klebanoff, S. J. in Encyclopedia of Immunology, eds. Delves, P. J. & Roitt, I. M. (Academic, San Diego), pp. 1713-1718 (1998); Rosen, H. & Klebanoff, S. J., J. Biol. Chem.. 252. 4803-4810 (1997)).
  • O 2 * ⁇ is a vital reducing agent that regenerates Fe 2+ , thus facilitating the iron-catalyzed Haber- Weiss reaction, or the so-called superoxide-driven Fenton reaction that produces HO * (Esq. 1 and 2). Therefore, processes that facilitate the generation of O 2 * ⁇ will ultimately perpetuate and potentiate oxygen-dependent microbicidal action.
  • Another key component of the oxygen-scavenging cascade is singlet molecular oxygen ( ] O 2 ).
  • This particularly reactive species is an excited state of molecular oxygen in which both outer shell electrons are spin-paired (Kearns, D. R., Chem. Rev.. 71. 395-427 (1971)). It is important in pathological biological systems and has a very short life-time (ca. 4 ⁇ s) in vivo (Foote, C. S. in Free Radicals in Biology, ed. Pryor, W. A. (Academic, New York), pp. 85-133 (1976)).
  • Generation of ' O 2 during microbicidal processes is either direct, via the action of flavoprotein oxidases (Allen, R.
  • O 2 * + 2HO * 2 ⁇ O 2 + H 2 O 2
  • the high reactivity of O 2 with biomolecules has meant that it is generally considered to be an endpoint in the cascade of oxygen-scavenging agents.
  • antibodies as a class of proteins, have the intrinsic ability to intercept O 2 and efficiently reduce it to O 2 * ⁇ , thus offering a mechanism by which oxygen can be rescued and recycled during phagocyte action, thereby potentiating the microbial action of the immune system.
  • the rates of hydrogen peroxide formation were linear for more than 10% of the reaction, with respect to the oxygen concentration in PBS under ambient conditions (275 ⁇ M). With sufficient oxygen availability, the antibodies can generate at least 40 equivalents of H 2 O 2 per protein molecule without either a significant reduction in activity or structural fragmentation.
  • An example of the initial time course of hydrogen peroxide formation in the presence or absence of antibody 19G2 is shown in Figure 3 A. This activity is lost following denaturation of the protein by heating.
  • the data in Table 1 reveal a universal ability of antibodies to generate H 2 O 2 from O 2 . This function seems to be shared across a range of species and is independent of the heavy and light chain compositions investigated or antigen specificity.
  • the initial rates of hydrogen peroxide formation for the intact antibodies is highly conserved, varying from 0.15 nmol/min/mg [clone A95-l(rat IgG2b)] to 0.97 nmol/min/mg (clone PCP-21H3, a murine monoclonal IgG) across the whole panel.
  • the information available is more limited for the component antibody fragments, the activity seems to reside in both the Fab and F(ab') 2 fragments.
  • the rate of hydrogen peroxide formation is proportional to IgG concentration between 0.5 and 20 ⁇ M but starts to curve at higher concentrations (Figure 5C).
  • the lifetime of O 2 in protein solution is expected to be lower than in pure water due to the opportunity for reaction. It is therefore thought that the observed curvature may be due to a reduction in the lifetime of 1 0 2 due to reaction with the antibody.
  • the effect of oxygen concentration on the observed rate of H 2 O 2 production shows a significant saturation about 200 ⁇ M of oxygen (Figure 5D). Therefore, the mechanism of reduction may involve either one or more oxygen binding sites within the antibody molecule.
  • a - " m app(O 2 ) of 187 ⁇ M and a max app of 0.4 nmol/min/mg are obtained.
  • This antibody rate is equivalent to that observed for mitochondrial enzymes that reduce molecular oxygen in vivo. The mechanism by which antibodies reduce ] O 2 is still being determined.
  • Aromatic amino acids such as tryptophan (T ⁇ ) can be oxidized by O 2 via electron transfer (Grossweiner, L. I., Curr. Top. Radiat. Res. P.. JLi, 141-199 (1976)).
  • disulfides are sufficiently electron rich that they can also be oxidized (Bent. D. V. & Hayon, E., J. Am. Chem. Soc. 87, 2612-2619 (1975)).
  • chick ovalbumin which has only 2 T ⁇ residues (Feldhoff, R. & Peters, T. J., Biochem. J.. 159. 529-533 (1976)), is one of the most efficient proteins at reducing J O 2 .
  • Aromatic amino acids in proteins are modified by the abso ⁇ tion of ultraviolet light, especially in the presence of sensitizing agents such as molecular oxygen or ozone (Foote, C. S., Science. 162. 963-970 (1968); Foote, C. S., Free Radicals Biol..
  • T ⁇ reacts with ! O 2 via a [2 + 2] cycloaddition to generale N-formylkynurenine or kynurenine, which are both known to significantly quench the emission of buried T ⁇ residues (Mach, H., Burke, C. J., Sanyal, G., Tsai, P.-K, Volkin, D. B. & Middaugh, C. R. in Formulation and Delivery of Proteins and Peptides. eds. Cleland, J. L. & Langer, R. (American Chemical Society, Denver, CO) (1994)).
  • IgG 4C6 was digested with papain and the Fab' fragment purified using standard protocols (Harlow and Lane). The Fab' was crystallized from 13-18%) PEG 8 K, 0.2 M ZnAc, 0.1 M cacodylate, pH 6.5. Crystals were pressurized under xenon gas at 200 psi for two minutes (Soltis et al., J. Appl. Crvst.. 30. 190, (1997)) and then flash cooled in liquid nitrogen. Data were collected to 2.0 A resolution at SSRL BL9-2. The structure was solved by molecular replacement using coordinates from the native 4C6 structure, and xenon atom sites were identified from strong peaks in the difference Fourier map.
  • Inductively coupled plasma atomic emission spectroscopy ICP-AES
  • ICP-AES Inductively coupled plasma atomic emission spectroscopy
  • PCP21H3 Mouse monoclonal antibody (PCP21 H3) was exhaustively dialyzed into sodium phosphate buffered saline (PBS, 50 mM pH 7.4) with 20 mM EDTA.
  • PBS sodium phosphate buffered saline
  • EDTA sodium phosphate buffered saline
  • 300 ⁇ L of a 10.5 % HNO 3 solution was added to 100 ⁇ L of a 10 mg/mL antibody solution and was incubated at 70°C for 14 hours.
  • Oxygen isotope experiments In a typical experiment, a solution of antibody (6.7 ⁇ M, 100 ⁇ L) or non-immunoglobulin protein (50 ⁇ M, 100 ⁇ L) in PB (160 mM phosphate; pH 7.4) was lyophilized to dryness and then dissolved in H 2 0 2 (100 ⁇ L, 98 %). Sodium chloride was excluded to minimize signal suppression in the MS. The higher concentration of non-immunoglobulin protein was necessary to generate a detectable amount of H 2 0 2 for the MS assay. This protein solution was irradiated on a UV-transilluminator under saturating 16 0 2 aerobic conditions in a sealed quartz cuvette for 8 hours at 20°C.
  • the H 2 0 2 concentration was determined after 8 hours using the Amplex Red assay (Zhou et al., Anal. Biochem.. 253. 162 (1997)). The sample was then filtered by centrifugation through a microcon (size-exclusion filter) to remove the protein and the H 2 0 2 concentration re-measured.
  • TCEP freshly prepared 20 mM stock in H 2 18 0
  • TCEP was added (ca. 2 mol eq relative to H 2 0 2 ) and the solution was left to stand at 37°C for 15 minutes, after which time all the H 2 0 2 had reacted.
  • the TCEP solution in H 2 18 0 was prepared fresh prior to every assay because 18 0 is slowly inco ⁇ orated into the carboxylic acids of TCEP (over days). During the time course of the assay, no inco ⁇ oration of ls O occurs due to this pathway. Furthermore, there is no inco ⁇ oration of 18 0 from H 2 18 0 into the 16 0 phosphine oxide.
  • the peak at 249 m/z is the (M-H) " of TCEP. The peak at 249 is observed in all the MS because an excess of TCEP (twofold) relative to H 2 0 2 is used in the assay.
  • Antibodies from different species give similar ratios within the experimental constraints detailed below: 16 O: ]8 O: WD1-6G6 mlgG (murine) 2.1:1; polylgG (horse) 2.2:1; polylgG(sheep) 2.2:1; EP2-19G2 mlgG (murine) 2.1: 1; CH2-5H7 mlgG (murine) 2.0:1; polylgG (human) 2.1:1. Ratios are based on the mean value of duplicate determinations except for polylgG (horse) which is the mean value often measurements. All assays and conditions are as described above.
  • the assay is a modification of a procedure developed by H. Sakai and co-workers, Proc. SPIE-Int. Soc. Opt. Eng.. 2371. 264 (1995).
  • the horse polylgG (1 mg/mL) in PBS (50 mM, pH 7.4) and hematopo ⁇ hyrin IX (40 ⁇ M) is irradiated with white light from a transilluminator. Aliquots are removed (50 ⁇ L) and the concentration of H 2 O 2 and 3-aminophthalic acid measured simultaneously. H 2 O 2 concentration was measured by the amplex red assay (Zhou et al., Anal. Biochem.. 253. 162 (1997)).
  • the concentrations of luminol and 3-aminophthalic acid were determined by comparison of peak height and area to control samples.
  • the experimental data yields the amount of ] O 2 formed by hematopo ⁇ hyrin IX (being directly proportional to the amount of 3-aminophthalic acid formed) and the amount of H 2 O 2 formed by the antibody. ⁇ .B. There is no significant amount of ] O 2 formed by antibodies without hematopo ⁇ hyrin IX in white light.
  • amplex red assay may be detecting protein- hydroperoxide derivatives in addition to H 2 O 2 have been discounted because the apparent H 2 O 2 concentration measured using this method is independent of whether irradiated protein is removed from the sample (by size-exclusion filtration).
  • Antibodies are capable of generating hydrogen peroxide (H 2 O 2 ) from singlet molecular oxygen ( ] O 2 ). However, it was not known until now, as reported herein, that the process was catalytic and the source of electrons. It is now shown that antibodies are unique as a class of proteins in that they can produce up to 500 mole equivalents of H 2 O 2 from ] O 2 , without a reduction in rate, in the absence of any discernible cofactor and electron donor. Based on isotope inco ⁇ oration experiments and kinetic data, it is proposed that antibodies are capable of facilitating an unprecedented addition of H 2 O to O 2 to form H 2 O 3 as the first intermediate in a reaction cascade that eventually leads to H 2 O 2 .
  • Antibodies regardless of source or antigenic specificity, generate hydrogen peroxide (H 2 O 2 ) from singlet molecular oxygen ( ] O 2 ) thereby potentially aligning recognition and killing within the same molecule (Wentworth et al., Proc. Natl. Acad. Sci. U.S.A.. 97, 10930 (2000)). Given the potential chemical and biological significance of this discovery, the mechanistic basis and structural location within the antibody of this process has been investigated. These combined studies reveal that, in contrast to other proteins, antibodies may catalyze an unprecedented set of chemical reactions between water and singlet oxygen.
  • the ⁇ TCR shares a similar arrangement of its immunoglobulin fold domains with antibodies (Garcia et al., Science. 274. 209 (1996)). However, possession of this structural motif seems not necessarily to confer an H 2 O 2 -generating ability on proteins as demonstrated by ⁇ 2 -microglobulin which does not generate H 2 O 2 even though it is a member of the immunoglobulin superfamily (Welinder et al., Mol. Immunol., 28. 177 (1991)).
  • the antibody structure is remarkably inert against the oxidizing effects of H 2 O 2 .
  • a polyclonal horse IgG antibody sample becomes fully active once the inhibitory H 2 O 2 has been destroyed by catalase ( Figure 8E).
  • Figure 8E The ability to continue H 2 O 2 production for long periods at a constant rate, even after exposure to H 2 O 2 , reveals a remarkable, and hitherto unnoticed, resistance of the antibody structural fold to both chemical and photo-oxidative modifications suffered by other proteins.
  • RMSD root mean square difference
  • the mechanism problem posed by the antibody-mediated H 2 O 2 production from singlet oxygen has to be sha ⁇ ly divided into two sub-problems: one referring to the electron source for the process and the other concerning the chemical mechanism of the process.
  • the fact that antibodies can generate > 500 equivalents of H 2 O 2 per equivalent of antibody molecule raises an acute electron inventory problem.
  • the search for this electron source began with the most distinct possibilities. Since electron transfer through proteins can occur with remarkable facility and over notably large distances (Winkler et al., Pure & Appl. Chem.. 71, 1753 (1999); Winkler, Curr. Opin. Chem. Biol..
  • ROS reactive oxygen species
  • the photo-production of H 2 O 2 by T ⁇ and molecular oxygen is a well-characterized process that involves, at least in part, the fo ⁇ nation and reduction of O 2 to O 2 * that spontaneously dismutates into H 2 O 2 and 3 O 2 (McMormick and Thompson, J. Am. Chem. Soc. 100. 312 (1978)).
  • Tryptophan both as an individual amino-acid and as a constituent of proteins, is particularly sensitive to near-UN irradiation (300-375 nm) under aerobic conditions, owing to its conversion to N'-formylkynurenine ( ⁇ FK) that is a particularly effective near-UN ( ⁇ max 320 nm) photosensitizer (Walrant and Santus, Photochem.
  • the antibody's function as a catalyst would have to be the supply of a specific molecular environment that would stabilize the critical intermediate relative to its reversible formation and, or, would accelerate the consumption of the intermediate by channeling its conversion to H 2 O 2 .
  • An essential feature of such an environment might consist of a special constellation of organized water molecules at an active site conditioned by an antibody-specific surrounding.
  • Plesnicar and co-workers have shown that H 2 O 3 , reductively generated from ozone, decomposes into H 2 O and O 2 (Koller and Plesnicar, J. Am. Chem. Soc. 118, 2470 (1996)).
  • H 2 O 3 has a barrier of only 15.5 or 0 kcal/mol respectively, suggesting that H 2 O 3 is not stable in bulk water or water rich systems.
  • the best site within the antibody structure for producing and utilizing H 2 O 3 is expected to be one in which there are localized waters and water dimers next to hydrophobic regions without such waters.
  • the 16 O/ 18 O ratio in the phosphine oxide derived from the antibody-catalyzed photo-oxidation of water poses a significant constraint to the selection of reaction paths by which this primary intermediate H 2 O 3 would to convert to the final product H 2 O 2 .
  • the ratio is primarily determined by the number of 1 0 2 molecules that chemically participate in the production of two moles of H 2 O 2 from two moles of H 2 O as well as by mechanistic details of this process.
  • a ratio of 2.2:1 would coincide exactly with the value predicted for certain mechanisms in which two molecules of ] O 2 and two molecules of H 2 O are transformed into two molecules of H 2 O 2 and one molecule of molecular oxygen (which would have to be 3 O 2 for thermodynamic reasons).
  • the xenon I binding site (Xel site) has been analyzed here in more detail because it is conserved in all antibodies and the ⁇ TCR ( Figure 13B).
  • Xel is in the middle of a highly conserved region between the ⁇ -sheets of V L , 7 A from an invariant T ⁇ .
  • the Xel site is sandwiched between the two ⁇ -sheets that comprise the immunoglobulin fold of the N L , approximately 5 A from the outside molecular surface.
  • Xenon site two (Xe2) sits at the base of the antigen binding pocket directly above several highly conserved residues that form the structurally conserved interface between the heavy and light chains of an antibody ( Figure 13 A).
  • the residues in the N L N H interface are primarily hydrophobic and include conserved aromatic side chains, such as T ⁇ H109 .
  • the contacting side chains for Xel in Fab 4C6 are Ala L19 , Ile L21 , Leu L73 , and Ile L75 , which are highly conserved aliphatic side chains in all antibodies (Kabat et al., Sequences of Proteins of Immunological Interest (US Department of Health and Human Services, Public Health Service, ⁇ IH, ed. 5th, 1991)). Additionally, only slight structural variation was observed in this region in all antibodies surveyed. Notably, several other highly conserved and invariant residues are in the immediate vicinity of this xenon site, including T ⁇ L35 , Phe L62 , Tyr L86 , Leu L104 , and the disulfide-bridge between Cys L23 and Cys L88 .
  • T ⁇ L35 stacks against the disulfide-bridge and is only 7 ⁇ from the xenon atom.
  • T ⁇ L35 may be a putative molecular oxygen sensitizer, since it is the closest T ⁇ to Xel. Comparison with the 2C ⁇ TCR structure and all available TCR sequences shows that this Xel hydrophobic pocket is also highly conserved in TCRs ( Figure 5B) (Garcia, Science, 274. 209 (1996)).
  • Human ⁇ 2 -microglobulin which does not generate H 2 O 2 , does not have the same detailed structural characteristics that define the antibody Xel binding pocket, despite its overall immunoglobulin fold. Also, ⁇ 2 -microglobulin does not contain the conserved T ⁇ residue that occurs there in both antibodies and TCRs. If T ⁇ L35 (antibodies) or T ⁇ ⁇ 34 (TCR) is the oxygen sensitizer, the lack of a corresponding T ⁇ in ⁇ 2 -microglobulin may relate to the finding that it does not catalyze the oxidation of water.
  • the xenon experiments have identified at least one site that is both accessible to molecular oxygen and is in a conserved region (N L ) in close proximity to an invariant T ⁇ ; an equivalent conserved site is also possible in the fold of N H
  • N L conserved region
  • the structure and sequence around the Xel site is almost exactly reproduced in the N H domain by the pseudo two-fold rotation axis that relates N L to N H .
  • Antibodies are unique among proteins in their ability to catalytically convert O 2 into H 2 O 2 . It is thought that this process participates in killing by event-related production of H 2 O 2 . Alternatively, antibodies can fulfill the function of defending an organism against ! O 2 . This would require the further processing of hydrogen peroxide into water and triplet oxygen by catalase.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)

Abstract

The invention relates generally to the field of immunology. More specifically, the invention relates the finding that antibodies can generate superoxide and hydrogen peroxide from singlet oxygen. Accordingly, methods and compositions able to increase or decrease oxidative stress are provided. Also provided are screening assays to identify agents that modulate the ability of a antibody to generate superoxide and hydrogen peroxide. Such agents can be used therapeutically to treat patients in need. Further, the invention provides methods to use antibodies in immunoassays.

Description

METHODS AND COMPOSITIONS RELATING TO HYDROGEN PEROXIDE AND SUPEROXIDE PRODUCTION BY ANTIBODIES
Field of the Invention The invention relates to methods for the antibody-mediated generation of superoxide free radical from singlet oxygen. The invention also relates to the generation of hydrogen peroxide from singlet oxygen. Therapeutic methods are based upon both enhancing and inhibiting these processes. Screening methods relate to identifying modulators of antibody-mediated generation of hydrogen peroxide and superoxide free radical through the respective increase or decrease in detectable hydrogen peroxide or superoxide. The invention further relates to a simplified immunoassay based on detecting hydrogen peroxide. The invention also relates to therapeutic compositions that are engineered to increase the production of hydrogen peroxide and superoxide free radical as well as compositions that are engineered to prevent this production.
Background A relevant biological basis relating to varying disease mechanisms and conditions is that of oxidative stress and the consequent production of free radicals that paradoxically are both beneficial and detrimental to cellular metabolism. Human metabolism is oxygen based. As such, the chemical reactions relating to oxidative processes play a central role in cellular homeostasis.
In the oxygen cascade, reactive oxygen species resulting from incomplete reduction of oxygen include among others the free radicals, superoxide radical (O2 ") and hydroxyl radical (OH*), that have one or more unpaired electrons. Superoxide spontaneously reacts with itself in a dismutation reaction to form hydrogen peroxide (H2O2). The formed hydrogen peroxide, while not being a free radical, under certain situations, e.g., in the absence of catalase, becomes a cytotoxic oxidant through the formation of hydroxyl radical and hypochlorous acid (HOCl) (McCord, Amer. J. Med.. 108:652-659 (2000)). Intracellularly, most of the superoxide is generated as a result of mitochondrial respiration (McCord, Amer. J. Med.. 108:652-659 (2000)). At low superoxide concentration, the conversion to hydrogen peroxide is catalyzed by superoxide dismutase, a process that helps maintain a lower steady-state concentration of superoxide (Babior et al., Amer. J. Med.. 109:33-34 (2000)).
Another highly reactive molecule involved in the oxygen cascade is singlet oxygen ('O2). Singlet oxygen results from irradiation by light of metal- free porphyrin precursors that are present in the skin of porphyria sufferers. Singlet oxygen is also generated by neutrophils and is thought to be responsible for damage created by phagocytes on their targets (Babior et al., Amer. J. Med.. 109:33-34 (2000)). Based on its high reactivity with biomolecules, singlet oxygen has generally been considered to be an endpoint in the cascade of oxygen-scavenging agents.
The reactive nature of free radicals causes them to have both positive and negative effects on cells and on whole organisms. Methods to inhibit the negative effects of these reactive species would be tremendously beneficial in the treatment of many conditions. Also, methods to utilize the positive effects of these reactive species would be beneficial to control such things as cell proliferation and infection. Accordingly, methods and agents are needed to modulate the generation of free radicals and other reactive species.
Summary of the Invention The invention provides methods for utilizing the newly discovered abilities of an antibody to reduce singlet oxygen to superoxide. This catalytic reaction ultimately results in the formation of hydrogen peroxide. The invention also provides methods to utilize antibodies to produce hydrogen peroxide from singlet oxygen by the oxidation of water. Hydrogen peroxide, under certain biological conditions, itself generates reactive molecules. Thus, the invention generally provides methods to inhibit and facilitate these processes depending on the desired outcome. The invention further relates to screening methods to identify agents that modulate the newly discovered antibody-mediated processes. The invention further contemplates an improved immunoassay format based on the direct detection of hydrogen peroxide that is produced by antibody catalyzed oxidation of water. The invention also provides an improved immunoassay based on hydrogen peroxide produced from antibody-generated superoxide in the presence of singlet oxygen. The invention also contemplates therapeutic compositions, preferably antibody compositions, that are engineered to exhibit increased or decreased oxidative function.
Brief Description of the Drawings Figure 1 illustrates the oxygen-dependent microbicidal action of phagocytes. The interconversion of O2 and O2 *" is indicated and is an intrinsic ability to antibodies.
Figure 2 illustrates the amplex red assay.
Figure 3 shows the initial time course of H2O2 production in PBS (pH 7.4) in the presence (□) or absence (Δ) of murine monoclonal IgG EP2-19G2 (20 μM). Error bars show the range of the data from the mean.
Figure 4 shows the fluorescent micrograph of a single crystal of murine antibody 1D4 Fab fragment after UN irradiation and H2O2 detection with the amplex red reagent.
Figure 5 illustrates the (A) HP sensitization assay. Time course of H2O2 formation in PBS (pH 7.4) with HP (40 μM) and visible light, in the presence (O) or absence (♦) of 31127 (horse IgG, 20 μM). (B) Initial time course of H2O2 production with HP (40 μM) and visible light, in the presence of 31127 (horse IgG, 6.7 μM) with no additive in PBS (pH 7.4) (D) or ΝaΝ3 in PBS (pH 7.4) (O, 100 μM) or in a D2O solution of PBS (pH 7.4) (0). (C) Protein concentration (31127, horse IgG) versus rate of H2O2 formation. (D) Oxygen concentration on the rate of H2O2 generation with 31127 (horse IgG, 6.7 μM). All points are mean values of at least duplicate experimental determinations. Error bars are the range of experimentally measured values from the mean. Figure 6 is a bar graph showing the measured initial rate of H2O2 formation for a panel of proteins and comparison with antibodies (data from Table I). All points are mean values of at least duplicate experimental determinations. Error bars are the range of experimentally measured values form the mean. ONA, chick-egg ovalbumin; SOD, superoxide dismutase.
Figure 7 shows (A) the rate of H2O2 formation by UN irradiation of horse IgG (6.7 μM) in PBS (pH 7.4). (B) simultaneous fluorescence emission of the horse IgG, measured at 326 nm (excitation = 280 nm).
Figure 8 shows H2O2 production. (A) Production of H2O2 by immunoglobulins and non-immunoglobulin proteins. Assays were performed by near-UV irradiation (312 nm, 800 μW cm"2) of individual protein samples (100 μL, 6.7 μM) in phosphate-buffered saline (PBS) [10 mM sodium phosphate, 150 mM ΝaCl (pH 7.4)] in a sealed glass vial on a transilluminator (Fischer Biotech) under ambient aerobic conditions at 20°C. Aliquots (10 μL) were removed throughout the assay. H2O2 concentration was determined by the amplex red method. Each data point is reported as the mean ± SEM of at least duplicate measurements: [• polyclonal (poly) immunoglobulin (Ig) G, human; O poly IgG, horse; D polylgG, sheep; V monoclonal (m) IgG (WD1-6G6), murine; Δ polylgM, human; o mlgG (92H2), murine; ■ β-galactosidase (β-gal); * chick ovalbumin (ONA); ▼ α-lactalbumin (α-lact); ♦ bovine serum albumin (BSA)]. (B) Long-term production of H2O2 by sheep polylgG (6.7 μM, 200 μL). Νear-UN irradiation for 8 hours in PBS in a sealed well of a 96-well quartz plate. H2O2 concentration was measured as described in (A). (C) A solution of PCP-21H3, mlgG (murine) (6.7 μM, 200 μL), was irradiated in PBS in a sealed well of a 96 well quartz plate for 510 min. The H2O2 was assayed by the amplex red assay and then destroyed by addition of catalase (10 mg, 288 mU) immobilized on Eupergit C. The catalase was removed by filtration and the antibody solution re-irradiated for 420 min. Rate (0-510 min) = 0.368 , μM min ' (r2 = 0.998); rate (511-930 min) = 0.398 μM min 1 (r2 = 0.987). (D) Determination of IC50 of H2O2 on the photo-production of H2O2 by horse polylgG. A solution of horse IgG (6.7 μM) was incubated with varying concentrations of H2O2 (0-450 μM) and the initial rate of H2O2 formation measured as described in (A). The graph is a plot of rate of H2O2 formation versus H2O2 concentration and reveals an IC50 of 225 μM. (E) Long-term inhibition of antibody photo-production of H2O2 by H2O2 and complete re-establishment of activity. The assay involved an initial UN. irradiation of horse polylgG (6.7 mM in PBS pH 7.4) in the presence of H2O2 (450 μM) for 360 min. The H2O2 was then removed by catalase (immobilized on Eupergit C) and the polylgG sample was re-irradiated with UN light for a further 480 minutes. H2O2 formation throughout the assay was measured by the amplex red assay. (F) A solution of αβ-TCR (6.7μM, 200 μL) was irradiated as described in (C) for periods of 360, 367 and 389 min. The H2O2 generated during each irradiation was assayed and destroyed as described in (C). Rate (0-360 min) = 0.693 μM min"1 (r2 = 0.962). The curvature in the progress curve above 200 μM conforms to the expected inhibition by H2O2 (vide infra); rate (361-727 min) = 0.427 μM min ' (r2 = 0.987); rate (728-1117 min) = 0.386 μM min ' (r2 = 0.991).
Figure 9 illustrates the superposition of native 4C6 Fab (light blue and pink in a color photograph) and 4C6 Fab in the presence of H2O2 (dark blue and red in a color photograph) (A). The native 4C6 crystals were soaked for 3 minutes in 4 mM H2O2, and immediately flash frozen for data collection at SSRL BL 9-1. The overall structural integrity of the secondary and tertiary structure is clearly preserved in the presence of H2O2 (RMSD Ca - 0.33 A, side chain = 0.49 A). The RMSD was calculated in CΝS. (B) High resolution x-ray structures show that Fab 4C6 is cross-reactive with benzoic acid. Superposition of the 4C6 combining site with and without H2O2 demonstrates that even the side chain conformations within the binding site are preserved (light and dark colored side chains in a color photograph correspond to + and - H2O2 respectively). Moreover, clear electron density for the benzoic acid underscores that the binding properties of Fab 4C6 remain unaltered in 4mM H2O2. The electron density map is a 2f0-fc sigma weighted map contoured at 1.5σ, and the figures were generated in Bobscript.
Figure 10 shows the absorbance spectra of horse polyclonal IgG measured on a diode array HP8452A spectrophotometer, Absmax 280 nm (A). (B) Action spectra of horse polyclonal IgG, between 260 and 320 nm showing maximum activity of H2O2 formation at 280 nm. The assay was performed in duplicate and involved addition of an antibody solution [6.7 μM in PBS (pH 7.4)] to a quartz tube that was then placed in a light beam produced by a xenon arc lamp and monochromator of an SLM specfrofluorimeter for 1 hour. H2O2 concentration was measured by the amplex red assay.
Figure 11 shows the production of H2O2. (A) Production of H2O2 by tryptophan (20 μM). The conditions and assay procedures were as described in Figure 8 A. (B) Effect of chloride ion on antibody-mediated photo-production of H2O2 A solution of sheep polylgG ■ (6.7 μM, 200 μL) or horse polylgG * (6.7 μM, 200 μL) was lyophilized to dryness and then dissolved in either deionized water or NaCl (aq.) such that the final concentration of chloride ion were (0-160 mM). The samples were then irradiated, in duplicate, in sealed glass vials on a transilluminator (800 μW cm"2) under ambient aerobic conditions at 20 °C. Aliquots (10 μL) were removed throughout the assay and the H2O2 concentration determined by the amplex red assay. The rate of H2O2 formation is plotted as the mean ± S.E.M. versus [NaCl] for each antibody sample. (C) Effect of dialysis into EDTA-containing buffers on antibody-mediated photo-production of H2O2. The photo-production of H2O2 by two antibody preparations, mouse monoclonat antibody PCP21H3 and horse polyclonal IgG, were compared before and after dialysis into PBS containing EDTA (20 mM). The conditions and assay procedures were as described in Figure 8A. Each data point is reported as the mean ± SEM of at least duplicate measurements: [• murine mlgG PCP21H3 before dialysis; ■ murine mlgG PCP21H3 after dialysis; * polylgG, horse before dialysis; ♦ polylgG, horse after dialysis.
Figure 12 shows ESI (negative polarity) mass spectra of TCEP [(M-H)" 249] and its oxide [(M-H)" 265 (16O) and (M-H)" 267 (18O)] produced by oxidation with H2O2. (A) MS of TCEP and its oxides after irradiation of sheep polylgG (6.7/μM) under 16O2 aerobic conditions in H2 18O (98 % 18O) PB. (B) MS of TCEP and its oxides after irradiation of sheep polylgG (6.7 μM) under enriched 18O2 (90 % 18O) aerobic conditions in H2 16O PB. (C) MS of TCEP and its oxides after irradiation of the polylgG performed under 16O2 aerobic concentration in H2 16O PB. The assay conditions and procedures were as described in the methods and materials (Example II) with the exception that H2 16 O replaced H2 18O. (D) MS of TCEP and its oxides after irradiation of sheep polylgG (6.7 μM) and H2 16O2 (200 μM) under anaerobic (degassed and under argon) conditions in H2 18O PB for 8 hours at 20°C. Addition of TCEP was as described in the methods and materials (Example II). (E) MS of TCEP and its oxides after irradiation of 3-methylindole (500 μM) under 16O2 aerobic conditions in H2 18O PB. The assay conditions and procedures were as described in the methods and materials (Example II) with the exception that size-exclusion filtration was not performed because 3-methyl indole is of too low molecular weight. Therefore, TCEP was added to the 3-methyl indole-containing PB solution. (F) MS of TCEP and its oxides after irradiation of β-gal (50 μM) under 16O2 aerobic conditions in H2 18O PB. Assay conditions and procedures are as described in the methods and materials (Example II).
Figure 13 shows the Xe binding sites in antibody 4C6 as described in materials and methods (Example II). (A) Standard side view of the Ca trace of Fab 4C6 with the light chain in pink and the heavy chain in blue in a color photograph. Three bound xenon atoms (green in a color photograph) are shown with the initial F0-Fc electron density map contoured at 5 σ. (B) Overlay of Fab 4C6 and the 2C αβ TCR (PDB/TCR) around the conserved xenon site 1. The backbone Cα trace of NL (pink in a color photograph) and side chains (yellow in a color photograph) and the corresponding Nα of the 2C αβ TCR (red and gold in a color photograph) are superimposed (figure generated using Insight2000).
Detailed Description of the Invention The present invention concerns the discovery that antibodies, as a class of molecules, have an inherent capability to intercept singlet oxygen and convert it to either superoxide or hydrogen peroxide. This process acts to rescue and recycle oxygen, particularly during phagocyte-mediated processes, thereby contributing to microbicidal action of the immune system. These properties are common to all antibodies and were not known prior to the present invention. The common ability to convert singlet oxygen to superoxide or hydrogen peroxide, regardless of source or antigenic specificity, is thought to link the previously appreciated recognition properties of antibodies with killing events. The present invention provides methods that relate to the ability of an antibody to reduce singlet oxygen (!O2) to superoxide radical (O2 ") and hydrogen peroxide. In view of the critical nature and role of oxygen metabolism in an aerobic organism, the identification of this biological process provides multiple and varied methods as described herein. The detailed determination and characterization of the antibody-mediated reduction of singlet oxygen is described in examples I and II.
As demonstrated in the examples, these properties are universal abilities of all antibodies.
Superoxide Production by Antibodies
The ability to produce superoxide from singlet oxygen is present in both intact immunoglobulins and well as Fab and F(ab')2 fragments (see examples). The activity does not reside in molecules, including RΝaseA, superoxide dismutase, and Bowman-Birk inhibitor protein, that can be oxidized (example I and Table 1). Also, the activity is not associated with the presence of disulfides in a molecule, even though they are sufficiently electron rich that they can be oxidized (Bent et al. J. Am. Chem. Soc. 87:2612-2619 (1975T). Rather, the activity resides in an aromatic amino acid such as tryptophan that can be oxidized by singlet molecular oxygen via electron transfer (Grossweiner, Curr. Top. Radiat. Res. P..11:141-199 (1976)). The activity is further attributed to the indole component of the tryptophan residue. Thus, the indole acts as a reductive center in connection with the redox reaction. The indole portion becomes oxidized to form a radical cation in the course of reducing singlet molecule oxygen to superoxide free radical. In the same context, the antibody is called a reductant because it is oxidized in providing an electron to singlet molecular oxygen. It is believed that oxidized antibody interaction with an in vivo antioxidant completes the catalytic cycle and returns the antibody to neutrality. The ability of an antibody to generate superoxide from singlet oxygen is abolished if the antibody is denatured. This indicates that the location of the oxidized molecules in the reactive center of the antibody is relevant to the reduction process used to generate superoxide. In particular, the reduction of singlet molecular oxygen is primarily due to the two tryptophan residues that are buried in the molecule rather than the solvent-exposed ones (example I). Such buried aromatic residues in proteins, including antibodies, are generally considered to contribute to structure stability (Burley, et al., Science. 229:23-28 (1985)). Furthermore, two aromatic tryptophan resides are conserved, referred to as TRP-36 and TRP-47, and are both deeply buried (Kabat, et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD (1991)). The ability of antibodies as a class of proteins to reduce singlet molecular oxygen to superoxide anion is thus based on the presence of the conserved buried aromatic tryptophan residues. Hydrogen Peroxide Production by Antibodies
The ability to produce hydrogen peroxide in an efficient and long term manner from singlet oxygen is present in immunoglobulins and in the T-cell receptor (example II, Figure IF). The T-cell receptor shares a similar arrangement of its immunoglobulin fold domains with antibodies (Garcia et al., Science, 274:209 (1996)). However, possession of this structural motif does not appear necessary to confer a hydrogen peroxide-generating ability on proteins. β2-macroglobulin, a member of the immunoglobulin superfamily having this structural motif, does not generate hydrogen peroxide (Welinder et al., Mol. Immunol.. 28:177 (1991)). Structural studies suggest that a conserved tryptophan residue found in both the T-cell receptor and in antibodies may play a role in the oxidation of water. The catalytic role of the tryptophan conserved in antibodies and in the T-cell receptor is further supported by the observation that the β2-macroglobulin lacks the conserved residue as well as the catalytic activity. Furthermore, the sequence and structure surrounding the conserved tryptophan residue is highly conserved between antibodies and the T-cell receptor indicating that it may also play a role in allowing catalysis of singlet oxygen to hydrogen peroxide.
Information relating the structure to the function of immunoglobulins and the T-cell receptor allows molecules to be designed that will catalyze the oxidation of water. This information also provides many new methods and treatment schemes that may be utilized based on existing molecules.
Definitions Abbreviations: (HP) hematoporphyrin; (PBS) phosphate buffered saline; (ONA) chick-egg ovalbumin; (SOD) superoxide dismutase; (PO) peroxidase enzymes; (phox) phagocyte oxidase; (HRP) horseradish peroxidase; (MS) mass spectroscopy; (AES) ICP-atomic emission spectroscopy; (MS) mass-spectral, (QC) quantum chemical.
The term "agent" herein is used to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials such as bacteria, plants, fungi, or animal
(particularly mammalian) cells or tissues. Agents are evaluated for potential activity as antibody modulatory agents by inclusion in screening assays as described herein.
The term "antibody" as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab')2, and Fv which are capable of binding an epitope. These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows:
(1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
(2) Fab', the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds;
(4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and
(5) Single chain antibody ("sFv"), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green, et al., Production of Polyclonal Antisera, in: Immunochemical Protocols (Manson, ed.), pages 1-5 (Humana Press); Coligan, et al., Production of Polyclonal Antisera in Rabbits, Rats Mice and Hamsters, in: Current Protocols in Immunology, section 2.4.1 (1992), which are hereby incorporated by reference.
The preparation of monoclonal antibodies is also conventional. See, for example, Kohler & Milstein, Nature. 256:495 (1975); Coligan, et al., sections 2.5.1-2.6.7; and Harlow, et al., in: Antibodies: A Laboratory Manual, page 726 (Cold Spring Harbor Pub. (1988)), which are hereby incorporated by reference. Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, e.g., Coligan, et al., sections 2.7.1-2.7.12 and sections 2.9.1-2.9.3; Barnes, et al., Purification of Immunoglobulin G (IgG), in: Methods in Molecular Biology. Vol. 10, pages 79-104 (Humana Press (1992).
Methods of in vitro and in vivo manipulation of monoclonal antibodies are well known to those skilled in the art. One particular manipulation involves the process of humanizing a monoclonal antibody by recombinant means to generate antibodies containing human specific and recognizable sequences. See, for review, Holmes, et al., J. Immunol..158:2192-2201 (1997) and Naswani, et al., Annals Allergy. Asthma & Immunol.. 81:105-115 (1998).
Methods of making antibody fragments are known in the art (see for example, Harlow and Lane, Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, New York, (1988), incorporated herein by reference). Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, in US Patents No. 4,036,945 and No. 4,331 ,647, and references contained therein. These patents are hereby incorporated in their entireties by reference.
Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody. For example, Fv fragments comprise an association of NH and NL chains. This association may be noncovalent or the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise NH and NL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DΝA sequences encoding the NH and NL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two N domains. Methods for producing sFvs are described, for example, by Whitlow, et al., Methods: a Companion to Methods in Εnzymology. Vol. 2, page 97 (1991); Bird, et al, Science. 242:423-426 (1988); Ladner, et al, US Patent No. 4,946,778; and Pack, et al., Bio/Technology.11:1271-77 (1993). Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick, et al., Methods: a Companion to Methods in Εnzymology. Nol. 2, page 106 (1991).
The terms "effective amount", "effective reducing amount", "effective ameliorating amount", "effective tissue injury inhibiting amount", "therapeutically effective amount" and the like terms as used herein are terms to identify an amount sufficient to obtain the desired physiological effect, e.g., treatment of a condition, disorder, disease and the like or reduction in symptoms of the condition, disorder, disease and the like. Such an effective amount of an antioxidant in the context of therapeutic methods is an amount that results in reducing, reversing, ameliorating, inhibiting, and the like improving directions, the effects of an oxidant generated by an antibody.
An "engineered molecule" is a polypeptide that has been produced through recombinant techniques. Such molecules can include a reactive center that can catalyze the production of superoxide or hydrogen peroxide from singlet oxygen. Such engineered molecules may have a reactive indole contained within a polypeptide structure. The indole of such a molecule may be present as a tryptophan residue. Engineered molecules may also contain non- natural amino acids and linkages as well as peptidomimetics. Engineered molecules also include antibodies that are modified to eliminate the reaction center such that they are no longer able to generate superoxide or hydrogen peroxide. As used herein, the term "epitope" means any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Antigens can include polypeptides, fatty acids, lipoproteins, lipids, chemicals, hormones and the like. In some embodiments, antigens include, but are not limited to, proteins from viruses such as human immunodeficiency virus, influenza virus, herpesvirus, papillomavirus, human T-cell leukemia virus and the like. In other embodiments, antigens include, but are not limited to, proteins expressed on cancer cells such as lung cancer, prostate cancer, colon cancer, cervical cancer, endometrial cancer, bladder cancer, bone cancer, leukemia, lymphoma, brain cancer and the like. Antigens of the invention also include chemicals such as ethanol, tetrahydrocanabinol, LSD, heroin, cocaine and the like.
The term "modulate" refers to the capacity to either enhance or inhibit a functional property of an antibody or engineered molecule of the invention, such as production of superoxide or hydrogen peroxide.
A "non-natural" amino acid includes D-amino acids as well as amino acids that do not occur in nature, as exemplified by 4-hydroxyproline, γ- carboxyglutamate, O-phosphoserine, N-acetylserine, N-formylmethionine, 3- methylhistidine, 5-hydroxylysine and other such amino acids and imino acids. The term "peptidomimetic" or "peptide mimetic" describes a peptide analog, such as those commonly used in the pharmaceutical industry as non- peptide drugs, with properties analogous to those of the template peptide. (Fauchere, J., Adv. Drug Res.. 15: 29 (1986) and Evans et al., J. Med. Chem.. 30:1229 (1987)). Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage such as, -CH2NH-, ~CH2S~, -CH2-CH2-, -CH=CH- (cis and trans), -COCH2-, ~CH(OH)CH2~, and ~CH2SO-, by methods known in the art. Advantages of peptide mimetics over natural polypeptide embodiments may include more economical production, greater chemical stability, altered specificity, reduced antigenicity, and enhanced pharmacological properties such as half-life, absorption, potency and efficacy.
As used herein, the terms "phamiaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
The terms "protein" and "polypeptide" are used to describe a native protein, fragments, or analogs of a polypeptide sequence. These terms may be used interchangeably. Antibodies
The invention provides therapeutic antibodies. All antibody molecules belong to a family of plasma proteins called immunoglobulins. Their basic building block, the immunoglobulin fold or domain, is used in various forms in many molecules of the immune system and other biological recognition systems. A typical immunoglobulin has four polypeptide chains, contains an antigen binding region known as a variable region, and contains a non- varying region known as the constant region. An antibody contemplated for use in the present invention can be in any of a variety of forms, including a whole immunoglobulin, Fv, Fab, other fragments, and a single chain antibody that includes the variable domain complementarity determining regions (CDR), or other forms. All of these terms fall under the broad term "antibody" as used herein. The present invention contemplates the use of any specificity of an antibody, polyclonal or monoclonal, and is not limited to antibodies that recognize and immunoreact with a specific antigen. In preferred embodiments, in the context of both the therapeutic and screening methods described herein, an antibody or fragment thereof is used that is immunospecific for an antigen.
The preparation of a therapeutic antibody of this invention can be accomplished by recombinant expression techniques as well as protein synthesis, methods of which are well known to one of ordinary skill in the art. For recombinant approaches, mutation of a nucleic acid that encodes an antibody or fragment thereof can be conducted by a variety of means, but is most conveniently conducted using mutagenized oligonucleotides that are designed to introduce mutations at predetermined sites that then encode an altered amino acid sequence in the expressed molecule. Such alterations include substitutions, additions, and/or deletions of particular nucleotide sequences that similarly encode substitutions, additions, and/or deletions of the encoded amino acid residue sequence. Site-directed mutagenesis, also referred to as oligonucleotide-directed mutagenesis and variations thereof, and the subsequent cloning of the altered genes are well known techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed., Chapter 15, Cold Spring Harbor Laboratory Press, (1989)). Another recombinant approach includes synthesizing the gene encoding a therapeutic molecule of this invention by combining long oligonucleotide strands that are subsequently annealed and converted to double-stranded DNA suitable for cloning and expression (Ausebel et al., Current Protocols in Molecular Biology. Units 10 and 15, Wiley and Sons, Inc. (2000)). Such techniques can be used to create engineered molecules that contain a reduction center and are able to generate hydrogen peroxide or superoxide from singlet oxygen. It is contemplated that such engineered molecules can be designed based on antibody structure and on the T-cell receptor, in the case of hydrogen peroxide. Thus, the present invention contemplates an antibody that has been engineered to generate more superoxide free radical or hydrogen peroxide in a desired location. The antibody is engineered to contain additional reductive centers, as described in examples I and II herein, that increase the reduction of singlet molecular oxygen to superoxide free radical or hydrogen peroxide. The invention also contemplates an antibody that has been engineered to have at least a diminished capacity to generate superoxide free radical or hydrogen peroxide from singlet oxygen. In that context, the antibody lacks at least one of its reductive centers and preferably is substantially free of a reductive center. Such antibody compositions are readily prepared with methods well known to one of ordinary skill in the art.
If desired, polyclonal or monoclonal antibodies prepared for use as therapeutic compositions or in the methods of invention can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (Coligan, et al., Unit 9, Current Protocols in Immunology. Wiley Interscience, (1991)). 1. Therapeutic Methods
Because aerobic organisms rely on oxygen metabolism in a chemical environment where the toxicity of oxygen and metabolites thereof are paramount consequence, these organisms have evolved a multitude of mechanisms to maintain homeostasis and the overall health of the organism. The toxic potential of oxygen is attributed to the formation, in vivo, of reactive free radicals. To become toxic, oxygen must be activated, a process that occurs either by photoactivation resulting in singlet oxygen production or by reduction followed by the formation of hydrogen peroxide and the hydroxyl radical. The latter process is accelerated by the presence of transition metals, such as iron and copper, and/or specific enzymes such as monooxygenase. These processes occur in cellular compartments including mitochondria, microsomes, peroxysomes and the cytoplasmic membrane. See, Sahnoun et al., Therapie, 52:251-270 (1997).
The free radicals that result from oxygen activation are by definition chemical species that possess one or several mismatched electrons. Free radicals are generated when a single electron is removed from the molecule. This results in a molecule that has at least one of its electrons unpaired to another electron. The resultant free radical is reactive since it seeks out available electrons from other molecules, the process of which can create a second reactive molecule thereby setting off a chain reaction. Free radicals, also referred to as oxidants herein include superoxide, hydroxyl radical, halogenated oxygens and nitrogen containing molecules. Superoxide radical generated from the antibody-mediated reduction of singlet oxygen is itself an oxidant and also provides for the production of hydrogen peroxide. The latter, which while not itself an oxidant or reactive molecule, can generate reactive oxygen species that include hydroxyl radical, its secondary products such as carbon, oxygen, nitrogen or sulfur, which can react with other compounds to produce yet other free radicals creating a free radical chain reaction. (Babior et al., Am. J. Med.. 109:33-44 (2000)). Other reactive species that are a consequence of the oxygen cascade include oxidized halogens, such as hypochlorous acid (HOCl), the HOCl-generated reactive species chloramine (NH2C1) and aldehydes, and reactive nitrogen species.
A potential consequence of uncontrolled reactivity of free radicals is damage to DNA, RNA, membrane lipids, lipoproteins or enzymes, ultimately affecting the body. An end result is poor cell function leading to disease and even tissue death. Paradoxically, free radicals aid the process of riding the body of unwanted bacteria or viruses. However, when the production of radicals is excessive or in the wrong location, acute and chronic cellular and tissue injury can occur.
To counteract these reactions, aerobic organisms have evolved certain built-in mechanisms to keep the equilibrium of oxygen metabolism in check. These mechanisms broadly include inhibition of oxygen activation processes as well as neutralization of free radicals already formed. Neutralizing processes include 1) enyzmes such as superoxide dismutase and catalase that together produce peroxidases and 2) molecules such as tocopherols, carotenoids, ubiquinones, flavonoids, ascorbic acid, uric acid and similar molecules that serve as a source of electrons that are provided to free radicals without damaging cellular components. Such processes are considered beneficial to the well being of an organism. For example, the authors of a recent paper have correlated an increase in life span in an animal with exposure to superoxide dismutase/catalase mimetics (Melov et al., Science, 289:1567-1569 (2000)). In the context of the present invention, any molecule that inhibits the antibody mediated generation of hydrogen peroxide or superoxide that ultimately leads to hydrogen peroxide formation is referred to as an antioxidant. Such prefeπed antioxidants of this invention are described below.
When the balance of oxidants to antioxidants tips in favor of the former, the oxidative state is generally referred to as "oxidative stress". This situation occurs in the presence of an excess production of oxidants or free radicals and a diminishing of the control antioxidant mechanisms. Advantages of the present invention are that the discovery of the role an antibody plays in the generation of oxidants in the oxygen cascade provides the basis for therapeutic methods that are useful in maintaining oxygen balance and control of oxygen metabolism, depending on the desired outcome. In other words, the methods of this invention provide 1) for the production of oxidants when their production is warranted, such as in promoting wound healing, lysing bacteria, eliminating viruses, targeting cancer cells for oxidant-induced lysis and the like processes, and 2) for the inhibition of antibody generated oxidants by exposure of antioxidants when the inhibition of antibody generated oxidants is warranted, such as in inflammation, heart conditions, diabetes and unwanted cellular proliferation. For example, one may want to use antibody mediated generation of superoxide or hydrogen peroxide to supplement the local concentration of superoxide concentration generated by phagocytic neutrophils to combat a bacterial infection in a wound. Here the neutrophil that contains NADPH oxidase produces superoxide radical in the presence of molecular oxygen. The superoxide in effect acts as bactericidal agent destroying the bacteria and ultimately the neutrophil in the process. Thus, to enhance this process, one would use the method of this invention to provide an antibody composition to the area to cause an increase in the local concentration of superoxide. On the other hand, neutrophil-generated superoxide is deleterious in inflamed joints such as in patients with rheumatoid arthritis who are concomitantly undergoing intensive humoral antibody-mediated immune responses. In such conditions, one would want to employ the opposing therapeutic method of this invention in providing an antioxidant to control the production of damaging oxidants produced by both neutrophils and antibodies in the local environment. The decision to use the methods of this invention to inhibit or promote the antibody- mediated generation of superoxide and hydrogen peroxide and their derivatives (i.e., molecules derived therefrom) products and/or their effects is thus dependent on the desired outcome.
A. Inhibiting Antibody Activity
According to the invention, certain therapeutic methods for affecting "antibody mediated production of hydrogen peroxide" have been developed. Thus, the term "antibody mediated production of hydrogen peroxide" encompasses the reactive species that are both precursor and derivative to the generation of hydrogen peroxide.
The use of molecules that effect the antibody mediated production of hydrogen peroxide is applicable to any situation in which unwanted, deleterious, damaging production of reactive oxidant species that are generated by antibodies. The molecules that are useful in these situations are referred to generally as "antioxidants", defined as any molecule that has an antagonist effect to an oxidant. An antioxidant so defined includes 1) inhibitors of an antibody thereby inhibiting superoxide generation, 2) inhibitors of hydrogen peroxide generation, 3) inhibitors of the reactions converting hydrogen peroxide into derivative reactive oxidants; and 4) inhibitors of the reactive oxidants themselves. Preferred antioxidants include those that inhibit the activation of oxygen producing reactive oxidants as well as those neutralizing those already formed. The antioxidant effect can occur by any mechanism, including catalysis. Antioxidants as a category include oxygen scavengers or free radical scavengers. Antioxidants may be of different types so they are available if and when they are needed. In view of the presence of oxygen throughout an aerobic organism, antioxidants may be available in different cellular, tissue, organ and extracellular compartments. The latter include extracellular fluid spaces, intraocular fluids, synovial fluid, cerebrospinal fluid, gastrointestinal secretions, interstitial fluid, blood and lymphatic fluid. Antioxidants are present within an organism but are also provided by supplementing the diet and in the methods of this invention. Particularly preferred antioxidants include but are not limited to ascorbic acid, α-tocopherol, γ-glutamylcysteinylglycine, γ-glutamyl transpeptidase, α-lipoic acid, dihydrolipoate, -acetyl-5-methoxytryptamine, flavones, flavonenes, flavanols, catalase, peroxidase, superoxide dismutase, metallothionein, and butylated hydroxytoluene. A further preferred molecule that has the capacity to function as an antioxidant in the context of the methods of this invention is an engineered antibody in which the ability to generate superoxide free radical from reducing singlet oxygen is diminished or preferably absent altogether. Such antibody molecules are described herein.
The use of antioxidants is directed to situations in which an antioxidant is required to prevent, control, minimize, reduce, or inhibit the damage of an oxidant. Thus, the invention contemplates the use of an antioxidant for reducing the antibody mediated production of hydrogen peroxide in a cell. In such situations, without intervention, the cellular damage may be so extensive that tissue injury results, for example, in inflammatory conditions, in trauma conditions, in organ transplantation and the like. In the context of using an engineered antibody as an antioxidant, the antibody, having diminished or substantially no ability to generate superoxide or hydrogen peroxide since it lacks the reductive centers that reduce singlet oxygen, provides a therapeutic benefit in promoting a desired immune response without inducing additional tissue damage resulting from excess superoxide production. Preferred engineered therapeutic antibody compositions retain their antigen binding site so that targeting to a particular antigen is achieved in concert with the desired therapeutic benefits. The present invention further contemplates a method of ameliorating oxidative stress in a subject as well as alleviating a symptom in a subject where the symptom is associated with production of oxidant. Exemplary of conditions in which the therapeutic methods of inhibiting the antibody mediated production of hydrogen peroxide with an antioxidant of the present invention include but are not limited to inhibiting aberrant smooth muscle disorder, inhibiting liver disease, proliferation of cancer cells, inhibiting inflammation in cancer patients receiving radiotherapy, inflammatory diseases (arthritis, vasculitis, glomerulonephritis, systemic lupus erythematosus, and adult respiratory distress syndrome), ischemic diseases (heart disease, stroke, intestinal ischemia, and reperfusion injury), hemochromatosis, acquired immunodeficiency syndrome, emphysema, organ transplantation, gastric ulcers, hypertension, preeclampsia, neurological diseases (multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and muscular dystrophy) alcoholism and smoking-related diseases. Cells in which oxidative stress is deleterious include but are not limited to endothelial, interstitial, epithelial, muscle (smooth, skeletal or cardiac), phagocytic (including neutrophils and macrophages), white blood cells, dendritic, connective tissue and nervous system cells. Effected tissues include but are not limited to muscle, nervous, skin, glandular, mesenchymal, splenic, sclerous, epithelial and endothelial tissues.
The literature as well as patented inventions describe the use of antioxidants and oxygen scavengers to treat various conditions induced by oxidative stress, other than that relating to the generation of oxidants by an antibody as described in the present invention. Thus, the disclosures of US Patents 5,362,492; 5,599,712; 5,637,315; 5,647,315; 5,747,026; 5,848,290;
5,994,339; 6,030,611 and 6,040,611 support the therapeutic uses of antioxidants in the present invention, and as such, the disclosures of which patents are hereby incorporated by reference.
The oxidants and oxygen scavengers of the invention may be formulated into a variety of acceptable compositions. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, - ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts are obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids also are made.
The oxidants and oxygen scavengers may be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., . orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the oxidants and oxygen scavengers may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of oxidants and oxygen scavengers in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices. The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts may be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient that are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the oxidants and oxygen scavengers in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the oxidants and oxygen scavengers plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the oxidants and oxygen scavengers may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid. Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
Examples of useful dermatological compositions that can be used to deliver the oxidants and oxygen scavengers of the present invention to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
Useful dosages of the oxidants and oxygen scavengers of the present invention can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the oxidants and oxygen scavengers of the present invention in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%), preferably about 0.5-2.5 wt-%.
The amount of the oxidants and oxygen scavengers, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
The oxidants and oxygen scavengers are conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. Ideally, the oxidants and oxygen scavengers should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the oxidants and oxygen scavengers, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the oxidants and oxygen scavengers. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the oxidants and oxygen scavengers. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
In a preferred embodiment, an antioxidant enters the cell and reacts with the hydrogen peroxide or its precursor oxygen molecules thereby reducing the hydrogen peroxide concentration in the cell. In an alternative embodiment, an antioxidant enters the cell or is present in the surrounding extracellular milieu and reacts with the oxidants generated from hydrogen peroxide.
The therapeutic compositions of this invention, the antioxidants described herein, antibodies that include both engineered antibodies and other molecules containing additional reductive centers as described herein for promoting antibody activity, are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount . The quantity to be administered and timing depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for various types of applications depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at intervals to result in the desired outcome of the therapeutic treatment.
Antioxidants contemplated for use in the present invention are delivered to the site of interest to mediate the desired outcome in a composition such as a liposome, the preparation of which is well known to one of ordinary skill in the art of liposome-mediated delivery. Alternative delivery means include but are not limited to administration intravenously, topically, orally, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, and subcutaneously. Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with an antioxidant as described herein or an antibody as described herein for providing antibody activity, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes. The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
The therapeutic compositions of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.
Other therapeutic conditions that would benefit from the antioxidant inhibition of antibody mediated oxidant production in a cell, tissue, or organs as well as extracellular compartments are well known to those of ordinary skill in the art and have been reviewed by McCord, Am. J. Med.. 108:652-659 (2000) and Babior et al., Am. J. Med.. 109:33-44 (2000), the disclosures of which are hereby incorporated by reference.
B. Providing Antibody Activity The present invention also generally contemplates the use of any antibody to generate superoxide radical or hydrogen peroxide in a situation where the production of superoxide or hydrogen peroxide is warranted. The present invention also contemplates the use of engineered molecules including engineered antibodies that have been altered to contain a reductive center, the presence of which provides for the capability to generate superoxide or hydrogen peroxide from singlet oxygen when such production is desired. In the case of superoxide, the use of engineered molecules having more than two reductive centers compared to a non-engineered antibody having the two conserved tryptophan residues is waπanted when enhanced production of superoxide is needed. Thus, for the therapeutic methods that benefit from a production of superoxide free radical, also called superoxide, the present invention contemplates the use of antibodies as defined above that contain the naturally occurring buried tryptophan residues as well as the engineered antibodies and other molecules described herein. In the case of hydrogen peroxide, the use of engineered molecules having additional reductive centers is warranted when enhanced production of hydrogen peroxide is needed. Thus, for the therapeutic methods that benefit from a production of hydrogen, the present invention contemplates the use of antibodies as defined above that contain naturally occurring tryptophan residue as well as the engineered antibodies and other molecules described herein.
The conditions under which hydrogen peroxide or superoxide radical and its consequent production of hydrogen peroxide is generated by an antibody is more completely described in examples I and II. The minimum requirement for generating hydrogen peroxide or superoxide is the presence of oxygen, i.e., aerobic conditions. The biological reduction of singlet oxygen to hydrogen peroxide or superoxide radical that results in hydrogen peroxide occurs both visible light and ultraviolet irradiation conditions. In the former, the production of hydrogen peroxide is enhanced in the presence of photosensitizer molecules such as hematoporphyrin. Moreover, ultraviolet light irradiation is not essential for the antibody mediated reduction events. In the absence of light, antibody mediated production of superoxide or hydrogen peroxide occurs when aerobic conditions are present along with a superoxide or hydrogen peroxide generating amount of photosensitizer.
In view of the minimal requirements for the antibody mediated generation of hydrogen peroxide or superoxide that results in hydrogen peroxide production, the present invention contemplates the therapeutic use of an antibody to create an superoxide or hydrogen peroxide environment where one does not exist or enhance an already existing one. Such conditions are well known to practitioners in the art of oxygen cascade chemistry and the generation of oxidants to provide a desired beneficial outcome such as those described herein.
In one embodiment, the invention contemplates a method for exposing an antigen to superoxide and hydrogen peroxide where the antigen is contacted with a composition including an antibody able to generate hydrogen peroxide or superoxide from singlet oxygen. As previously discussed, the method is successful with either nonspecific or immunospecific (antigen directed ) intact antibody, fragments derived therefrom and further including single chain antibodies as well as the engineered molecules and antibodies described herein. Exemplary concentrations of antibody at the cell surface range from 1 to 5 micromolar. However, the concentration may vary depending on the desired outcome where the amount of antibody provided is that amount of antibody that is sufficient to obtain the desired physiological effect, i.e, the generation of hydrogen peroxide or superoxide radical and its derivative oxidants to generate oxidative stress. Dosing and timing of the therapeutic treatments with antibody compositions are compatible with those described for antioxidants above. The antigen is preferably presented on a cell but need not be so limited. The antigen can be any antigen that is present in a cell, tissue or organ including extracellular fluids where the presence of superoxide and the antibody mediated process of producing it is warranted. In a preferred embodiment, the antigen is a fatty acid, a low density lipoprotein, an antigen associated with inflammation, a cancer cell antigen, a bacterial antigen or a similar molecule. Cells on which antigens are associated include but are not limited to endothelial, interstitial, epithelial, muscle, phagocytic, blood, dendritic, connective tissue and nervous system cells. Particularly preferred target cells for the present therapeutic approach are neutrophils or macrophages.
The invention further contemplates exposing a target cell to irradiation with either ultraviolet, infrared or visible light in the method of generating antibody superoxide or hydrogen peroxide.
To enhance the production of superoxide or hydrogen peroxide, a superoxide or hydrogen peroxide generating amount of a photosensitizer, also referred to as a sensitizer, is utilized in the therapeutic methods described herein. As defined herein, a sensitizer is any molecule that induces or increases the concentration of singlet oxygen. Sensitizers are generally used in the presence of irradiation, the process of which includes exposure to ultraviolet, infrared or visible light for a period sufficient to activate the sensitizer. Exemplary exposures are described in examples I and II. A superoxide or hydrogen peroxide generating amount of sensitizer is the amount of sensitizer that is sufficient to obtain the desired physiological effect, e.g., generation of superoxide or hydrogen peroxide from singlet oxygen mediated by an antibody in any situation where superoxide or hydrogen peroxide presence and the derivatives thereof is warranted. In a preferred embodiment, a sensitizer is conjugated to the antibody. In a particularly preferred embodiment, a sensitizer conjugated antibody is capable of binding to a antigen, i.e., retains an active antigen binding site, allowing for antigen recognition and complexing to occur. Exemplary sensitizers include but are not limited to pterins, flavins, hematoporphyrin, tetrakis(4-sulfonatophenyl)porphyrin, bipyridyl ruthemium(II) complexes, rose bengal dye, quinones, rhodamine dyes, phtalocyanine, and hypocrellins. In a further embodiment, the generation of superoxide or hydrogen peroxide is enhanced by administering a means to enhance the production of singlet oxygen. Reduced singlet oxygen is the source of superoxide or hydrogen peroxide as previously discussed. Such reduction can occur through the action of an antibody or molecule containing greater than two reductive centers. One preferred means is referred to as a prodrug that is any molecule, compound, reagent and the like that is useful in generating singlet oxygen. A preferred prodrug is endoperoxide, that is administered at a time subsequent to the administering or contacting of an antibody with a desired target cell, tissue or organ as described below. In this context, endoperoxide is preferably delivered after a superoxide or hydrogen peroxide producing antibody or molecule has immunoreacted with its target antigen forming an antibody- antigen complex. A preferred concentration of endoperoxide to achieve at the antibody-antigen complex site is about 10 micromolar. This embodiment has particular advantages. For example, the ability to create an increased local accumulation of singlet oxygen provides the necessary reactant to be reduced to the therapeutically desirable superoxide or hydrogen peroxide at a desired site or location.
Preferred therapeutic methods based on the use of an antibody including an engineered antibody or molecule having reductive centers to generate superoxide or hydrogen peroxide from singlet oxygen includes a method for killing a cancer cell where the cancer cell is contacted with a composition including an antibody capable of generating superoxide or hydrogen peroxide from singlet oxygen. In a preferred embodiment, the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell. Such methods are therapeutically useful for a subject with lung cancer, prostate cancer, colon cancer, cervical cancer, endometrial cancer, bladder cancer, bone cancer, leukemia, lymphoma, or brain cancer. In one aspect, the cancer cell is removed from a subject with cancer and cultured ex vivo for exposing to an antibody, and can further be exposed to ultraviolet light, infrared light or visible light for the cell to then be returned to the subject. In other aspects, the antibody composition is delivered in vivo to a subject with cancer. Preferred in vivo delivery methods include administration intravenously, topically, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, subcutaneously or by liposome containing the antibody.
In still further aspects, the antibody is a recombinant antibody, that is provided as above or alternatively is expressed from an expression vector delivered to the cell. The expression vector in this context can also express a sensitizer molecule. Therapeutic compositions in pharmaceutically acceptable excipients and pharmaceutically effective amounts as described for antioxidant containing compositions are applicable to the use of antibody containing compositions.
Additional therapeutic methods based on using an antibody that is able to generate superoxide or hydrogen peroxide from singlet oxygen are 1) for inhibiting proliferation of a cancer cell, 2) for targeting and killing a cancer cell in a patient where the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell, 3) for inhibiting tissue injury associated with neutrophil mediated inflammation in a subject, for example where the inflammation results from a bacterial infection or when the subject has an autoimmune disease, 4) for enhancing the bactericidal effectiveness of a phagocyte in a subject, 5) for promoting wound healing in a subject having a open wound where the superoxide or hydrogen peroxide stimulates fibroblast proliferation and/or the immune response that further includes lymphocyte proliferation, 6) for stimulating cell proliferation, such as stimulating fibroblast proliferation in a wound in a subject, and the like situations. For wound healing, topical application to a wound on a subject is a preferable delivery approach such as with a bandage containing an antibody. Other therapeutic conditions that would benefit from the creation or enhancement of superoxide or hydrogen peroxide in a cell, tissue, organ or extracellular compartment are well known to those of ordinary skill in the art and have been reviewed by
McCord, Am. J. Med.. 108:652-659 (2000), the disclosure of which are hereby incorporated by reference.
2. Screening Methods
The invention further contemplates screening methods that are based on the newly discovered antibody reduction of singlet oxygen to hydrogen peroxide or superoxide radical.
Thus, in one embodiment, the invention contemplates a method for identifying an agent that modulates antibody mediated production of hydrogen peroxide or superoxide. A modulator is a molecule that either inhibits or promotes the production of superoxide or hydrogen peroxide. Either type of modulator is identifiable with the same method. In a preferred embodiment, the method includes the steps of: a) contacting a composition comprising an antibody capable of generating superoxide or hydrogen peroxide with an agent to form an admixture in an assay solution in the presence of molecular oxygen; b) irradiating the admixture to generate singlet oxygen from molecular oxygen, wherein the singlet oxygen is reduced to hydrogen peroxide or superoxide by the antibody, wherein the superoxide dismutates to form hydrogen peroxide; c) detecting the formed hydrogen peroxide; and d) comparing the detected hydrogen peroxide with a suitable control, thereby determining how the agent modulates the production of hydrogen peroxide or superoxide.
The irradiating step is performed with either ultraviolet light or visible light. With the latter form, a sensitizer as previously described can be added with the antibody composition.
The formed hydrogen peroxide is detected through reaction directly with a hydrogen peroxide where the reacted substrate is detected with a fluorescent means, such as with fluorescent microscopy or fluorescent spectrometry. In fluorescent spectrometry, detection is ELISA based or with done with a standard cuvette. Exemplary assay methods are performed as described in examples I and II.
In a separate screening method of the present invention, a method for performing an immunoassay to detect antibody immunoreactivity with an antigen is also contemplated based on the discovery of antibody generated superoxide or hydrogen peroxide. The method comprises the steps of: a) contacting in a singlet oxygen-generating medium a substrate having immobilized thereon a composition comprising a first reagent comprising an antigen or an antibody, with a second composition comprising an antigen or an antibody that is reactive with the first reagent to form an immobilized antigen-antibody complex, wherein the antibody generates superoxide or hydrogen peroxide from singlet oxygen in the presence of oxygen; and b) detecting the antibody-generated superoxide or hydrogen peroxide, thereby detecting the antibody immunoreactivity with the antigen.
The reaction and detection means are those as described herein. In one aspect, the first composition is an antigen and the second composition is an antibody. In the opposite aspect, the first composition is an antibody and the second composition is an antigen.
The invention further contemplates a similar method for performing an immunoassay to detect antibody immunoreactivity with an antigen where an antigen is immobilized and contacted with an antibody composition.
Such immunoassay methods are an improvement over those that are well known as methods to assess antigen-antibody immunoreactivity and to identify antigens and/or antibodies. The advantage of the present method over previous other immunoassay methods lies in the present elimination of at least one method step and/or the incorporation of a secondary labeled immunoreactive molecule, the labeling either being a radioactive or enzymatic compound.
In the present invention, the minimum requirements are oxygen, an antibody reagent, an antigen reagent, and a detectable reactant that reacts with hydrogen peroxide generated from the antibody. A preferred reactant is a fluorogenic substrate. One such reactant used as described in examples I and II is called
AMPLEX™ Red. It is a commercially available reagent sold by Molecular Probes (Eugene, Oregon) for reacting antibody generated hydrogen peroxide in the immunoassay. It is sold in a kit that provides a one-step fluorometric method for measuring hydrogen peroxide using a fluorescent microplate or fluorimeter for detection. The assay is based on the detection of hydrogen peroxide using 10-acetyl- 3,7-dihyroxyphenoxazine, a highly sensitive and stable probe for hydrogen peroxide. In the presence of horseradish peroxidase, the AMPLEX™ Red reagent reacts with hydrogen peroxide in a 1 :1 stoichiometry to produce highly fluorescent resorufin, that provides a detection mechanism to detect as little as 10 picomoles of hydrogen peroxide in a 200 microliter volume. In contrast, prior immunoassay techniques, including radioimmunoassays
(RIA), enzyme-immunoassays (EIA), and the classic enzyme-linked immunosorbent assay (ELISA), all require either the use of a radioactively labeled immunoreactive molecule as in RIA or an additional labeled immunoreactive molecule. The present invention neither requires potentially harmful radioactive isotopes to label a molecule or requires an additional immunoreactive reagent that generally is referred to as a secondary antibody that is usually conjugated with an enzyme to allow for the detection of the complex formed with the first antibody with the antigen. In the latter assays, the reaction of the secondary antibody with the formed antigen- antibody complex (generally through an anti-first antibody specificity immunoreactivity) is detected through a color-producing substrate solution specific for the conjugated enzyme. In summary, in the present invention, the antibody mediated generation of hydrogen peroxide is detected with high detection capacity without radioactive agents, without requiring an additional reagent and or admixing step such as those practiced in US Patents 3,905,767; 4,016,043; USRE032696; and 4,376,110, the disclosures of which are hereby incorporated by reference. 3. Therapeutic Compositions
The present invention contemplates therapeutic compositions useful in practicing the therapeutic methods as described above. Antibodies, as a class of proteins, are now known to act as reductants in reducing singlet molecular oxygen (also referred to herein as singlet oxygen) to generate superoxide free radical (also referred to herein as superoxide). As a result of the redox reaction, the antibody becomes oxidized. The oxidation of the antibody is now known to occur at the two buried tryptophan residues as further discussed in example I. The activity is further ascribed to the indole component of the tryptophan residue. Thus, in view of the redox reaction where the indole portion becomes oxidized forming a radical cation in the reaction of reducing singlet molecule oxygen to superoxide free radical, the indole is referred to as a reductive center. A reductive center as defined in the present invention as having the ability to reduce singlet oxygen to superoxide and becoming oxidized in the process. Preferably, a reductive center is more efficient if it is not solvent-exposed, i.e., is buried within the therapeutic composition defined herein.
Therapeutic compositions may also be produced and used according to the therapeutic methods described above with antibodies and engineered molecules that produce hydrogen peroxide through oxidation of water. Antibodies, as a class of proteins, are now known to catalyze the oxidation of water to produce hydrogen peroxide. The activity is ascribed to a conserved tryptophan residue.
Thus, the present invention contemplates therapeutic compositions that are useful in either acting to reduce the local concentration of hydrogen peroxide or superoxide production or in the alternative useful in acting to enhance it. Such compositions contain reagents referred to generally as being "engineered", defined herein to connote a reagent, such as an antibody or fragment thereof as defined herein, or other molecule, that has been altered in some form to either increase or decrease the number of reductive centers as defined herein.
The invention thus contemplates an antibody that has been engineered to have at least a diminished capacity to generate hydrogen peroxide or superoxide free radical from singlet oxygen. In that context, the antibody lacks at least one of its reductive centers and preferably is substantially free of a reductive center. Such antibody compositions are readily prepared with recombinant expression methods well known to one of ordinary skill in the art. In preferred embodiments, the antibody retains the same amino acid residue number but the reductive center has been replaced or substituted with a component that lacks the ability to reduce singlet oxygen. In such aspects, the reductive center comprises a buried indole and preferably, in the case of superoxide, two buried indoles. In particularly preferred embodiments, the reductive center comprises an indole on a tryptophan residue that is substituted by another amino acid that does not have reductive capacity. Such preferred substitutions includes the amino acids phenylalanine and alanine. In other aspects, the present invention also contemplates deletion of the tryptophan without replacement or substitution thereof as long as the desired antibody activity, particularly antigen binding activity, is not adversely affected. As previously discussed, an engineered antibody having reduced or absent reductive centers while retaining antigen targeting ability provides the therapeutic advantage of providing an antibody to stimulate a desired immune response in particular situations while reducing or eliminating altogether the undesirable production of hydrogen peroxide or superoxide and its byproducts that can further damage cells and tissues. Methods for making an engineered antibody that functions as an antioxidant in the context of the therapeutic methods described herein are well known in the art, such as site- directed mutagenesis of a nucleotide sequence encoding the antibody of interest as previously discussed.
Engineered antibodies that function as an antioxidant according to the methods of the invention are contemplated for any of the methods as described herein. The present invention also contemplates engineered therapeutic molecules including engineered antibodies that have been altered to contain a reductive center where they were in an insufficient amount to effect adequate production of superoxide or hydrogen peroxide, or where they are needed to increase the number of reductive centers to a number in excess of those that were naturally occurring in the molecule or antibody. Introduction of a reductive center in a engineered molecule or antibody is accomplished by methods well known to one of ordinary skill in the art. Preferred means including recombinant expression methods and well as direct protein synthesis methods have been previously described. The choice of method is necessarily dependent on the length of the molecule being engineered. Regardless of the methods employed, the positioning, i.e., the location, of the engineered reductive center is based upon the ability of the engineered molecule to exhibit reducing activity on singlet oxygen. Preferably, the incorporation of reductive centers are positioned such that they are deeply buried in the folded molecule allowing a retention of structural ability without comprising superoxide or hydrogen peroxide production. In one embodiment, in an antibody where it is desired to retain antigen binding function, the location of an engineered reductive center is adjacent to a variable binding domain. In certain aspects, one reductive center is contemplated. In other aspects, two reductive centers are contemplated. Still, in other aspects, more than three reductive centers are contemplated. Preferably, the reductive centers comprise indole. Also contemplated are reductive centers comprising indole present in tryptophan residue. Any technique to engineer such reductive centers in a molecule or antibody is contemplated for use in the present invention. In a prefeπed embodiment, the reductive centers are introduced by site-directed mutagenesis of nucleotide sequences encoding the engineered antibody such that the substituted nucleotides encode tryptophan residues at predeteraiined locations in the encoded molecule.
In the embodiment of preparing an engineered molecule such as an antibody to include desired reductive centers, such molecule that is produced by recombinant technology is also contemplated to be in the form of a fusion conjugate, where the conjugate provides a sensitizer molecule as previously described for use in therapeutic methods as described herein.
Engineered antibodies or other molecules, which can be any protein or polypeptide such that they contain reductive centers that function according to the methods of the invention, are contemplated for any of the methods as described herein. The invention is further described in detail by reference to the non-limiting examples that follow. While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed. Example I
Antibodies have the intrinsic capacity to destroy antigens Materials and Methods Antibodies: The following whole antibodies were obtained from PharMingen: 49.2 (mouse IgG2b K), G155-178 (mouse IgG2a K), 107.3 (mouse IgG, K), A95-1 (rat IgG2b), G235-2356 (hamster IgG), R3-34 (rat IgG K), R35-95 (rat IgG2a K), 27-74 (mouse IgE), Al 10-1 (rat IgG, X), 145-2C11 (hamster IgG groupl K), Ml 8-254 (mouse IgA K), and MOPC-315 (mouse IgA λ). The following were obtained from Pierce: 31243 (sheep IgG), 31154 (human IgG), 31127 (horse IgG), and 31146 (human IgM).
The following F(ab')2 fragments were obtained from Pierce: 31129 (rabbit IgG), 31189 (rabbit IgG), 31214 (goat IgG), 31165 (goat IgG), and 31203 (mouse IgG). Protein A, protein G, trypsin-chymotrypsin inhibitor (Bowman-Birk inhibitor), β-lactoglobulin A, α-lactalbumin, myoglobin, β-galactosidase, chicken egg albumin, aprotinin, trypsinogen, lectin (peanut), lectin (Jacalin), BSA, superoxide dismutase, and catalase were obtained from Sigma. Ribonuclease I A was obtained from Amersham Pharmacia. The following immunoglobulins were obtained in-house using hybridoma technology: OB2-34C12 (mouse IgG, κ)5 SHO1-41G9 (mouse IgG, K), OB3-14F1 (mouse IgG2a K), DMP-15G12 (mouse IgG2a K), AD1-19G1 (mouse IgG2b K), NTJ-92C12 (mouse IgG, K), NBA-5G9 (mouse IgG, K), SPF-12H8 (mouse IgG2a K), TIN-6C11 (mouse IgG2a K), PRX-1B7 (mouse IgG2a K), HA5-19A11 (mouse IgG2a K), EP2-19G2 (mouse IgG, K), GNC- 92H2 (mouse IgG, K), WD1-6G6 (mouse IgG, K), CH2-5H7 (mouse IgG2b K), PCP- 21H3 (mouse IgG, K), and TM1-87D7 (mouse IgG, K). DRB polyclonal (human IgG) and DRB-M2 (human IgG) were supplied by Dennis R. Burton (The Scripps Research Institute). 1D4 Fab (crystallized) was supplied by Ian A. Wilson (The Scripps Research Institute).
All assays were carried out in PBS (10 mM phosphate/160 mM sodium chloride, pH 7.4). Commercial protein solution samples were dialyzed into PBS as necessary. Amplex Red hydrogen peroxide assay kits (A- 12212) were obtained from Molecular Probes. Antibody/Protein Irradiation. Unless otherwise stated, the assay solution
(100 μl, 6.7 μM protein in PBS, pH 7.4) was added to a glass vial, sealed with a screw-cap, and irradiated with either UN (312 nm, 8000 μWcm"2 Fischer-Biotech transilluminator) or visible light.
Quantitative Assay for Hydrogen Peroxide. An aliquot (20 μl) from the protein solution was removed and added into a well of a 96-well microtiter plate (Costar) containing reaction buffer (80 μl). Working solution (100 μl/400 μM
Amplex Red reagent 1/2 ύnits/ml horseradish peroxidase) was then added, and the plate was incubated in the dark for 30 min. The fluorescence of the well components was then measured using a CytoFluor Multiwell Plate Reader (Series 4000,
PerSeptive Biosystems, Framingham, MA; Ex/Em: 530/580 nm). The hydrogen peroxide concentration was determined using a standard curve. All experiments were run in duplicate, and the rate is quoted as the mean of at least two measurements.
Sensitization and Quenching Assays. A solution of 31127 (100 μl of horse
IgG, 6.7 μM) in PBS (pH 7.4, 4% dimethylformamide) and hematopo hyrin IX (40 μM) was placed in proximity to a strip light. Hydrogen peroxide concentration was determined as described herein. The assay was also performed in the presence of
ΝaΝ3 (100 mM) or PBS in D2O.
Oxygen Dependence. A solution of 31127 (1.6 ml, horse IgG, 6.7 μM) in
PBS (pH 7.4) was rigorously degassed using the freeze/thaw method under argon. Aliquots (100 μl) were introduced into septum-sealed glass vials that had been purged with the appropriate O2/Ar mixtures (0-100%)) via syringe. Dissolved oxygen concentrations were measured with an Orion 862A dissolved oxygen meter.
These solutions were then vortexed vigorously, allowed to stand for 20 min, and then vortexed again. A syringe containing the requisite O2/Ar mixture was used to maintain atmospheric pressure during the course of the experiment. Aliquots (20 μl) were removed using a gas-tight syringe and hydrogen peroxide concentration measured as described herein. The data from three separate experiments were collated and analyzed using the Enzyme Kinetics vl .1 computer program (for determination of Vmax and Km parameters). Antibody Production of Hydrogen Peroxide in the Dark, Using a Chemical
:O2 Source. A solution of sheep IgG 31243 (100 μl, 20 μM) in PBS (pH 7.4) and the endoperoxide of disodium 3,3'-(l,4-naphthylidene) dipropionate (25 mM in D2O) was placed in a warm room (37°C) for 30 min in the dark. Hydrogen peroxide concentration was determined as described herein.
Hydrogen Peroxide Formation by the FablD4 Crystal. A suspension of crystals of the Fab fragment of 1D4 (2 μl) was diluted with PBS (198 μl, pH 7.4) and vortexed gently. Following centrifugation, the supernatant was removed, and the washing procedure was repeated twice further. The residual crystal suspension was then diluted into PBS, pH 7.4 (100 μl), and added into a well of a quartz ELISA plate. Following UN irradiation for 30 min, Amplex Red working solution (100 μl) was added, and the mixture was viewed on a fluorescence microscope.
Antibody Fluorescence Versus Hydrogen Peroxide Formation. A solution of 31127 (1.0 ml of horse IgG, 6.7 μM) in PBS (pH 7.4) was placed in a quartz cuvette and irradiated with UN light for 40 min. At 10-min intervals, the fluorescence of the solution was measured using an SPF-500C spectrofluorimeter (SLM-Aminco, Urbana, IL; Ex/Em, 280/320). At the same time point, an aliquot (20 μl) of the solution was removed, and the hydrogen peroxide concentration was determined as described herein.
Consumption of Hydrogen Peroxide by Catalase. A solution of EP2-19G 12 (100 μl of mouse IgG, 20 μM in PBS, pH 7.4) was irradiated with UV light for 30 min, after which time the concentration of hydrogen peroxide was determined by stick test (EM Quant Peroxide Test Sticks) to be 2 mg/liter. Catalase [1 μl, Sigma, 3. 2 M (ΝH4)2SO4, pH 6.0] was added, and after 1 min, the concentration of H2O2 was found to be 0 mg/liter.
Denaturation. IgG 19G12 (100 μl, 6.7 μM) was heated to 100°C in an Eppendorf tube for 2 min. The resultant solution was transferred to a glass, screw- cap vial and irradiated with UV light for 30 min. The concentration of H2O2 was determined after 30 min.
Results and Discussion Research throughout the last century has led to a consensus as to the strategy of the humoral component of the immune system. The essence is that, for killing, the antibody molecule activates additional systems that respond to antibody-antigen union. It is now reported that the immune system has a previously unrecognized chemical potential intrinsic to the antibody molecule itself. All antibodies studied, regardless of source or antigenic specificity, can convert molecular oxygen into hydrogen peroxide, thereby potentially aligning recognition and killing within the same molecule. Aside from pointing to a new chemical arm for the immune system, these results are thought to be important to the understanding of how antibodies evolved and what role they may play in human diseases.
The antibody is a remarkable adaptor molecule, having evolved both targeting and effector functions that place it at the frontline of vertebrate defense against foreign invaders (Burton, D. R., Trends Biochem. Sci.. 15. 64-69 (1990)). In terms of the effector mechanism, the central idea is that antibodies themselves do not possess destructive ability but mark foreign substances for removal by the complement cascade and/or phagocytosis (Arlaud et al., Immunol. Today. 8, 106- 111 (1987): Sim & Reid. Immunol. Today. 12. 307-311 (1991)). The advent of antibody catalysis has demonstrated that antibodies are capable of much more complex chemistry than simple binding (Wentworth & Janda, Curr. Opin. Chem. Biol.. 2, 138-144 (1998)). This has inevitably led to the question as to whether more sophisticated chemical mechanisms are part of the strategy of the antibody molecule itself. Thus far, there has been no evidence to support this idea, and we are left with the notion that just because antibodies are capable of complex chemistry, it does not mean that they use it in host defense. However, it is now reported that a hitherto unremarked capacity of antibodies to convert molecular oxygen into hydrogen peroxide, thereby effectively linking recognition and killing events. The preliminary step in the phagocytic oxidative burst is the single electron reduction of ground-state molecular oxygen (3O2) by the NADPH-dependent transmembrane phagocyte oxidase enzyme system that generates superoxide anion (O2 *~) (Figure 1) (Klebanoff, S. J. in Encyclopedia of Immunology, eds. Delves, P. J. & Roitt, I. M. (Academic, San Diego), pp. 1713-1718 (1998); Rosen, H. & Klebanoff, S. J., J. Biol. Chem.. 252. 4803-4810 (1997)).
Superoxide anion occupies a critical position in the cycling of oxygen- dependent microbicidal agents in vivo because although it is not itself considered to be cytotoxic (Fee, J. A. in International Conference on Oxygen and Oxygen- Radicals, eds. Rodgers, M. A. J. & Powers, E. L. (Academic, San Diego, and University of Texas at Austin), pp. 205-239 (1981)), it is a direct precursor of hydrogen peroxide and the toxic derivatives it spawns, such as hydroxyl radical (HO*) and hypohalous acid (HOCl). In addition, when iron concentrations are limiting, O2 *~ is a vital reducing agent that regenerates Fe2+, thus facilitating the iron-catalyzed Haber- Weiss reaction, or the so-called superoxide-driven Fenton reaction that produces HO* (Esq. 1 and 2). Therefore, processes that facilitate the generation of O2 *~ will ultimately perpetuate and potentiate oxygen-dependent microbicidal action.
Fe3+ + O2 *~ → Fe2+ + O2 [1]
Fe2+ + H2O2 → Fe3+ + -OH + HO* [2]
Another key component of the oxygen-scavenging cascade is singlet molecular oxygen (]O2). This particularly reactive species is an excited state of molecular oxygen in which both outer shell electrons are spin-paired (Kearns, D. R., Chem. Rev.. 71. 395-427 (1971)). It is important in pathological biological systems and has a very short life-time (ca. 4 μs) in vivo (Foote, C. S. in Free Radicals in Biology, ed. Pryor, W. A. (Academic, New York), pp. 85-133 (1976)). Generation of ' O2 during microbicidal processes is either direct, via the action of flavoprotein oxidases (Allen, R. C, Stjernholm, R. L., Benerito, R. R. & Steele, R. H., eds. Cormier, M. J., Hercules, D. M. & Lee, J. (Plenum, New York), pp. 498-499 (1973); Klebanoff, S. J. in The Phagocytic Cell in Host Resistance (National Institute of Child Health and Human Development, Orlando, FL) (1974)), or indirect, via the nonenzymatic disproportionation of O2 *~ in solutions at low pH, as found in the phagosome (Eq. 3) (Stauff, J., Sander, U. & Jaeschke, W., Chemiluminescence and Bioluminescence. eds., Williams, R. C. & Fudenberg, H. H. (Intercontinental Medical Book Corp., New York), pp. 131-141 (1973); Allen, R. C, Yevich, S. J., Orth, R. W. & Steele, R. H., Biochem. Biophvs. Res. Commun.. 60, 909-917 (1974)).
O2 *" + 2HO* 2 → O2 + H2O2 [3] The high reactivity of O2 with biomolecules has meant that it is generally considered to be an endpoint in the cascade of oxygen-scavenging agents. However, it has been found that antibodies, as a class of proteins, have the intrinsic ability to intercept O2 and efficiently reduce it to O2 *~, thus offering a mechanism by which oxygen can be rescued and recycled during phagocyte action, thereby potentiating the microbial action of the immune system.
The measured values for the initial rate of formation of hydrogen peroxide by a panel of intact immunoglobulins and antibody fragments are collected in Table 1. It is believed that Ig-generated O2 *~ dismutates spontaneously into H2O2, which is then utilized as a cosubstrate with N-acetyl-3,7-dihydroxyphenazine 1 (Amplex Red) for horseradish peroxidase, which produces the highly fluorescent resorufin 2 (excitation maxima 563 nm, emission maxima 587 nm) (Figure 2) (Zhou, M., Diwu, Z., Panchuk-Voloshina, Ν. & Haugland, R. P., Anal. Biochem.. 253, 162-168 (1997)). To confirm that irradiation of the buffer does not generate O2 *~ and that the antibodies are not simply acting as protein dismutases (Petyaev, I. M. & Hunt, J. V., Redox Report. 2, 365-372 (1996)), the enzyme superoxide dismutase was irradiated in PBS. Under these conditions, the rate of hydrogen peroxide generation is the same as irradiation of PBS alone.
Table 1. Production of hydrogen peroxide* by immunoglobulins
Entry Clone Source Isotype Rate,f nmol/min/mg
1 CH25H7 Mouse IgG2b, K 0.25
2 WD16G6 Mouse IgGl, κ 0.24
3 SHO-141G9 Mouse IgGl, κ 0.26
4 OB234C12 Mouse IgGl, κ 0.22
5 OB314F1 Mouse IgG2a, K 0.23
6 DMP15G12 Mouse IgG2a, K 0.18
7 AD19G1 Mouse IgG2b, K 0.22
8 ΝTJ92C12 Mouse IgGl, κ 0.17
9 NBA5G9 Mouse IgGl, κ 0.17
10 SPF12H8 Mouse IgG2a, K 0.29
11 TIN6C11 Mouse IgG2a, K 0.24 Entry Clone Source Isotype Rate/ nmol/min/mg
12 PRX1B7 Mouse IgG2a, K 0.22
13 HA519A4 Mouse IgGl, κ 0.20
14 92H2 Mouse IgGl, κ 0.41
15 19G2 Mouse IgGl, κ 0.20
16 PCP-21H3 Mouse IgGl. K 0.97
17 TM1-87D7 Mouse IgGl, κ 0.28
18 49.2 Mouse IgG2b, K 0.24
19 27-74 Mouse IgE, std. isotype 0.36
20 Ml 8-254 Mouse IgA, κ 0.39
21 MOPC-315 Mouse IgA, λ 0.39
22 31203 Mouse F(ab')2 0.21
23 bl2 Human IgG 0.45
24 polyclonal Human IgG 0.34
25 31154 Human IgG 0.18
26 31146 Human IgM 0.22
27 R3-34 Rat IgGl, κ 0.27
28 R35-95 Rat IgG2a, K 0.17
29 A95-1 Rat IgG2b 0.15
30 Al lO-1 Rat IgGl, λ 0.34
31 G235-2356 Hamster IgG 0.24
32 145-2C11 Hamster IgG, gp 1, K 0.27
33 31243 Sheep IgG 0.20
34 31127 Horse IgG 0.18
35 polyclonal Horse IgG 0.34
36 31229 Rabbit F(ab')2 0.19
37 31189 Rabbit F(ab')2 0.14
38 31214 Goat F(ab')2 0.24
39 31165 Goat F(ab')2 0.25
* Assay conditions are described in Materials and Methods. f Mean values of at least two determinations. The background rate of H2O2 formation is 0.005 nmol/min in PBS and 0.003 nm/min in PBS with SOD.
The rates of hydrogen peroxide formation were linear for more than 10% of the reaction, with respect to the oxygen concentration in PBS under ambient conditions (275 μM). With sufficient oxygen availability, the antibodies can generate at least 40 equivalents of H2O2 per protein molecule without either a significant reduction in activity or structural fragmentation. An example of the initial time course of hydrogen peroxide formation in the presence or absence of antibody 19G2 is shown in Figure 3 A. This activity is lost following denaturation of the protein by heating.
The data in Table 1 reveal a universal ability of antibodies to generate H2O2 from O2. This function seems to be shared across a range of species and is independent of the heavy and light chain compositions investigated or antigen specificity. The initial rates of hydrogen peroxide formation for the intact antibodies is highly conserved, varying from 0.15 nmol/min/mg [clone A95-l(rat IgG2b)] to 0.97 nmol/min/mg (clone PCP-21H3, a murine monoclonal IgG) across the whole panel. Although the information available is more limited for the component antibody fragments, the activity seems to reside in both the Fab and F(ab')2 fragments.
If this activity were due to a contaminant, it would have to be present in every antibody and antibody fragment obtained from diverse sources. However, to further rule out contamination, crystals of the murine antibody 1D4 Fab from which high-resolution x-ray structures have been obtained (at 1.7 A) were investigated for their ability to generate H2O2 (Figure 4). Reduction of O2 is clearly observed in these crystals.
Investigations into this antibody transformation support singlet oxygen as the intermediate being reduced. No formation of hydrogen peroxide occurs with antibodies under anaerobic conditions either in the presence or absence of UV irradiation. Furthermore, no generation of hydrogen peroxide occurs under ambient aerobic conditions without irradiation. Irradiation of antibodies with visible light in the presence of a known photosensitizer of 3O2 in aqueous solutions (Kreitner, M., Alth, G., Koren, H., Loew, S. & Ebermann, R., Anal. Biochem.. 213. 63-67 (1993)), hematopoφhyrin (HP), leads to hydrogen peroxide formation (Figure 5A). The curving in the observed rates is due to consumption of oxygen from within the assay mixture. Concerns that the interaction between photoexcited HP and oxygen may be resulting in O2 *~ formation (Beauchamp, C. & Fridovich, I., Anal. Biochem.. 44. 276-287 (1971); Srinivasan, V. S., Podolski, D., Westrick, N. J. & Neckers, D. C, J, Am. Chem. Soc. 100. 6513-6515 (1978)) were largely discounted by suitable background experiments with the sensitizer alone (data shown in Figure 5A). The efficient formation of H2O2 with HP and visible light both reaffirm the intermediacy of ]O2 and show that UV radiation is not necessary for the Ig to perform this reduction.
Furthermore, incubation of sheep antibody 31243 in the dark at 37°C, with a chemical source of O2 [the endoperoxide of 3',3'-(l,4-naphthylidene)dipropionate] leads to hydrogen peroxide formation.
The rate of formation of H2O2, by horse IgG with HP (40 μM) in visible light, is increased in the presence of D2O and reduced with the 102 quencher NaN3 (40 mM) (Figure 5B) (Hasty, N., Merkel, P. B., Radlick, P. & Kearns, D. R. Tetrahedron Lett.. 49-52 (1972)). The substitution of D2O for H2O is known to promote ]O2-mediated processes via an increase of approximately 10-fold in its lifetime (Merkel, P. B., Nillson, R. & Kearns, D. R., J. Am. Chem. Soc. 94, 1030- 1031 (1972)).
The rate of hydrogen peroxide formation is proportional to IgG concentration between 0.5 and 20 μM but starts to curve at higher concentrations (Figure 5C). The lifetime of O2 in protein solution is expected to be lower than in pure water due to the opportunity for reaction. It is therefore thought that the observed curvature may be due to a reduction in the lifetime of 102 due to reaction with the antibody.
Significantly, the effect of oxygen concentration on the observed rate of H2O2 production shows a significant saturation about 200 μM of oxygen (Figure 5D). Therefore, the mechanism of reduction may involve either one or more oxygen binding sites within the antibody molecule. By treating the raw rate data to nonlinear regression analysis and by fitting to the Michaelis-Menten equation, a -" mapp(O2) of 187 μM and a maxapp of 0.4 nmol/min/mg are obtained. This antibody rate is equivalent to that observed for mitochondrial enzymes that reduce molecular oxygen in vivo. The mechanism by which antibodies reduce ]O2 is still being determined. However, the participation of a metal-mediated redox process has been largely discounted because the activity of the antibodies remains unchanged after exhaustive dialysis in PBS containing EDTA (4 mM). This leaves the intrinsic ability of the amino acid composition of the antibodies themselves. Aromatic amino acids such as tryptophan (Tφ) can be oxidized by O2 via electron transfer (Grossweiner, L. I., Curr. Top. Radiat. Res. P.. JLi, 141-199 (1976)). In addition, disulfides are sufficiently electron rich that they can also be oxidized (Bent. D. V. & Hayon, E., J. Am. Chem. Soc. 87, 2612-2619 (1975)). - Therefore, there is the potential that Tφ residues and/or the intrachain or interchain disulfide bonds homologous to all antibodies are responsible for ]O2 reduction. To both investigate to what extent this ability of antibodies is shared by other proteins and to probe the mechanism of reduction, a panel of other proteins was studied (Figure 6).
Whereas other proteins can convert 1O2 into O2 *~, in contrast to antibodies it is by no means a universal property. RNase A and superoxide dismutase, which do not possess Tφ residues but have several disulfide bonds, do not reduce ]O2. Similarly, the Bowman-Birk inhibitor protein (Voss, R.-H., Ermler, U., Essen, L.-O., Wenzl, G., Kim, Y.-M. & Flecker, P., Eur. J. Biochem.. 242. 122-131 (1996); Baek, J. & Kim, S., Plant Phvsiol.. 102. 687 (1993)) that has seven disulfide bonds and zero Tφ residues does not reduce ]O2. In contrast, chick ovalbumin, which has only 2 Tφ residues (Feldhoff, R. & Peters, T. J., Biochem. J.. 159. 529-533 (1976)), is one of the most efficient proteins at reducing JO2.
Given the loss of antibody activity upon denaturation, the location of key residues in the protein is likely to be more critical than their absolute number. Because the majority of aromatic residues in proteins are generally buried to facilitate structural stability (Burley, S. K. & Petsko, G. A., Science. 229. 23-28 (1985)), the nature of the reduction process was explored in terms of relative contribution of surface and buried residues by fluorescence-quenching experiments. Aromatic amino acids in proteins are modified by the absoφtion of ultraviolet light, especially in the presence of sensitizing agents such as molecular oxygen or ozone (Foote, C. S., Science. 162. 963-970 (1968); Foote, C. S., Free Radicals Biol.. 2, 85- 133 (1976); Gollnick, K., Adv. Photochem.. 6, 1-122 (1968)). Tφ reacts with !O2 via a [2 + 2] cycloaddition to generale N-formylkynurenine or kynurenine, which are both known to significantly quench the emission of buried Tφ residues (Mach, H., Burke, C. J., Sanyal, G., Tsai, P.-K, Volkin, D. B. & Middaugh, C. R. in Formulation and Delivery of Proteins and Peptides. eds. Cleland, J. L. & Langer, R. (American Chemical Society, Denver, CO) (1994)). The intrinsic fluorescence of horse IgG is rapidly quenched to 30% of its original value during a 40-min irradiation, whereas hydrogen peroxide generation is linear throughout (r2 = 0.998) (Figure 7). If the reduction of singlet oxygen is due to antibody Tφ residues, then the solvent-exposed Tφ seem to contribute to a lesser degree than the buried ones. This factor may help to explain why this ability is so highly conserved among antibodies. In greater than 99% of known antibodies there are two conserved Tφ residues, and they are both deeply buried: Tφ-36 and Tφ-47 (Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. & Foeller, C, Sequences of Proteins of Immunological Interest (U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD) (1991)).
Throughout nature, organisms have defended themselves by production of relatively simple chemicals. At the level of single molecules, this mechanism has thought to be largely abandoned with the appearance in vertebrates of the immune system. It was considered that once a targeting device had evolved, the killing mechanism moved elsewhere. The present results realign recognition with killing within the same molecule. In a certain sense this chemical immune system parallels the purely chemical defense mechanism of lower organisms, with the exception that a more sophisticated and diverse targeting element is added. Given the constraints that an ideal killing system must use host molecules in a localized fashion while minimizing self damage, one can hardly imagine a more judicious choice than ]O2. Because one already has such a reactive molecule, it is important to ask what might be the advantage of its further conversion by the antibody. The key issue is that by conversion of the transient singlet oxygen molecule (lifetime 4 μs) into the more stable O2 *", one now has access to hydrogen peroxide and all of the toxic products it can generate. In addition, superoxide is the only molecular oxygen equivalent remaining at the end of the oxygen-scavenging cascade. Therefore, this "recycling" may serve as a crucial mechanism for potentiation of the microbicidal process. Another benefit of singlet molecular oxygen is that it is only present when the host is under assault, thereby making it an "event-triggered" substrate. Also, because there are alternative ways to defend that use accessory systems, this chemical arm of the immune system might be silent under many circumstances. This said, however, there may be many disease states where antibody and singlet oxygen find themselves juxtaposed, thereby leading to cellular and tissue damage. Given that diverse events in man lead to the production of singlet oxygen, its activation by antibodies may lead to a variety of diseases ranging from autoimmunity to reperfusion injury and atherosclerosis (Skepper et al., Microsc Res. Tech.. 42, 369-385 (1998)).
Example II Antibodies Catalyze the Oxidation of Water
Methods and Materials Crystalography: IgG 4C6 was digested with papain and the Fab' fragment purified using standard protocols (Harlow and Lane). The Fab' was crystallized from 13-18%) PEG 8 K, 0.2 M ZnAc, 0.1 M cacodylate, pH 6.5. Crystals were pressurized under xenon gas at 200 psi for two minutes (Soltis et al., J. Appl. Crvst.. 30. 190, (1997)) and then flash cooled in liquid nitrogen. Data were collected to 2.0 A resolution at SSRL BL9-2. The structure was solved by molecular replacement using coordinates from the native 4C6 structure, and xenon atom sites were identified from strong peaks in the difference Fourier map. Refinement of the structure was done in CNS (Briinger et al., Acta. Crvstallogr.. D54. 905 (1998)) to final R = 23.1% and R^-. = 25.7%o. The occupancies of the two xenon atoms were refined after fixing their B values fifty percent higher than the B factors of the immediately surrounding protein. The figures were generated in Bobscript (R.M. Esnouf, Acta Crvstallog., D55, 938 (1999)). Scanning of the Kabat database: The Kabat database of human and mouse sequences was analyzed to determine the number of Tφ, Tyr, Cys, Met in their structures. Sequences were rejected if there were too many residue deletions or missing fragments. This allowed a high certainty analysis for 2068 of the 3894 sequences available. The values are reported as the mean totals with the range in parentheses of the CH, VH, CL and VL (K and λ.) regions: Tφ 15.5 (14 to 31), Tyr 30.4 (13 to 47), Cys 19.3 (15 to 29), Met 11.6 (7 to 32), His 13.3 (8 to 28). Grand total = 90.1 (49 to 167).
Inductively coupled plasma atomic emission spectroscopy: Inductively coupled plasma atomic emission spectroscopy (ICP-AES) of mAb PCP21H3 was performed on a Varian, Axial Vista Simultaneous ICP-AES spectrometer. Mouse monoclonal antibody (PCP21 H3) was exhaustively dialyzed into sodium phosphate buffered saline (PBS, 50 mM pH 7.4) with 20 mM EDTA. In a typical assay 300 μL of a 10.5 % HNO3 solution was added to 100 μL of a 10 mg/mL antibody solution and was incubated at 70°C for 14 hours. This solution was then diluted to 2 mL with MQH2O and then analyzed by comparison to standards. ICP-AES analysis results are reported in parts per million (μg/mL): Ag 0.0026 (0.0072 atoms per antibody molecule); Al 0.0098 (0.113 atoms per antibody molecule); As 0.0062 (0.025 atoms per antibody molecule); Ba below level of detection; Ca 0.0355 (0.266 atoms per antibody molecule). The high Ca concentration is a result of contamination of the phosphate buffer system utilized in our assay system. To investigate the effect of Ca(II) on the rate of antibody-mediated H202, the irradiation of antibody samples was performed using the assay procedure outlined in the legend of Figure 8 A with the addition of varying concentrations of CaCl2 (0 - 100 μM). The process was found to be independent of Ca(II) concentration; Cd 0.0007 (0.0187 atoms per antibody molecule); Ce 0.0012 (0.003 atoms per antibody molecule); Co 0.0013 (0.007 atoms per antibody molecule); Cr 0.0010 (0.006 atoms per antibody molecule); Cu 0.0014 (0.007 atoms per antibody molecule); Fe 0.0089 (0.048 atoms per antibody molecule); Gd 0.0008 (0.001 atoms per antibody molecule); K 0.0394 (0.302 atoms per antibody molecule); La 0.0007 (0.002 atoms per antibody molecule); Li 0.0013 (0.056 atoms per antibody molecule); Mg 0.0027 (0.033 atoms per antibody molecule); Mn 0.0007 (0.004 atoms per antibody molecule); Mo
0.0023 (0.007 atoms per antibody molecule); Na 102.0428 (1332 atoms per antibody molecule); Ni 0.0007 (0.004 atoms per antibody molecule); P 14.3521 (138.9 atoms per antibody molecule); Pb below level of detection; Rb 0.0007 (0.002 atoms per antibody molecule); Se below level of detection; V 0.0109 (0.019 atoms per antibody molecule); W 0.0119 (0.019 atoms per antibody molecule); Zn 0.0087 (0.040 atoms per antibody molecule).
Oxygen isotope experiments: In a typical experiment, a solution of antibody (6.7 μM, 100 μL) or non-immunoglobulin protein (50 μM, 100 μL) in PB (160 mM phosphate; pH 7.4) was lyophilized to dryness and then dissolved in H202 (100 μL, 98 %). Sodium chloride was excluded to minimize signal suppression in the MS. The higher concentration of non-immunoglobulin protein was necessary to generate a detectable amount of H202 for the MS assay. This protein solution was irradiated on a UV-transilluminator under saturating 1602 aerobic conditions in a sealed quartz cuvette for 8 hours at 20°C. The H202 concentration was determined after 8 hours using the Amplex Red assay (Zhou et al., Anal. Biochem.. 253. 162 (1997)). The sample was then filtered by centrifugation through a microcon (size-exclusion filter) to remove the protein and the H202 concentration re-measured. TCEP (freshly prepared 20 mM stock in H2 180) was added (ca. 2 mol eq relative to H202) and the solution was left to stand at 37°C for 15 minutes, after which time all the H202 had reacted. The TCEP solution in H2 180 was prepared fresh prior to every assay because 180 is slowly incoφorated into the carboxylic acids of TCEP (over days). During the time course of the assay, no incoφoration of lsO occurs due to this pathway. Furthermore, there is no incoφoration of 180 from H2 180 into the 160 phosphine oxide. The peak at 249 m/z is the (M-H)" of TCEP. The peak at 249 is observed in all the MS because an excess of TCEP (twofold) relative to H202 is used in the assay.
The reproducibiliry of the IδO/180 ratio from protein samples lyophilized together is reasonable (±10 %). However, problems with removing protein-bound water molecules during the lyophilization process means that the observed ratios can vary between samples from different lyophilization batches by as much as 2:1 to 4:1 (when lyophilizing from H2 160). It is, therefore, important that rigorous lyophilization and degassing procedures are followed. In this regard, the 1802 and H2 16O experiments exhibit far less inter-assay variability due to the relative ease of removing protein-bound oxygen molecules.
Antibodies from different species give similar ratios within the experimental constraints detailed below: 16O:]8O: WD1-6G6 mlgG (murine) 2.1:1; polylgG (horse) 2.2:1; polylgG(sheep) 2.2:1; EP2-19G2 mlgG (murine) 2.1: 1; CH2-5H7 mlgG (murine) 2.0:1; polylgG (human) 2.1:1. Ratios are based on the mean value of duplicate determinations except for polylgG (horse) which is the mean value often measurements. All assays and conditions are as described above.
In a typical experiment, a solution of sheep or horse polylgG (6.7 μM, 100 μL) in PB (160 mM phosphate; pH 7.4) was degassed under an argon atmosphere for 30 min. This solution was then saturated with I8O2 (90 %>) and irradiated as described above. Assays and procedures are then as described herein.
Assay for H2O2 production as a function of the efficiency of O2 formation via 3O2 sensitization with hematopoφhyrin IX: The assay is a modification of a procedure developed by H. Sakai and co-workers, Proc. SPIE-Int. Soc. Opt. Eng.. 2371. 264 (1995). In brief, the horse polylgG (1 mg/mL) in PBS (50 mM, pH 7.4) and hematopoφhyrin IX (40 μM) is irradiated with white light from a transilluminator. Aliquots are removed (50 μL) and the concentration of H2O2 and 3-aminophthalic acid measured simultaneously. H2O2 concentration was measured by the amplex red assay (Zhou et al., Anal. Biochem.. 253. 162 (1997)).
3-Aminophthalic acid concentration was measured by reversed-phase HPLC on a Hitachi D4000 series machine with an Adsorbosphere-C18 column, a UN detector at 254 nm, and a mobile phase of acetonitrile/water (0.1%> TFA) of 18:82 at 1 mL/min (retention time of luminol = 7.4 min and 3-aminophthalic acid 3.5 min). The concentrations of luminol and 3-aminophthalic acid were determined by comparison of peak height and area to control samples. The experimental data yields the amount of ]O2 formed by hematopoφhyrin IX (being directly proportional to the amount of 3-aminophthalic acid formed) and the amount of H2O2 formed by the antibody. Ν.B. There is no significant amount of ]O2 formed by antibodies without hematopoφhyrin IX in white light.
Any concerns that the amplex red assay may be detecting protein- hydroperoxide derivatives in addition to H2O2 have been discounted because the apparent H2O2 concentration measured using this method is independent of whether irradiated protein is removed from the sample (by size-exclusion filtration).
Quantum Chemical Methods: All QC calculations were carried out with Jaguar [Jaguar 4.0, Schrodinger, Inc. Portland, Oregon, 1998. See B. H. Greeley, T. N. Russo, D. T. Mainz, R. A. Friesner, J.-M. Langlois, W. A. Goddard III, R. E. Donnelly, J. Chem. Phvs.. 101. 4028 (1994)] using the B3LYP flavor of density functional theory (DFT) [J. C. Slater in Quantum Theory of Molecules and Solids, Vol. 4: The Self-Consistent Field of Molecules and Solids, McGraw Hill, New York, (1974)], that includes the generalized gradient approximation and exact exchange. The 6-31G** basis set was used on all atoms. All geometries were fully optimized. Nibrational frequencies were calculated to ensure that each minimum is a true local minimum (only positive frequencies) and that each transition state (TS) has only a single imaginary frequency (negative eigenvalue of the Hessian). Such QC calculations have been demonstrated to have an accuracy of ~3 kcal/mol for simple organic molecules. Νon-closed shell molecules such as O2 and 3O2 are expected to have larger errors. However, such errors are expected to be systematic such that the mechanistic implications of the QC results should be correct. All energetics are reported in kcal/mol without correcting for zero point energy or temperature.
Results and Discussion Antibodies are capable of generating hydrogen peroxide (H2O2) from singlet molecular oxygen (]O2). However, it was not known until now, as reported herein, that the process was catalytic and the source of electrons. It is now shown that antibodies are unique as a class of proteins in that they can produce up to 500 mole equivalents of H2O2 from ]O2, without a reduction in rate, in the absence of any discernible cofactor and electron donor. Based on isotope incoφoration experiments and kinetic data, it is proposed that antibodies are capable of facilitating an unprecedented addition of H2O to O2 to form H2O3 as the first intermediate in a reaction cascade that eventually leads to H2O2. X-ray crystallographic studies with xenon point to conserved oxygen binding sites within the antibody fold where this chemistry could be initiated. This findings suggest a unique protective function of immunoglobulins against O2 and raise the question of whether the need to detoxify ]O2 has played a decisive role in the evolution of the immunoglobulin fold.
Antibodies, regardless of source or antigenic specificity, generate hydrogen peroxide (H2O2) from singlet molecular oxygen (]O2) thereby potentially aligning recognition and killing within the same molecule (Wentworth et al., Proc. Natl. Acad. Sci. U.S.A.. 97, 10930 (2000)). Given the potential chemical and biological significance of this discovery, the mechanistic basis and structural location within the antibody of this process has been investigated. These combined studies reveal that, in contrast to other proteins, antibodies may catalyze an unprecedented set of chemical reactions between water and singlet oxygen.
Kinetic studies. Long term UN irradiation studies reveal that antibody-mediated H2O2 production is a much more efficient process than is the case for the non-immunoglobulin proteins (Figure 8A). Typically antibodies exhibit linearity in H2O2 fonnation for up to 40 mole equivalents of H2O2 before the rate begins to decline asymptotically (Figure 8B). By contrast, non-immunoglobulin proteins display a short 'burst' of H2O2 production followed by quenching as photo-oxidation occurs (Figure 8A).
In contrast to other proteins, antibodies are able to resume photo-production of H2O2 at the same initial rate as at the start of the experiment if the H2O2 generated during the assay is removed by catalase, as shown for murine monoclonal IgG PCP21H3 (Figure 8C). This profile of continued linear production of H2O2 after catalase-mediated destruction of H2O2 was conserved for all antibodies assayed. Thus, the H2O2 that accumulates during the process is inhibiting (reversibly) its own formation. The apparent IC50 was estimated as 225 μM (Figure 8D). Inhibition of the catalytic function of an enzyme either by substrates, transition state analogs or reaction products is often taken as strong evidence for an active site phenomenon. It has already been noted that the antibody-mediated photo-production of H2O2 is saturable with molecular oxygen (Kmapp(O2 187 μM) (Wentworth et al., Proc. Νatl. Acad. Sci. U.S.A.. 97, 10930 (2000)). This formal product inhibition of H2O2 provides further evidence for such a binding site phenomenon. An earlier report concerning the photo-production of H2O2 by antibodies did not probe the maximum amount of H2O2 that could be generated (Wentworth et al., Proc Natl. Acad. Sci. U.S.A.. 97, 10930 (2000)). This issue has been examined by repetitive cycles of UN irradiation of antibody samples followed by removal of the generated H2O2 by catalase (Figure 8C shows two such cycles). In one series of experiments, the cycle of UN-irradiation and addition of catalase was carried out for up to 10 cycles (horse poly IgG in PBS, pH 7.4). During these experiments > 500 mole equivalents (equiv.) of H2O2 were generated, with only a slight reduction in the initial rate being observed. Beside antibodies, the only other protein that was found thus far to generate H2O2 in such an efficient and long-term manner was the αβ T cell receptor (αβ TCR) (Figure 8F). Interestingly, the αβ TCR shares a similar arrangement of its immunoglobulin fold domains with antibodies (Garcia et al., Science. 274. 209 (1996)). However, possession of this structural motif seems not necessarily to confer an H2O2-generating ability on proteins as demonstrated by β2-microglobulin which does not generate H2O2 even though it is a member of the immunoglobulin superfamily (Welinder et al., Mol. Immunol., 28. 177 (1991)).
The antibody structure is remarkably inert against the oxidizing effects of H2O2. When exposed to standard UN irradiation conditions for 6 hours in the presence of H2O2 (at a concentration high enough to fully inhibit H2O2 production), a polyclonal horse IgG antibody sample becomes fully active once the inhibitory H2O2 has been destroyed by catalase (Figure 8E). The ability to continue H2O2 production for long periods at a constant rate, even after exposure to H2O2, reveals a remarkable, and hitherto unnoticed, resistance of the antibody structural fold to both chemical and photo-oxidative modifications suffered by other proteins. SDS-PAGE gel analysis of antibody samples after UN irradiation under standard conditions for 8 hours reveals neither significant fragmentation nor agglomeration of the antibody molecule. To ensure that there was no change in the protein structure in the presence of H2O2 (that may be contributing to the apparent inhibitory effect of H2O2) even at the level of side-chain position, x-ray crystal structures of Fab 4C6 were determined in the presence and absence of H2O2. Fab 4C6 was selected because its native crystals diffract to a higher resolution than any other published antibody (~1.3 A). The root mean square difference (RMSD) of key structural parameters were compared for the 4C6 structure before and after a soak experiment with 3 mM H2O2 RMSD of all atoms = 0.412 A, RMSD Cα atoms = 0.327 A, RMSD main chain atoms = 0.328 Λ, RMSD side-chain atoms = 0.488 A. The overlayed native and H2O2-treated structures of murine Fab 4C6 (Li et al., J. Am. Chem. Soc. 117. 3308 (1995)) are superimposable, reinforcing the evidence of stability of the antibody fold to H2O2 (Figure 9).
An action spectrum of the antibody-mediated photo-production of H2O2 and the corresponding absorbance spectrum of the antibody protein for the same wavelength range (260 - 320 nm) are juxtaposed in figure 10. The two spectra are virtually superimposable with maximal efficiency of H2O2 production being observed at an excitation wavelength that coincides with the UN absorbance maxima of tryptophan in proteins.
Probing the efficiency of H2O2 production by horse IgG as a function of the efficiency of O2 formation via 3O2 sensitization with hematopoφhyrin IX (φA = 0.22 in phosphate buffer pH 7.0 and visible light reveals that for every 275 ± 25 mole equivalents of O2 generated by sensitization, 1 mole equivalent of H2O2 is generated by the antibody molecule (Wilkinson et al., J. Phys. Chem. Ref. Data. 22, 113 (1993); Sakai et al., Proc. SPIE-Int. Soc Opt. Eng.. 2371. 264 (1995)). The question of the electron source. The mechanism problem posed by the antibody-mediated H2O2 production from singlet oxygen has to be shaφly divided into two sub-problems: one referring to the electron source for the process and the other concerning the chemical mechanism of the process. Given that the conversion of O2 to H2O2 requires two mole equivalents electrons, the fact that antibodies can generate > 500 equivalents of H2O2 per equivalent of antibody molecule raises an acute electron inventory problem. The search for this electron source began with the most distinct possibilities. Since electron transfer through proteins can occur with remarkable facility and over notably large distances (Winkler et al., Pure & Appl. Chem.. 71, 1753 (1999); Winkler, Curr. Opin. Chem. Biol.. 4, 192 (2000)), the first considered was that a collection of the residues implicated as electron donors cited in normal protein photo-oxidation processes might be involved. The nearly constant rate of H2O2 production by antibodies and the αβ-TCR during the repetitive cycles of irradiation and catalase treatment (Figure 8C and 8E) argued against such a mechanism because a marked reduction of rate would have to accompany H2O2 production as the residues capable of being oxidized become exhausted. This reduction of rate would be further exacerbated because the redox potentials of the remaining unoxidized residues would have to rise as the protein becomes more positively charged.
Normal protein photo-oxidation is a complex cascade of processes that leads to the generation of O2 and other reactive oxygen species (ROS), such as superoxide anion (O2 *~), peroxyl radical (HO2 *) and H2O2 (Foote, Science. 162. 963 (1968)).
Present mechanistic thinking links the sensitivity of proteins to photo-oxidation with up to five amino acids: tryptophan (Tφ), tyrosine (Tyr), cysteine (and cystine), methionine (Met), and histidine (His) (Straight and Spikes, in Singlet O2. A.A. Frimer, Ed. (CRC Press, Inc., Boca Raton, Florida, 1985), vol IV9, pp. 91-143; Michaeli and Feitelson. Photochem. Photobiol.. 59. 284 f 1994V). The photo-production of H2O2 by Tφ and molecular oxygen is a well-characterized process that involves, at least in part, the foπnation and reduction of O2 to O2 * that spontaneously dismutates into H2O2 and 3O2 (McMormick and Thompson, J. Am. Chem. Soc. 100. 312 (1978)). Tryptophan, both as an individual amino-acid and as a constituent of proteins, is particularly sensitive to near-UN irradiation (300-375 nm) under aerobic conditions, owing to its conversion to N'-formylkynurenine (ΝFK) that is a particularly effective near-UN (λmax 320 nm) photosensitizer (Walrant and Santus, Photochem. Photobiol.. 19, 411 (1974)). However, Tφ photo-oxidation is accompanied by substoichiometric production of H2O2 (ca. 0.5 mole equivalents) during near-UN irradiation (Figure 11 A) (McMormick and Thompson, J. Am. Chem. Soc. 100, 312 (1978)) and the most efficient non-immunoglobulin protein at H2O2 photo-production, β-galactosidase, generates only 5.9 mol eq. of H2O2 from its 39 Tφ residues (Figure 8 A) (Fowler and Zabin, J. Biol. Chem.. 253, 5521 (1978)). Scanning of the Kabat database of human and mouse antibody heavy- and light-chain sequences (2068 of 3894 sequences were analyzed) revealed that antibodies rarely have more than 15 Tφ residues in their entire structure (mean value = 15.5 with a range of 14 to 31 Tφ residues)(Kabat et al., Sequences of Proteins of Immunological Interest (US Department of Health and Human Services, Public Health Service, NIH, ed. 5th, 1991); Martin, PROTEINS: Struct.. Funct. and Genet.. 25, 130 (1996)). In fact, even if all of the amino acids that are implicated in protein photo-oxidation processes vide supra are collectively involved in antibody-mediated H202-production, there is still an insufficient number of these residues (mean value = 90.1 with a range of 49 to 167 reactive residues) to account for the 500 mole equivalents of H202 generated. The potential of chloride ion (present at 150 mM in PBS) as a reducing equivalent was then investigated given that chloride ion is known to be a suitable electron source for photo-production of H202 via a triplet excited state of an anthraquinone (Scharf and Weitz, Symp. Quantum Chem. Biochem.. Jerusalem vol. 12 (Catal. Chem. Biochem.: Theory Exp.), pp. 355-365 (1979)). This possibility was quickly discounted when the rate of H202 production by immunoglobulins was found to be independent of chloride ion concentration (Figure 1 IB).
The possible role of metal ions was investigated. While such ions could hardly be present in antibodies in such amounts that they could serve as an electron source, trace amounts of them might play a central role as catalytic redox centers. Experiments were performed that, for all practical puφoses, allow the implication of trace metals in this process to be ruled out. The rate of antibody-mediated photo- production of H202 is unchanged before and after exhaustive dialysis of antibody samples with EDTA-containing buffer (Figure 11C). After EDTA treatment of antibody samples, ICP-atomic emission spectroscopy (AES) revealed the presence of trace metal ions remaining in amounts that are far below parts per million. For a trace metal to be implicated in this reaction it must be common to all antibodies because all antibodies assayed have this intrinsic ability. It is generally accepted that metal-binding is not an implicit feature of antibodies and is consistent with our own analysis of antibody crystals as well as the approximate 300 antibody structures available on the Brookhaven database.
All of the observations thus far forcibly pointed towards the need to identify an electron source that would not imply a deactivation of the protein catalyst and that could account for the high turnover numbers and hence, for a quasi unlimited source of electrons. A more broad consideration of the chemical potential of O2 was done. The participation of this energized form of molecular oxygen in the antibody- mediated mechanism was clearly inferred from a previous report (Wentworth et al., Proc. Natl. Acad. Sci. U.S.A.. 97, 10930 (2000)). In brief, the antibody-mediated rate of H202 photo-production is increased in D20 and reduced in the presence of the J02 quencher, sodium azide. Furthermore, antibodies have been shown to generate H202 via sensitization of 302 with hematopoφhyrin IX in visible light, and in the dark with the endoperoxide of disodium 3 ',3 '-(1 ,4-naphthylidene) dipropionate (a chemical ]02 source). The involvement of O2 is also in line with the close similarity of the action spectrum of antibody-mediated H2O2 production and the absorbance spectrum of antibody constituent tryptophans (Figure 10).
Given that the known chemistry of O2 can be conceptualized as the chemistry of the super-electrophile "dioxa-ethene" (Foote, Ace Chem. Res., 1, 104 (1968), the heretofore unknown possibility was considered that a molecule of water may, in the presence of an antibody, add as a nucleophile to O2 and form H2O3 as an intermediate. Thus, water becoming oxidized to H2O2 would fulfil the role of the electron source. Oxygen isotope experiments were undertaken to test the hypothesis of an antibody-catalyzed photo-oxidation of H2O by !O2 through determination of the source of oxygen found in the H2O2. Contents of 16O/18O in H2O2 were measured by modification of a standard H2O2 detection method (Han et al., Anal. Biochem.. 234. 107 (1996)). Briefly, this method involves reduction with tris carboxyethyl phosphine (TCEP), followed by mass-spectral (MS) analysis of the corresponding phosphine oxides (Figure 12).
These experiments revealed that UN-irradiation of antibodies, in the presence of oxygen, leads to oxygen incoφoration from water into H2O2 (Figs. 12A and 12B). The relative abundance of the 16O/18O ratio observed in the MS of the phosphine oxide after irradiation of sheep polylgG under conditions of saturating I6O2 concentration in a solution of H2 18O (98 % 18O) phosphate buffer (PB) is 2.2 ± 0.2:1 (Figure 12 A). When the converse experiment is performed, with an 18O enriched molecular oxygen mixture (90 % 18O) in H2 16O PB, the reverse ratio (1 :2.0 ± 0.2) is observed (Figure 12B). These values of the ratios exhibit good reproducibility (+ 10 %, n = 10) and are found for all antibodies studied. The following control experiments were performed. First, under conditions of 16O2 and H2 16O, irradiation of polylgG (horse) generated H2 16O2 (Figure 12C). There is no incoφoration of 18O when H2 16O2 (400 μM in PB, pH 7.0) itself is irradiated for 4 hours in H2 18O. This result alleviates concerns that 18O incoφoration into H2O2 may be occurring via either an acid-catalyzed exchange with water or by a mechanism that involves homolytic cleavage of H2 I6O2 and recombination with H18O* from water. To check the possibility that antibodies may catalyze both the production of H2 16O2 and its acid-catalyzed exchange with H2 l8O, the isotopic exchange of H2 16O2 (200 μM) in H2 16O2 (98 % 18O) PB in the presence of sheep polylgG (6.7 μM) after UN-irradiation under an inert atmosphere was determined. Only a trace of incoφoration of 18O into H2 16O2 was observed (Figure 12D).
Isotope experiments were also performed with β-galactosidase, the most efficient non-immunoglobulin protein at generating H2O2 as well as 3-methylindole. In both cases, photo-oxidation led to negligible I8O incoφoration into the H2O2 (Figures 12E and 12F), illustrating the view that the indole ring itself and tryptophan residues in this protein are behaving simply as reductants of ]O2.
This view is further supported because irradiation of 3-methylindole generates H2O2 that does not include oxygen incoφoration from H2 18O. The same experiment performed with tryptophan does give rise to exchange with a ratio 16O/18O 1.2:1. This result is thought to be due to the ammonium functionality acting as an intramolecular general acid, protonating the internal oxygen of a diastereomeric mixture of 3'-hydroperoxides (inset Below). It should be noted that while this is interesting from a chemical point of view, it cannot account for the catalytic production of H2O2 by antibodies both because it is a stoichiometric process and Tφ residues in proteins do not possess a free ammonium group. H2 *
The chemical mechanism. All antibodies studied can catalyze the oxidation of water by singlet oxygen. The thermodynamic balance between reactants and products for the oxidation of H2O by O2 (heat of reaction, ΔHr = + 28.1 kcal/mol) (D.R. Lide, in Hanbook of Chemistry and Physics. 73rd ed. (CRC, 1992)), demands a stoichiometry in which more than one molecule of ]O2 would have to participate per molecule of oxidized water during its conversion into two molecules of H2O2. This stoichiometry assumes that no further light energy before that involved in the production of singlet from triplet oxygen is participating in the process. Qualitative chemical reasoning on hypothetical mechanistic pathways, together with thermodynamic considerations, makes the likely overall stoichiometries as in either equations lb or c (all energetics are calculated from gas phase experimental heats of formation and are reported in kcal/mol):
O2 + 2H2O H2O2 ; ΔH-° = 28.1 (la)
2 O2 + 2H2O 2H2O2 + 3O2 ; AH; = 5.6 (lb)
3 O2 + 2H2O 2H2O2 + 2 3O2 ; Δffr° = -16.9 (lc)
A recent report of a transition metal-catalyzed conversion of ]O2 and water into hydrogen peroxide, via a tellurium-mediated redox process (Detty and Gibson, J. Am. Chem. Soc. 112, 4086 (1990)), provides experimental evidence for a process in which 102 and H2O can be converted into H2O2 and, hence that the energetic demands of this process can be overcome. It is thought that the mechanism for the antibody-mediated photo-oxidation process involves the addition of a molecule water to a molecule of ]O2 to form dihydrogen trioxide as the first intermediate on the way to H2O2. The antibody's function as a catalyst would have to be the supply of a specific molecular environment that would stabilize the critical intermediate relative to its reversible formation and, or, would accelerate the consumption of the intermediate by channeling its conversion to H2O2. An essential feature of such an environment might consist of a special constellation of organized water molecules at an active site conditioned by an antibody-specific surrounding.
While H2O3 has not yet been detected in biological systems, its chemistry in vivo has been a source of considerable speculation and its in vitro properties have been the subject of numerous experimental and theoretical treatments (C. Deby, La Recherche. 228. 378 (1991); Sawyer, in Oxygen Chemistry (Oxford University Press, Oxford, 1991 ); Cerkovnik and Plesnicar, J. Am. Chem. Soc. 115, 12169
(1993); Vincent and Hillier, J. Phvs. Chem.. 99, 3109 (1995); Plesnicar et al., Chem. Eur. J.. 6, 809 (2000); Corey et al., J. Am. Chem. Soc. 108. 2472 (1986); Koller and Plesnicar, J. Am. Chem. Soc. 118. 2470 (1996); Cacace et al, Science. 285. 81 (1999)). Plesnicar and co-workers have shown that H2O3, reductively generated from ozone, decomposes into H2O and O2 (Koller and Plesnicar, J. Am. Chem. Soc. 118, 2470 (1996)). Applying the principle of microscopic reversibility, it was surmised that the reverse reaction should also be catalyzed by one or more molecules of water. To delineate plausible reaction routes and energetics of such a process, first principles quantum chemical (QC) methods were used (B3LYP Density Functional Theory) as described herein. The results are illustrated in equations 2a-c (all energetics are in kcal/mol):
H^ + 'O-, → TS → H2O3 (2a)
0.0 69.5 15.5
2H2O + 1O2 → TS → H2O3 + H2O (2b)
0.0 31.5 15.5
3H2O + ]O2 → TS → H2O3 + 2H2O (2c)
0.0 15.5 15.5
The direct reaction of water and l02 to give H2O3 is quite unfavorable, with an activation barrier of 70 kcal/mol (Eqn. 2a). However, with the addition of a second or third water molecule a concerted process is found that decreases the activation barrier to 31.5 and 15.5 kcal/mol respectively. Indeed these additional waters do play the role of a catalyst (in eqn. 2b the H of the 2nd water goes to the product HOOOH, simultaneous with the H of the 1st water replacing it). These barriers are small compared with the first HO bond energy of water (119 kcal/mol) and the bond energy of O2 (96 kcal/mol). Note that the reverse reaction in eqn. 2b and eqn. 2c has a barrier of only 15.5 or 0 kcal/mol respectively, suggesting that H2O3 is not stable in bulk water or water rich systems. Thus, the best site within the antibody structure for producing and utilizing H2O3 is expected to be one in which there are localized waters and water dimers next to hydrophobic regions without such waters.
The 16O/18O ratio in the phosphine oxide derived from the antibody-catalyzed photo-oxidation of water poses a significant constraint to the selection of reaction paths by which this primary intermediate H2O3 would to convert to the final product H2O2. The ratio is primarily determined by the number of 102 molecules that chemically participate in the production of two moles of H2O2 from two moles of H2O as well as by mechanistic details of this process. A ratio of 2.2:1 would coincide exactly with the value predicted for certain mechanisms in which two molecules of ]O2 and two molecules of H2O are transformed into two molecules of H2O2 and one molecule of molecular oxygen (which would have to be 3O2 for thermodynamic reasons). An example of such a mechanism is an SN2-type disproportionation of two molecules of H2O3 into H2O4 and H2O2, followed by the decomposition of the former into H2O2 and 3O2. The complex problem of defining theoretically feasible reaction pathways for the conversion of H2O3 into H2O2 with or without the participation of ]O2 has been tackled in a systematic way using quantum chemical methods (B3LYP Density Functional Theory). These studies show extensive docking calculations of H2O3 and the transition states for its formation and conversion into H2O2 to a number of proteins. Indeed there are unique sites of stabilizing these species in a region of antibodies (and the αβ-T cell receptor) in a region with isolated waters and next to hydrophobic regions. This extended study revealed the potential existence of a whole spectrum of theoretically feasible chemical pathways for the H2O3 to H2O2 conversion.
Structural studies of xenon binding to antibodies. Given the conserved ability of antibodies, regardless of origin or antigen specificity, or of the αβ- TCR to mediate this reaction, X-ray structural studies were instigated to search for a possible conserved reaction site within these immunoglobulin fold proteins. A key constraint for any potential locus is that molecular oxygen (either ]O2 or triplet with a potential sensitizing residue in proximity, preferably tryptophan) and water must be able to co-localize, and the transition-states and intermediates along the pathway must be stabilized either within the site or in close proximity.
There is strong evidence to support the notion that Xe and O2 co-localize in the same cavities within proteins (Tilson et al., J. Mol. Biol., 199. 195 (1988); Schoenborn et al., Nature, 207, 28 (1965)). Accordingly, xenon gas was used as a heavy atom tracer to locate cavities within the murine monoclonal antibody 4C6 that may be accessible to molecular oxygen (Li et al., J. Am. Chem. Soc. 117. 3308 (1995)).
Three xenon sites were identified (Figure 13 A), and all occupy hydrophobic cavities as observed in other Xe-binding sites in proteins (Scott and Gibson, Biochemistry. 36, 11909 (1997); Prange et al., PROTEINS: Struct.. Funct. and Genet, 30, 61 (1998)). Supeφosition of the refined native and Xe-derivatized structures shows that, aside from addition of xenon, there is little discernible change in the protein backbone or side chain conformation or in the location of bound water molecules.
The xenon I binding site (Xel site) has been analyzed here in more detail because it is conserved in all antibodies and the αβ TCR (Figure 13B). Xel is in the middle of a highly conserved region between the β-sheets of VL, 7 A from an invariant Tφ. The Xel site is sandwiched between the two β-sheets that comprise the immunoglobulin fold of the NL, approximately 5 A from the outside molecular surface. Xenon site two (Xe2) sits at the base of the antigen binding pocket directly above several highly conserved residues that form the structurally conserved interface between the heavy and light chains of an antibody (Figure 13 A). The residues in the NL NH interface are primarily hydrophobic and include conserved aromatic side chains, such as TφH109.
The contacting side chains for Xel in Fab 4C6 are AlaL19, IleL21, LeuL73, and IleL75, which are highly conserved aliphatic side chains in all antibodies (Kabat et al., Sequences of Proteins of Immunological Interest (US Department of Health and Human Services, Public Health Service, ΝIH, ed. 5th, 1991)). Additionally, only slight structural variation was observed in this region in all antibodies surveyed. Notably, several other highly conserved and invariant residues are in the immediate vicinity of this xenon site, including TφL35, PheL62, TyrL86, LeuL104, and the disulfide-bridge between CysL23 and CysL88. TφL35 stacks against the disulfide-bridge and is only 7 Λ from the xenon atom. In this structural context, TφL35 may be a putative molecular oxygen sensitizer, since it is the closest Tφ to Xel. Comparison with the 2C αβ TCR structure and all available TCR sequences shows that this Xel hydrophobic pocket is also highly conserved in TCRs (Figure 5B) (Garcia, Science, 274. 209 (1996)).
Human β2-microglobulin, which does not generate H2O2, does not have the same detailed structural characteristics that define the antibody Xel binding pocket, despite its overall immunoglobulin fold. Also, β2-microglobulin does not contain the conserved Tφ residue that occurs there in both antibodies and TCRs. If TφL35 (antibodies) or Tφα34 (TCR) is the oxygen sensitizer, the lack of a corresponding Tφ in β2-microglobulin may relate to the finding that it does not catalyze the oxidation of water.
Thus, the xenon experiments have identified at least one site that is both accessible to molecular oxygen and is in a conserved region (NL) in close proximity to an invariant Tφ; an equivalent conserved site is also possible in the fold of NH The structure and sequence around the Xel site is almost exactly reproduced in the NH domain by the pseudo two-fold rotation axis that relates NL to NH. Although a xenon binding-site was not located in this domain, it is thought that molecular oxygen can still access the corresponding cavity in NH The proposed heavy chain xenon site may not have been found because the crystals were pressurized for only two minutes, which may have been insufficient time to establish full equilibrium, or simply because xenon is too large compared to oxygen for the corresponding cavity on the NH side, or due to crystal packing. In other antibody experiments, Xe binding sites were found in only one of the two molecules of the asymmetric unit that suggests that crystal packing can modulate access of Xe in crystals. Analysis of the sequence and structure around these sites shows that they are highly conserved in both antibodies and TCRs thus providing a possible understanding of why the Ig-fold in antibodies and the TCR can be involved in this unusual chemistry.
Antibodies are unique among proteins in their ability to catalytically convert O2 into H2O2. It is thought that this process participates in killing by event-related production of H2O2. Alternatively, antibodies can fulfill the function of defending an organism against !O2. This would require the further processing of hydrogen peroxide into water and triplet oxygen by catalase.
Publications Burton, D. R., Trends Biochem. Sci.. 15, 64-69 (1990).
Arlaud, G. J., Colomb, M. G. & Gagon, J., Immunol. Today. 8, 106-111 (1987). Sim, R. B. & Reid, K. B., Immunol. Today. 12, 307-311 (1991). Wentworth, P., Jr. & Janda, K. D., Curr. Opin. Chem. Biol.. 2, 138-144 (1998). Klebanoff, S. J. in Encyclopedia of Immunology, eds. Delves, P. J. & Roitt, I. M. (Academic, San Diego), pp. 1713-1718 (1998).
Rosen, H. & Klebanoff, S. J., J. Biol. Chem.. 252, 4803-4810 (1997).
Fee, J. A. in International Conference on Oxygen and Oxygen-Radicals, eds.
Rodgers, M. A. J. & Powers, E. L. (Academic, San Diego, and University of Texas at Austin), pp. 205-239 (1981). Kearns, D. R., Chem. Rev.. 71_, 395-427 (1971).
Foote, C. S. in Free Radicals in Biology, ed. Pryor, W. A. (Academic, New York), pp. 85-133 (1976). Allen, R. C, Stjernholm, R. L., Benerito, R. R. & Steele, R. H., eds. Cormier, M. J., Hercules, D. M. & Lee, J. (Plenum, New York), pp. 498-499 (1973). Klebanoff, S. J. in The Phagocytic Cell in Host Resistance (National Institute of Child Health and Human Development, Orlando, FL) (1974). Stauff, J., Sander, U. & Jaeschke, W., Chemiluminescence and Bioluminescence. eds., Williams, R. C. & Fudenberg, H. H. (Intercontinental Medical Book
Corp., New York), pp. 131-141 (1973). Allen, R. C, Yevich, S. J., Orth, R. W. & Steele, R. H., Biochem. Biophvs. Res. Commun.. 60, 909-917 (1974).
Zhou, M., Diwu, Z., Panchuk-Voloshina, N. & Haugland, R. P., Anal. Biochem..
253, 162-168 (1997). Petyaev, I. M. & Hunt, J. V., Redox Report. 2, 365-372 (1996). Kreitner, M., Alth, G., Koren, H., Loew, S. & Ebermann, R., Anal. Biochem., 213. 63-67 (1993).
Beauchamp, C. & Fridovich, I., Anal. Biochem.. 44, 276-287 (1971). Srinivasan, V. S., Podolski, D., Westrick, N. J. & Neckers, D. C, J. Am. Chem. Soc. 100, 6513-6515 (1978).
Hasty, N., Merkel, P. B., Radlick, P. & Kearns, D. R. Tetrahedron Lett.. 49-52 (1972).
Merkel, P. B., Nillson, R. & Kearns, D. R., J. Am. Chem. Soc. 94, 1030-1031 (1972).
Grossweiner, L. I., Curr. Top. Radiat. Res. 0.. H, 141-199 (1976). Bent. D. V. & Hayon, E., J. Am. Chem. Soc. 87, 2612-2619 (1975). Voss, R.-H., Ermler, U., Essen, L.-O., Wenzl, G., Kim, Y.-M. & Flecker, P., Eur. J.
Biochem.. 242. 122-131 (1996V _ Baek, J. & Kim, S., Plant Phvsiol.. 102. 687 (1993). Feldhoff, R. & Peters, T. J., Biochem. J.. 159. 529-533 (1976). Burley, S. K. & Petsko, G. A., Science. 229. 23-28 (1985). Gollnick, K., Adv. Photochem.. 6, 1-122 (1968).
Mach, H., Burke, C. J., Sanyal, G., Tsai, P.-K, Volkin, D. B. & Middaugh, C. R. in
Formulation and Delivery of Proteins and Peptides. eds. Cleland, J. L. &
Langer, R. (American Chemical Society, Denver, CO) (1994). Skepper, J., Pierson, R., Young, V., Rees, J., Powell, J., Navaratnam, V., Gary, N., Tew, D., Bacon, P., Wallwork, J. et al., Microsc Res. Tech.. 42, 369-385
(1998). A.D. Wentworth, L. H Jones, P. Wentworth, Jr., K. D. Janda, R. A. Lerner, Proc.
Natl. Acad. Sci. U.S.A.. 97, 10930 (2000).
M. Zhou, Z. Diwu, N. Paάchuk-Voloshina, R. P. Haugland, Anal. Biochem.. 253, 162 (1997). K. C. Garcia et al., Science. 274. 209 (1996).
K. G. Welinder, H. M. Jespersen, J. W.-Rasmussen, K. Skoedt, Mol. Immunol.. 28. 177 (1991). "
T. Li, S. Hilton, K. D. Janda, J. Am. Chem. Soc. 117. 3308 (1995).
F. Wilkinson, W. P. Helman, A. B. Ross, J. Phvs. Chem. Ref. Data. 22, 113 (1993). J. R. Winkler, A. J. Di Bilio, N. A. Farrow, J. H. Richards, H. B. Gray, Pure & Appl. Chem.. 71. 1753 f 1999V
J. R. Winkler, Curr. Opin. Chem. Biol.. 4, 192 (2000).
C. S. Foote, Science. 162. 963 (1968).
R. C. Straight, J. D. Spikes, in Singlet Q2. A. A. Frimer, Ed. (CRC Press, Inc., Boca Raton, Florida, 1985), vol. IV9, pp. 91-143.
A. Michaeli, J. Feitelson, Photochem. Photobiol.. 59, 284 (1994).
J.P. McCormick, T. Thomason, J. Am. Chem. Soc. 100. 312 (1978).
P. Walrant, R. Santus, Photochem. Photobiol.. 19, 411 (1974).
A. V. Fowler, I. Zabin, J. Biol. Chem.. 253. 5521 (1978). E. A. Kabat, T. T. Wu, H. M. Perry, K. S. Gottesman, C. Foeller, Sequences of Proteins of Immunological Interest (US Department of Health and
Human Services, Public Health Service, NIH, ed. 5th, 1991).
A. C. R. Martin, PROTEINS: Struct.. Funct. and Genet.. 25, 130 (1996).
H.D. Scharf, R. Weitz, Symp. Quantum Chem. Biochem.. Jerusalem vol. 12 (Catal. Chem. Biochem.: Theory Exp.), pp. 355-365 (1979).
C. S. Foote, Ace Chem. Res..1, 104 (1968).
J. Han, S. Yen, G. Han, P. Han, Anal. Biochem.. 234, 107 (1996).
D.R. Lide, in Handbook of Chemistry and Physics. 73rd ed. (CRC, 1992).
M. Detty, S. L. Gibson, J. Am. Chem. Soc. 112. 4086 (1990). C. Deby, La Recherche. 228. 378 (1991).
D.T. Sawyer, in Oxygen Chemistry (Oxford University Press, Oxford, 1991). J. Cerkovnik, B. Plesnicar, J. Am. Chem. Soc. 115. 12169 (1993).
M.A. Vincent, I. A. Hillier, J. Phvs. Chem.. 99, 3109 (1995).
B. Plesnicar, J. Cerkovnik, T. Tekavec, J. Koller, Chem. Eur. J.. 6, 809 (2000).
E.J. Corey, Mehrotra, M. M.; Khan, A. U., J. Am. Chem. Soc. 108. 2472 (1986). J. Koller, B. Plesnicar, J. Am. Chem. Soc. 118. 2470 (1996).
F. Cacace, G. de Petris, F. Pepi, A. Troiani, Science. 285. 81 (1999).
B. H. Greeley, T. V. Russo, D. T. Mainz, R. A. Friesner, J.-M. Langlois, W. A. Goddard III, R. E. Donnelly, J. Chem. Phvs.. 101. 4028 (1994)
J. C. Slater in Quantum Theory of Molecules and Solids. Vol. 4: The Self-Consistent Field of Molecules and Solids, McGraw Hill, New York, (1974)
R. F. Tilson Jr., U. C. Singh, I. D. Kuntz Jr. P. A. Kollman, J. Mol. Biol.. 199. 195 (1988).
B. P. Schoenborn. H. C. Watson, J. C. Kendrew, Nature. 207. 28 (1965).
E.E. Scott, Q. H. Gibson, Biochemistry. 36, 11909 (1997). T. Prange et al., PROTEINS: Struct.. Funct. and Genet.. 30, 61 (1998).
S. M. Soltis, M. A. B. Stowell. M. C. Wiener, G. N. Phillips Jr, D. C. Rees, J. Appl. Cryst, 30, 190, (1997)
A. T. Briinger et al., Acta. Crvstallogr.. D54. 905 (1998)
R.M. Esnouf, Acta Crvstallog.. D55. 938 (1999)]. J. R. Kanowsky, Chem. Biol. Interactions. 70, 1 (1989).
V. Cannac-Caffrey, et al., Biochimie. 80, 1003 (1998).
All publications, patents and patent applications are incoφorated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for puφoses of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

Claims

What Is Claimed Is:
1. A method of treating a cell comprising contacting the cell with an antioxidant, wherein the antioxidant is effective in reducing antibody mediated generation of superoxide or hydrogen peroxide in the cell.
2. The method of claim 1 wherein the antioxidant is ascorbic acid, α- tocopherol, γ-glutamylcysteinylglycine, γ-glutamyl transpeptidase, α-lipoic acid, dihydrolipoate, N-acetyl-5-methoxytryptamine, flavones, flavonenes, flavanols, catalase, peroxidase, superoxide dismutase, metallothionein, or butylated hydroxytoluene.
3. The method of claim 1 wherein the antioxidant is contained in a liposome.
4. The method of claim 1 wherein the cell is an endothelial, interstitial, epithelial, muscle, phagocytic, white blood cells, dendritic, connective tissue or nervous system cell.
5. The method of claim 4 wherein the phagocytic cell is a neutrophil or a macrophage.
6. The method of claim 4 wherein the muscle cell is a smooth muscle cell, a skeletal muscle cell or a cardiac muscle cell.
7. A method of treating a subject comprising administering an antioxidant in a pharmaceutically acceptable excipient to the subject, wherein the antioxidant is effective in reducing antibody mediated generation of superoxide or hydrogen peroxide in a cell in the subject.
8. The method of claim 7, wherein the antibody mediated generation of superoxide or hydrogen peroxide causes oxidative stress in the subject.
9. The method of claim 8 wherein the oxidative stress is present in a subject presenting with disease conditions for cancer, inflammatory diseases, ischemic diseases, hemochromatosis, acquired immunodeficiency syndrome, emphysema, organ transplantation, gastric ulcers, hypertension, preeclampsia, neurological diseases, alcoholism and smoking-related diseases.
10. The method of claim 9 wherein the inflammatory diseases are arthritis, vasculitis, glomerulonephritis, systemic lupus erythematosus, and adult respiratory distress syndrome.
11. The method of claim 9 wherein the ischemic diseases are heart disease, stroke, intestinal ischemia, and reperfusion injury.
12. The method of claim 9 wherein the neurological diseases are multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and muscular dystrophy.
13. The method of claim 7, wherein the antibody mediated generation of superoxide or hydrogen peroxide causes tissue injury in the subject.
14. The method of claim 13 wherein the tissue is selected from the group consisting of muscle, nervous, skin, glandular, mesenchymal, splenic, sclerous, epithelial and endothelial tissues.
15. The method of claim 7, wherein the antibody mediated generation of superoxide or hydrogen peroxide is associated with an inflammatory condition in the subject.
16. The method of claim 15 wherein the inflammatory condition is an inflammation of the lungs.
17. The method of claim 7, wherein the antibody mediated generation of superoxide or hydrogen peroxide is associated with a disorder resulting from aberrant smooth muscle function.
18. The method of claim 17 wherein the aberrant smooth muscle function is in the lung airways or vasculature.
19. The method of claim 7, wherein the antibody mediated generation of superoxide or hydrogen peroxide is associated with organ transplantation in the subject.
20. The method of claim 7 wherein the antioxidant is selected from the group consisting of ascorbic acid, α-tocopherol, γ-glutamylcysteinylglycine, γ- glutamyl transpeptidase, α-lipoic acid, dihydrolipoate, -acetyl-5-methoxytryptamine, flavones, flavonenes, flavanols, catalase, peroxidase, superoxide dismutase, metallothionein, and butylated hydroxytoluene.
21. The method of claim 7 wherein the composition is delivered to the subject intravenously, topically, orally, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, and subcutaneously.
22. The method of claim 7 wherein the composition comprises liposome containing the antioxidant.
23. A method for exposing an antigen to superoxide or hydrogen peroxide comprising contacting the antigen with an antibody capable of generating superoxide or hydrogen peroxide from singlet oxygen.
24. The method of claim 23 wherein singlet oxygen is induced with a sensitizer.
25. The method of claim 24 wherein the sensitizer is conjugated to the antibody.
26. The method of claim 25 wherein the sensitizer is selected from the group consisting of pterins, flavins, hematopoφhyrin, tetrakis(4- sulfonatophenyl)poφhyrin, bipyridyl ruthemium(II) complexes, rose bengal dye, quinones, rhodamine dyes, phtalocyanine, and hypocrellins.
27. The method of claim 23 wherein the antigen is a fatty acid or a low density lipoprotein.
28. The method of claim 23 wherein the antigen is presented on a cell.
29. The method of claim 23 wherein the cell is an endothelial, interstitial, epithelial, muscle, phagocytic, white blood cells, dendritic, connective tissue or nervous system cell.
30. The method of claim 29 wherein the phagocytic cell is a neutrophil or a macrophage.
31. The method of claim 29 wherein the muscle cell is a smooth muscle cell, a skeletal muscle cell or a cardiac muscle cell.
32. The method of claim 23 wherein the singlet oxygen is generated from irradiation of the cell.
33. The method of claim 32 wherein the irradiation of the cell is with ultraviolet light, infrared light or visible light.
34. The method of claim 23 wherein the antibody is a Fab, Fv, sFv or complete immunoglobulin molecule.
35. The method of claim 23 wherein the antibody is immunospecific for the antigen.
36. The method of claims 23 wherein the antibody is not immunospecific for the antigen.
37. The method of claim 23 wherein the antibody concentration at the cell surface is from 1-5 micromolar.
38. A method for inhibiting proliferation a cancer cell comprising contacting the cancer cell with a composition comprising an effective proliferation- inhibiting amount of antibody capable of generating superoxide or hydrogen peroxide from singlet oxygen.
39. The method of claim 38, wherein the amount of antibody is sufficient to kill the cancer cell.
40. The method of claim 38 wherein the antibody concentration at the cancer cell surface is from 1-5 micromolar.
41. The method of claim 38 wherein the antibody is a Fab, Fv, sFv or complete immunoglobulin molecule.
42. The method of claim 38 wherein the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell.
43. The method of claim 38 wherein the cancer cell is in a subject with cancer.
44. The method of claim 43 wherein the subject has lung cancer, prostate cancer, colon cancer, cervical cancer, endometrial cancer, bladder cancer, bone cancer, leukemia, lymphoma, or brain cancer.
45. The method of claim 43 wherein the cancer cell is removed from a subject with cancer and cultured ex vivo.
46. The method of claim 43 wherein the cell ex vivo is exposed to ultraviolet light, infrared light or visible light and is returned to the subject.
47. The method of claim 43 wherein the composition is delivered in vivo.
48. The method of claim 47 wherein the in vivo delivery is performed intravenously, topically, by inhalation, by cannulation, intracavitally, intramuscularly, transdermally, and subcutaneously.
49. The method of claim 38 wherein the composition comprises liposome containing the antibody.
50. The method of claim 49 wherein the antibody is a recombinant antibody.
51. The method of claim 50 wherein the recombinant antibody is expressed from an expression vector delivered to the cell.
52. The method of claim 51 wherein the expression vector further expresses a sensitizer molecule.
53. The method of claim 38 wherein the composition further comprises a sensitizer molecule.
54. The method of claim 53 wherein the sensitizer wherein the sensitizer molecule is selected from the group consisting of pterins, flavins, hematopoφhyrin, tetrakis(4-sulfonatophenyl)poφhyrin, bipyridyl ruthemium(II) complexes, rose bengal dye, quinones, rhodamine dyes, phtalocyanine, and hypocrellins.
55. The method of claim 53 wherein the sensitizer molecule is conjugated to the antibody.
56. The method of targeting and killing a cancer cell in a patient, the method comprising contacting the cancer cell with a composition comprising an effective killing amount of antibody in a pharmaceutically acceptable excipient, wherein the antibody is capable of generating superoxide or hydrogen peroxide from singlet oxygen, and wherein the antibody recognizes and immunoreacts with an antigen expressed on the cancer cell.
57. The method of claim 56 wherein the antibody concentration at the cell surface is from 1-5 micromolar.
58. The method of claim 56 further comprising placing the patient in a hyperbaric chamber.
59. The method of claim 56 wherein the composition further comprises a sensitizer molecule.
60. The method of claim 59 wherein the sensitizer wherein the sensitizer molecule is selected from the group consisting of pterins, flavins, hematopoφhyrin, tetrakis(4-sulfonatophenyl)poφhyrin, bipyridyl ruthemium(II) complexes, rose bengal dye, quinones, rhodamine dyes, phtalocyanine, and hypocrellins.
61. A method of treating a subject comprising administering to the subject a composition comprising a therapeutically effective amount of an antibody in a pharmaceutically acceptable excipient, wherein the antibody is capable of generating superoxide or hydrogen peroxide from singlet oxygen.
62. The method of claim 61 , wherein the antibody mediated production of superoxide or hydrogen peroxide is associated with neutrophil mediated inflammation in the subject.
63. The method of claim 61 , wherein the subject has an autoimmune disease.
64. The method of claim 61 , wherein the antibody mediated production of superoxide or hydrogen peroxide enhances bactericidal effectiveness of a phagocyte in a subject.
65. The method of claim 61 , wherein the antibody mediated production of superoxide or hydrogen peroxide promotes wound healing in a subject having a open wound.
66. The method of claim 65, wherein the superoxide or hydrogen peroxide stimulates fibroblast proliferation.
67. The method of claim 65, wherein the superoxide or hydrogen peroxide stimulates the immune response.
68. The method of claim 67, wherein the immune response includes lymphocyte proliferation.
69. The method of claim 61 , wherein the antibody mediated production of superoxide or hydrogen peroxide stimulates cell proliferation.
70. The method of claim 69, wherein the cell population comprises fibroblasts in a wound in a subject.
71. The method of claim 70, wherein the cell population comprises lymphocytes in a wound on a subject.
72. The method of claim 71, wherein the lymphocytes comprise B cells.
73. The method of claim 69, wherein the contacting comprises topical application to a wound on a subject.
74. The method of claim 73, wherein topical application comprises a bandage containing the antibody.
75. A method for identifying an agent that modulates the production of hydrogen peroxide generated by antibody-mediated superoxide or hydrogen peroxide generation, the method comprising the steps of: a) contacting a composition comprising an antibody capable of generating superoxide or hydrogen peroxide from singlet oxygen with the agent to form an admixture in an assay solution in the presence of molecular oxygen; b) irradiating the admixture to generate singlet oxygen from molecular oxygen, wherein the singlet oxygen is reduced to hydrogen peroxide or superoxide by the antibody, wherein the superoxide dismutates to form hydrogen peroxide; c) detecting the formed hydrogen peroxide; and d) comparing the detected hydrogen peroxide with a suitable control, thereby determining how the agent modulates the production of hydrogen peroxide.
76. The method of claim 75, wherein the modulation is inhibition of hydrogen peroxide production.
77. The method of claim 75, wherein the modulation is generation of hydrogen peroxide production.
78. The method of claim 75, wherein the irradiation is with ultraviolet light.
79. The method of claim 75, wherein the irradiation is with visible light.
80. The method of claim 75, wherein the visible light irradiation further comprises admixing a sensitizer with the antibody composition.
81. The method of claim 75, wherein detecting the formed hydrogen peroxide is by fluorescent means with a fluorescent substrate for hydrogen peroxide.
82. The method of claim 75, wherein the fluorescent means are fluorescent microscopy or fluorescent spectrometry.
83. The method of claim 82, wherein the fluorescent spectrometry is ELISA based or with a standard cuvette.
84. The method of claim 75, wherein the steps are performed as described in example I.
85. A method for performing an immunoassay to detect antibody immunoreactivity with an antigen, the method comprising the steps of: a) contacting in a singlet oxygen-generating medium a substrate having immobilized thereon a composition comprising a first reagent comprising an antigen or an antibody, with a second composition comprising an antigen or an antibody that is reactive with first reagent to form an immobilized antigen-antibody complex, wherein the antibody generates superoxide or hydrogen peroxide from singlet oxygen in the presence of oxygen; and b) detecting the antibody-generated superoxide or hydrogen peroxide, thereby detecting the antibody immunoreactivity with the antigen.
86. The method of claim 85, further comprising irradiating the formed complex.
87. The method of claim 85, wherein the irradiation is with ultraviolet light.
88. The method of claim 85, wherein the irradiation is with visible light.
89. The method of claim 88, wherein the visible light irradiation further comprises admixing a sensitizer with the antibody.
90. The method of claim 85, wherein detecting the formed hydrogen peroxide is by fluorescent means with a fluorescent substrate for hydrogen peroxide.
91. The method of claim 90, wherein the fluorescent means are fluorescent microscopy or fluorescent spectrometry.
92. The method of claim 91 , wherein the fluorescent spectrometry is
ELISA based or with a standard cuvette.
93. The method of claim 85, wherein the first composition is an antigen and the second composition is an antibody.
94. The method of claim 85, wherein the first composition is an antibody and the second composition is an antigen.
95. The method of claim 85, wherein step (b) detects superoxide.
96. The method of claim 85, wherein step (b) detects hydrogen peroxide.
97. A therapeutic antioxidant comprising an engineered antibody molecule having less than two reductive centers, wherein production of superoxide or hydrogen peroxide from singlet oxygen reduced by the reductive center is diminished.
98. The therapeutic antioxidant of claim 97 further comprising a pharmaceutically acceptable excipient.
99. The therapeutic antioxidant of claim 97, wherein the antibody molecule is substantially free of a reductive center, wherein production of superoxide from singlet oxygen reduced by the reductive center is substantially absent.
100. The therapeutic antioxidant of claim 97, wherein the reductive center comprises indole.
101. The therapeutic antioxidant of claim 100, wherein the indole is present in an amino acid residue in the molecule.
102. The therapeutic antioxidant of claim 101, wherein the indole is present in a tryptophan residue.
103. The therapeutic antioxidant of claim 97, wherein the antibody is a recombinant antibody.
104. The therapeutic antioxidant of claim 97, wherein the antioxidant is used according to the method of claim 1 or 7.
105. The method of claim 1 or 7 wherein the antioxidant is the therapeutic antioxidant according to claim 97.
106. An engineered therapeutic molecule comprising greater than two reductive centers capable of reducing singlet oxygen to superoxide or hydrogen peroxide.
107. The engineered therapeutic molecule of claim 106 further comprising a pharmaceutically acceptable excipient.
108. The engineered therapeutic molecule of claim 106, wherein the reductive centers comprise indole.
109. The engineered therapeutic molecule of claim 106, wherein the molecule comprises amino acid residues.
110. The engineered therapeutic molecule of claim 109, where the indole is present in an amino acid residue in the molecule.
111. The engineered therapeutic molecule of claim 110, wherein the indole is present in a tryptophan residue.
112. The engineered therapeutic molecule of claim 111, wherein the tryptophan residue is present in an antibody.
113. The engineered therapeutic molecule of claim 106, wherein the antibody is a recombinant antibody.
114. The engineered therapeutic molecule of claim 113, wherein the recombinant antibody is capable of binding to an antigen.
115. The engineered therapeutic molecule of claim 113, wherein the recombinant antibody is expressed as a fusion conjugate.
116. The engineered therapeutic molecule of claim 115, wherein the fusion conjugate comprises a sensitizer.
117. The engineered therapeutic molecule of claim 112, wherein the tryptophan residue is present in ovalbumin.
118. The engineered therapeutic molecule of claim 106, wherein the molecule is chemically synthesized.
119. The engineered therapeutic molecule of claim 112, wherein the antibody is used according to the method of claim 7, 38 or 61.
120. The method of claim 7, 38 or 61 wherein the antibody is an engineered therapeutic antibody according to claim 106.
121. An engineered therapeutic antibody comprising at least one reductive center capable of reducing singlet oxygen to superoxide or hydrogen peroxide, and a pharmaceutically acceptable excipient.
122. The engineered therapeutic antibody of claim 121, wherein the reductive center comprises indole.
123. The engineered therapeutic antibody of claim 122, wherein the indole is present in an amino acid residue in the antibody.
124. The engineered therapeutic antibody of claim 123, wherein the indole is present in a tryptophan residue.
125. The engineered therapeutic antibody of claim 121, wherein the antibody is capable of binding to an antigen.
126. The engineered therapeutic antibody of claim 121, wherein the reductive center is positioned adjacent to a variable binding domain of the antibody.
127. The engineered therapeutic antibody of claim 121, wherein the antibody has three tryptophan residues.
128. The engineered therapeutic antibody of claim 121, wherein the antibody is a recombinant antibody.
129. The engineered therapeutic antibody of claim 128, wherein the recombinant antibody is expressed as a fusion conjugate.
130. The engineered therapeutic antibody of claim 129, wherein the recombinant antibody is capable of binding to an antigen and wherein the fusion conjugate comprises a sensitizer.
131. The engineered therapeutic antibody of claim 121, wherein the antibody is used according to the method of claim 7, 38 or 61.
132. The engineered therapeutic antibody of claim 125, wherein the antibody is used according to the method of claim 7, 38 or 61.
133. The engineered therapeutic antibody of claim 130, wherein the recombinant conjugated antibody is used according to the method of claim 86, 91, 93 or 94.
134. The method of claim 38 wherein the antibody is capable of binding to an antigen.
135. The method of claim 134, wherein singlet oxygen is produced by administering a prodrug that is capable of generating singlet oxygen, wherein the prodrug is administered after an appropriate time period to allow the antibody to bind to the antigen to form an antibody-antigen complex.
136. The method of claim 135, wherein the prodrug is endoperoxide.
137. The method of claim 136, wherein endoperoxide is present in a concentration of about 10 micromolar in proximity to the formed antibody-antigen complex.
138. The method of claim 135, wherein the antibody and the prodrug are administered intramuscularly, intravenously, or subcutaneously.
139. The method of claim 134, wherein the antibody is an engineered therapeutic antibody according to claim 121.
140. The method of claim 134 further comprising irradiation with ultraviolet light, infrared light or visible light, wherein the antibody is an engineered therapeutic antibody according to claim 121, and wherein the fusion conjugate comprises a sensitizer.
141. A method to detect the presence of an antigen in a bodily fluid comprising: a) immobilizing a complex of the antigen with an antibody that is capable of generating superoxide or hydrogen peroxide; and b) detecting the superoxide or hydrogen peroxide generated by the antibody.
142. The method of claim 141, wherein the antigen is a drug.
143. The method of claim 141, wherein the antigen is a hormone.
144. The method of claim 141, wherein the bodily fluid is blood or urine.
145. A composition comprising a T-cell receptor that can generate hydrogen peroxide.
EP01981317A 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies Ceased EP1367998A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23270200P 2000-09-15 2000-09-15
US232702P 2000-09-15
US23547500P 2000-09-26 2000-09-26
US31590601P 2001-08-29 2001-08-29
US315906P 2001-08-29
PCT/US2001/029165 WO2002022573A2 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US235475P 2009-08-20

Publications (2)

Publication Number Publication Date
EP1367998A2 true EP1367998A2 (en) 2003-12-10
EP1367998A4 EP1367998A4 (en) 2004-03-17

Family

ID=27398334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01981317A Ceased EP1367998A4 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies

Country Status (5)

Country Link
EP (1) EP1367998A4 (en)
JP (1) JP2005524601A (en)
AU (2) AU1297002A (en)
CA (1) CA2422586A1 (en)
WO (1) WO2002022573A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2380481B (en) 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Means for treatment of atherosclerosis
CA2505932A1 (en) * 2002-11-14 2004-05-27 Novartis Ag Antimicrobial activity of antibodies producing reactive oxygen species
DE10258239A1 (en) * 2002-12-13 2004-06-24 Degussa Ag Formulation used for treating non-chronic alcoholic intoxication, contains alpha-lipoic acid for scavenging free radicals and activating alcohol metabolizing enzymes
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
JP4615470B2 (en) 2006-03-29 2011-01-19 卓郎 簑和田 Disease treatment and prevention methods and medicines using cerebral cognition
WO2008087803A1 (en) * 2007-01-16 2008-07-24 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
JP6389236B2 (en) * 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド Redox preparation
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
JP6269946B2 (en) * 2014-03-25 2018-01-31 国立大学法人名古屋大学 Bacterial growth inhibition
KR101774636B1 (en) * 2015-04-06 2017-09-04 한국생명공학연구원 Method for Label-free antibody detection basd on nano probe
JP7387603B2 (en) * 2017-11-29 2023-11-28 フィジーン、エルエルシー Interaction of fibroblasts and immune cells and their use for activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025645A1 (en) * 1996-12-12 1998-06-18 Karolinska Innovation Ab Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
FR2656866B1 (en) * 1990-01-10 1992-05-15 Cis Bio Int PORPHYRIN DERIVATIVES AND METALLOPORPHYRINS POTENTIALLY COUPLED TO A BIOLOGICALLY ACTIVE MOLECULE, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE4038563A1 (en) * 1990-12-04 1992-06-11 Gruenenthal Gmbh USE OF SUPEROXIDE DISMUTASES FOR PROPHYLAXIS AND / OR TREATMENT OF ORGAN FAILURE IN RISK PATIENTS WITH POLYTRAUMA
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
DE4407047A1 (en) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025645A1 (en) * 1996-12-12 1998-06-18 Karolinska Innovation Ab Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0222573A2 *

Also Published As

Publication number Publication date
AU1297002A (en) 2002-03-26
EP1367998A4 (en) 2004-03-17
WO2002022573A2 (en) 2002-03-21
AU2002212970B2 (en) 2007-05-31
JP2005524601A (en) 2005-08-18
CA2422586A1 (en) 2002-03-21
WO2002022573A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
Stölzel et al. Clinical guide and update on porphyrias
AU2002212970B2 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
Tang et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke
US20040116350A1 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
AU2002212970A1 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
Alhusaini et al. Role of Some Natural Antioxidants in the Modulation of Some Proteins Expressions against Sodium Fluoride‐Induced Renal Injury
Marchionatti et al. Effects of quercetin and menadione on intestinal calcium absorption and the underlying mechanisms
EP0782441B1 (en) Pharmaceutical control of inflammation
Chan et al. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties
Jimenez-Acosta et al. Demodex mites contain immunoreactive lipase
Higgins et al. Cyclosporin A in the treatment of lichen planus
Monteiro et al. Protective effects of kefir in the angiotensin II-dependent hypertension
Chen et al. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats
US20070009537A1 (en) Antimicrobial activity of antibodies producing reactive oxygen species
US20050129680A1 (en) Antimicrobial activity of antibodies
Zhu et al. Detection of IgE antibodies specific for 1-phenyl-2, 3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs
Krauter et al. Copper-thionein in melanoma
RU2115421C1 (en) Pharmaceutical composition showing immunomodulating and hypolipidemic effect
EP0946170B1 (en) Diclofenac for the treatment of vasculopathies
US20040157280A1 (en) Antibody mediated ozone generation
JP2006506419A5 (en)
US20060292076A1 (en) Antimicrobial mediated ozone generation
Everse et al. The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds
AU634307B2 (en) Orally administered porphyrins to control intestinal iron absorption
Harfenist et al. A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030415

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040203

17Q First examination report despatched

Effective date: 20040503

17Q First examination report despatched

Effective date: 20040503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100202